FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS.

Abstract

The present invention describes a fused heterocyclic compound of Formula (I) (see Formula), wherein R1, Y, Q, A, g, m, and E are as defined in the detailed description. The present invention further describes methods for preparing and using the compounds of Formula (I) as a pest control agent.

Description

FUSIONED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS FIELD OF THE INVENTION: The present invention relates to fused heterocyclic compounds. More particularly, the present invention relates to a fused heterocyclic compound of Formula (I) and a process for the preparation thereof. The present invention further relates to the use of fused heterocyclic compounds of Formula (I) as a pest control agent. BACKGROUND OF THE INVENTION: Currently available modern insecticides and acaricides have to satisfy many requirements, for example regarding the level of efficacy, residual activity and spectrum of activity and their effect and possible uses. During the last decades, efforts have been made to develop insecticides with selective properties that act specifically on biochemical modes of action present in insects or mites, but that also show properties that differ from known insecticides in a favorable way. Heterocyclic compounds with pesticidal activity are disclosed and described, for example, in documents WO2016091731, WO2016162318, WO2017061497, WO2017125340, WO2017001311, WO2018095953, WO2019068572 and WO2019038195. However, due to the long-term use of such pesticides, many pests develop resistance and effective control of existing insecticides and germicides that have been used conventionally over time becomes increasingly difficult, a phenomenon that even has increased in recent years. Furthermore, some of those existing pesticides are highly toxic or remain for a long time in the environment due to their residual properties, which can become a growing problem due to the alteration of ecosystems. npfrCLn / Lznz / e / YiAi Therefore, there is a continuing need for new compounds that are more effective, less toxic and environmentally safer and / or have different modes of action. In view of the above, the present invention contemplates compounds that satisfy or overcome the drawbacks associated with the prior art. Surprisingly, it has now been discovered that certain new heterocyclic compounds fused with active pesticidal properties with sulfur-containing substituents and which are the subject of the present invention have favorable properties as pesticides, as desired. BRIEF SUMMARY OF THE INVENTION: Accordingly, the present invention provides a fused heterocyclic compound of Formula (I) or agriculturally acceptable salts, structural isomers / isomers, stereoisomers, diastereomers, enantiomers, tautomers, metal complexes, polymorphs or N-oxides thereof. npfrCLn / Lznz / e / YiAi Formula (I) in which, R1, Y, Q, A, G, m and E are as defined in the detailed description. In one embodiment, the present invention provides a process for preparing the compound of Formula (I) or its agriculturally acceptable salts. In another embodiment, the present invention provides a composition for controlling or preventing invertebrate pests comprising a biologically effective amount of the compound of Formula (I), its salts, structural isomers / isomers, stereoisomers, diastereomers, enantiomers, tautomers, complexes. metallic, polymorphic or N-oxides acceptable for agriculture and at least one additional component selected from the group consisting of surfactants and auxiliaries. In yet another embodiment, the composition further comprises at least one additional biologically active and compatible compound selected from fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers or nutrients. In yet another embodiment, the present invention provides the use of the compound of Formula (I), its salts, structural isomers / isomers, stereoisomers, diastereomers, enantiomers, tautomers, agriculturally acceptable metal complexes, polymorphs or N-oxides, or the composition or combination thereof, to combat invertebrate pests in agricultural and / or horticultural crops or parasites in animals. In yet another embodiment, the present invention provides a method of combating invertebrate pests comprising the contact of invertebrate pests, their habitat, their breeding ground, their food supply, plants, seeds, soil, area, material or environment in which invertebrate pests grow or can grow, or the materials, plants, seeds, soils, surfaces or spaces to be protected from pest attack or infestation with a biologically effective amount of the compound of Formula (I) or its salts , structural isomers / isomers, stereoisomers, diastereomers, enantiomers, tautomers, agriculturally acceptable metal complexes, polymorphs or N-oxides, or the composition or combination thereof. DETAILED DESCRIPTION OF THE INVENTION: DEFINITIONS: The definitions provided herein of the terminology used for the present invention are for illustrative purposes only and in no way limit the scope thereof. As used herein, the terms comprises, comprising, includes, including, has, having, contains, containing, characterized by or any other variation thereof, are intended to cover a non-exclusive inclusion, subject to any explicitly stated limitations. For example, a composition, mixture, process or method comprising a list of elements is not necessarily limited only to those elements, but may include other elements that are not expressly mentioned or inherent in said composition. , mixture, process or method. The transition phrase consisting of excludes any unspecified element, step, or ingredient. If used in the claim, this would close the claim to the inclusion of materials other than those mentioned, with the exception of impurities commonly associated with them. When the phrase consisting of appears in the clause of a claim, instead of immediately following the preamble, it limits only the element set forth in that clause; Other elements are not excluded from the claim as a whole. The transition phrase consisting essentially of is used to define a composition or method that includes materials, steps, features, components or elements, in addition to those disclosed literally, provided that these additional materials, steps, features, components or elements do not materially affect the basic and novel characteristics of the claimed invention. The term consisting essentially of occupies a middle ground between comprising and consisting of. Furthermore, unless expressly stated otherwise, o refers to an inclusive or and not an exclusive or. For example, a condition A or B is satisfied by any of the following: A is true (or present) and B is false (or not present), A is false (or not present) and B is true (or present), and both A and B are true (or present). Furthermore, the indefinite articles a and an preceding an element or component of the present invention are intended not to be restrictive with respect to the number of instances (i.e., occurrences) of the element or component. Therefore, an or an should be read to include one or at least one, and the singular word form of the element or component also includes the plural, unless the number is obviously singular. As mentioned in this description, the term invertebrate pest includes arthropods, gastropods and nematodes of economic importance as pests. The term arthropod includes insects, mites, spiders, scorpions, centipedes, millipedes, bed bugs, and symphyla. The term gastropod included snails, slugs, and other stylomatophores. The term nematode refers to a living organism of the Phylum Nematoda. The term helminths includes roundworms, heartworms, phytophagous nematodes (Nematoda), trematodes (Tematoda), acanthocephala and tapeworms (Cestoda). The term agronomic refers to the production of field crops for food and fiber and includes the growth of corn, soybeans and other legumes, rice, cereals (e.g., wheat, oats, barley, rye, rice, corn), vegetables leafy vegetables (e.g. lettuce, cabbage and other cabbage crops), fruiting vegetables (e.g. tomatoes, peppers, eggplants, cruciferous and cucurbits), potatoes, sweet potatoes, grapes, cotton, tree fruits (e.g. pomo, stone and citrus), small fruits (berries, cherries) and other special crops (for example, canola, sunflower, olives). The term non-agronomic refers to other non-field crops, such as horticultural crops (e.g. greenhouses, nurseries or ornamental plants that do not grow in a field), residential, agricultural, commercial and industrial structures, turf (e.g. , turf, pasture, golf course, garden, sports field, etc.), applications to wood products, stored products, agroforestry and vegetation management, public health (i.e., human), and animal health (e.g., domestic animals such as pets, livestock and poultry, and non-domesticated animals such as wildlife). Non-agronomic applications include protecting an animal from a parasitic invertebrate pest by administering a parasitically effective (i.e., biologically effective) amount of a compound of the present invention, typically in the form of a composition formulated for veterinary use. As mentioned in the present disclosure and claims, the terms pesticide and parasiticide refer to observable effects on a pest of invertebrate parasites to protect an animal from the pest. Parasiticidal effects are generally related to decreasing the incidence or activity of the target invertebrate parasitic pest. Effects on the pest include necrosis, death, retarded growth, decreased mobility or ability to remain on the host animal, reduced feeding, and inhibition of reproduction. These effects on invertebrate parasite pests provide control (including prevention, reduction or elimination) of parasitic infestation or infection of the animal. The compounds of the present invention may be present in pure form or as mixtures of different possible isomeric forms, such as stereoisomers or constitutional isomers. The various stereoisomers include enantiomers, diastereomers, chiral isomers, atropisomers, conformers, rotamers, tautomers, optical isomers, polymorphs, and geometric isomers. Any desired mixture of these isomers falls within the scope of the claims of the present invention. One skilled in the art will appreciate that a stereoisomer may be more active and / or exhibit beneficial effects when enriched relative to another isomer(s) or when separated from the other isomer(s). Additionally, the person skilled in the art knows processes or methods or technology to separate, enrich and / or selectively prepare said isomers. The meaning of the different terms used in the description will now be illustrated. The term aliphatic compound(s) or aliphatic group(s) as used herein is an organic compound(s) whose carbon atoms are linked in straight chains, branched chains or non-aromatic rings. The term "alkyl", used alone or in compound words, such as "alkylthio" or "haloalkyl" or -N(alkyl) or alkylcarbonylalkyl or alkylsulfonylamino, includes straight-chain or branched O to C24 alkyl, preferably O1 to C15 alkyl, more preferably C1 to C10 alkyl, even more preferably C1 to Ce alkyl. Representative examples of alkyl include methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, pentyl, 1 -methylbutyl, 2methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1 -ethylpropyl, hexyl, 1,1 -dimethylpropyl, 1,2-dimethylpropyl, 1 -methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 ,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2 ,2-trimethylpropyl, 1 -ethyl1-methylpropyl and l-ethyl-2-methylpropyl or the different isomers. If the alkyl is at the end of a compound substituent, as, for example, in alkylcycloalkyl, the part of the compound substituent at the beginning, for example, cycloalkyl, may be mono- or polysubstituted identically or differently and independently npfrCLn / Lznz / e / YiAi for rent. The same also applies to compound substituents in which other radicals, for example alkenyl, alkynyl, hydroxyl, halogen, carbonyl, carbonyloxy and the like, are at the end. The term "alkenyl", used alone or in compound words, includes C2 to C24 straight or branched chain alkenes, preferably C2 to C15 alkenes, more preferably C2 to Cio alkenes, even more preferably C2 to Ce alkenes. Representative examples of alkenes include ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-lpropenyl, l-methyl-2-propenyl, 2 -methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, Imethyl-2-butenyl , 2-methyl-2-butenyl, 3-methyl-2-butenyl, l-methyl-3-butenyl, 2methyl-3-butenyl, 3-methyl-3-butenyl, 1,1-dimethyl-2-propenyl, 1 ,2-dimethyl-1-propenyl, 1,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, l-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl , 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl , 3-methyl2-pentenyl, 4-methyl-2-pentenyl, l-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4 -pentenyl, 2-methyl-4-pentenyl, 3-methyl4-pentenyl, 4-methyl-4-pentenyl, 1,1-dimethyl-2-butenyl, l,l-dimethyl-3-butenyl, 1,2dimethyl -l-butenyl, 1,2-dimethyl-2-butenyl, 1,2-dimethyl-3-butenyl, 1,3-dimethyl-1-butenyl, l,3-dimethyl-2-butenyl, l,3-dimethyl -3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl l, 3,3-dimethyl-l-butenyl, 3,3dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, l-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, l,l,2-trimethyl-2-propenyl, 1 -ethyl-l-methyl2-propenyl, l-ethyl-2-methyl-l- propenyl and l-ethyl-2-methyl-2-propenyl and the different isomers. "Alkenyl" also includes polyenes such as 1,2-propadienyl and 2,4hexadienyl. This definition also applies to alkenyl as part of a compound substituent, for example, haloalkenyl and the like, unless specifically defined elsewhere. The term "alkynyl", used alone or in compound words, includes C2 to C24 straight or branched chain alkynes, preferably C2 to C15 alkynes, more preferably C2 to C10 alkynes, even more preferably C2 to Ce alkynes. Examples of alkynes include, but are not limited to, ethinyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-penthynyl, 2-penthynyl, 3-penthynyl, 4 npfrCLn / Lznz / e / YiAi pentynyl, l-methyl-2-butynyl, l-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-l-butynyl, 1,1-dimethyl-2 -propynyl, 1 -ethyl -2-propyn1, 1 -hexinyl, 2-hexiniI, 3-hexinyl, 4-hexinyl, 5hexinyl, 1-methyl-2-pentynyl, l-methyl-3-pentynyl, 1-methyl-4 -pentynyl, 2-methyl-3pentynyl, 2-methyl-4-pentynyl, 3-methyl-l-pentynyl, 3-methyl-4-pentynyl, 4-methyl-lpentynyl, 4-methyl-2-pentynyl l, 1,1-dimethyl-2-butynyl, l,l-dimethyl-3-butynyl, l,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl , 3,3-dimethyl-l-butynyl, l-ethyl-2-butynyl, l-ethyl-3-butynyl, 2-ethyl-3-butynyl and 1 -ethyl-l-methyl-2-propynyl and the different isomers. This definition also applies to alkynyl as part of a compound substituent, for example haloalkinyl etc., unless specifically defined elsewhere. The term “alkynyl” can also include moieties that are composed of multiple triple bonds, such as 2,5-hexadiynyl. The term "cycloalkyl" means alkyl closed to form a ring. Examples include, but are not limited to, cyclopropyl, cyclopentyl and cyclohexyl. This definition also applies to cycloalkyl as part of a compound substituent, for example, cycloalkylalkyl, etc., unless specifically defined elsewhere. The term "cycloalkenyl" means alkenyl closed to form a ring including partially unsaturated, monocyclic hydrocarbyl groups. Examples include, but are not limited to, cyclopropenyl, cyclopentenyl and cyclohexenyl. This definition also applies to cycloalkenyl as part of a compound substituent, for example, cycloalkenylalkyl etc., unless specifically defined elsewhere. The term "cycloalkynyl" means alkynyl closed to form a ring, including partially unsaturated, monocyclic groups. Examples include, but are not limited to, cyclopropynil, cyclopentynyl and cyclohexinil. This definition also applies to cycloalkynyl as part of a compound substituent, for example, cycloalkynylalkyl, etc., unless specifically defined elsewhere. The term "cycloalkoxy", "cycloalkenyloxy" and the like are defined analogously. Examples of cycloalkoxy include, but are not limited to, cyclopropyloxy, cyclopentyloxy and cyclohexyloxy. This definition also applies to cycloalkoxy as part of a compound substituent, for example, cycloalkoxy alkyl etc., unless specifically defined elsewhere. npfrCLn / Lznz / e / YiAi The term "halogen", used alone or in compound words, such as "haloalkyl", includes fluorine, chlorine, bromine or iodine. Additionally, when used in compound words such as “haloalkyl,” said alkyl may be partially or fully substituted with halogen atoms that may be the same or different. Examples of "haloalkyl" include, but are not limited to, chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl , 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, 1,1dichloro-2 ,2,2-trifluoroethyl, and 1,1,1 -thfluoroprop-2-yl. This definition also applies to haloalkyl as part of a substituent compound, for example, haloalkylaminoalkyl, etc., unless specifically defined elsewhere. The terms "haloalkenyl", "haloalkynyl" are defined analogously except that, instead of alkyl groups, alkenyl and alkynyl groups are present as part of the substituent. The term "haloalkoxy" means straight or branched chain alkoxy groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms, as specified above. Examples of haloalkoxy include, but are not limited to, chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, dichlorofluoromethoxy, chlorodifluoromethoxy, 1-chloroethoxy, 1-bromoethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy , 2,2,2-trifluoroethoxy, 2chloro-2-fluoroethoxy¡, 2-chloro-2,2-difluoroethoxy¡, 2,2-dichloro-2-fluoroethoxy¡, 2,2,2trichloroethoxy, pentafluoroethoxy and l,l ,l-trifluoroprop-2-ox¡. This definition also applies to haloalkoxy as part of a substituent compound, for example, haloalkoxyalkyl, etc., unless specifically defined elsewhere. The term "haloalkylthio" means straight or branched chain haloalkylthio groups where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as specified above. Examples of haloalkylthio include, but are not limited to, chloromethylthio, bromomethylthio, dichloromethylthio, trichloromethylthio, fluoromethylthio, difluoromethylthio, trifluoromethylthio, chlorofluoromethylthio, dichlorofluoromethylthio, chlorodifluoromethylthio, 1 npirCLn / Lznz / e / YiAi chloroethylthio, 1-bromoethylthio, 1-fluoroethylthio, 2-fluoroethyl uncle , 2,2-difluoroethylthio, 2,2,2trifluoroethylthio, 2-chloro-2-fluoroethylthio, 2-chloro-2,2-difluoroethylthio, 2,2-dichloro-2fluoroethylthio, 2,2,2-trichloroethylthio, pentafluoroethylthio and l,l,l-trifluoroprop-2-ylthio. This definition also applies to haloalkylthio as part of a compound substituent, for example, haloalkylthioalkyl, etc., unless specifically defined elsewhere. Examples of “haloalkylsulfinyl” include, but are not limited to, CFsS(O), CCl3S(O), CF3CH2S(O), and CF3CF2S(O). Examples of “haloalkylsulfonyl” include CFsS(O)2, CCI3S(O)2, CF3CH2S(O)2 and CF3CF2S(O)2. The term "hydroxy" means -OH, Amino means -NRR, where R may be H or any possible substituent, such as alkyl. Carbonyl means -C(O)-, carbonyloxy means -OC(O)-, sulfinyl means SO, sulfonyl means S(O)2. The term "alkoxy" used alone or in compound words includes Ci to C24 alkoxy, preferably C1 to C15 alkoxy, more preferably C1 to C10 alkoxy, even more preferably Ci to Ce alkoxy. Examples of alkoxy include methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 1-methylpropoxy, 2-methylpropoxy, 1,1-dimethylethoxy, pentoxy, 1-methylbutoxy, 2-methylbutoxy, 3-methylbutoxy, 2,2-dimethylpropoxy , 1-ethylpropoxy, hexoxy, 1,1-dimethylpropoxy, 1,2-dimethylpropoxy, 1-methylpentoxy, 2-methylpentoxy, 3-methylpentoxy, 4-methylpentoxy, 1,1-dimethylbutoxy, 1,2-dimethylbutoxy, 1,3-dimethylbutoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy, 3,3-dimethylbutoxy, 1-ethylbutoxy, 2-ethylbutoxy, 1,1,2-trimethylpropoxy, 1,2,2-trimethylpropoxy, 1-ethyl-1methylpropoxy and l-ethyl -2-methylpropoxy and the different isomers. This definition also applies to alkoxy as part of a compound substituent, for example, haloalkoxy, alkynylalkoxy, etc., unless specifically defined elsewhere. The term "Alkoxyalkyl" indicates the substitution of alkoxy on alkyl. Examples of “alkoxyalkyl” include, but are not limited to, CH3OCH2, CH3OCH2CH2, CH3CH2OCH2, CH3CH2CH2CH2OCH2 and CH3CH2OCH2CH2. The term "alkoxyalkoxy" indicates the substitution of alkoxy into alkoxy. The term "alkylthio" includes branched or straight chain alkylthio moieties, such as methylthio, ethylthio, propylthio, 1-methylethylthio, butylthio, 1-methylpropylthio, 2-methylpropylthio, 1,1-dimethylethylthio, pentylthio, 1-methylbutylthio, 2 npfrCLn / Lznz / e / YiAi methylbutylthio, 3-methylbutylthio, 2,2-dimethylpropylthio, 1 -ethylpropylthio, hexylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio, 1 -methylpentylthio, 2-methylpentylthio, 3-methylpentylthio, 4-methylpentylthio, 1,1 -dimethylbutylthio, 1,2-dimethylbutylthio, 1,3-dimethylbutylthio, 2,2-dimethylbutylthio, 2,3-dimethylbutylthio, 3,3-dimethylbutylthio, 1-ethylbutylthio, 2-ethylbutylthio, 1,1,2-trimethylpropylthio, 1,2,2 -trimethylpropylium, 1-ethyl-1methylpropylium and l-ethyl-2-methylpropylium and the different isomers. Halocycloalkyl, halocycloalkenyl, alkylcycloalkyl, cycloalkylalkyl, cycloalkoxyalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, haloalkylcarbonyl, cycloalkylcarbonyl, haloalkoxylalkyl, and the like are defined analogously to the previous examples. The term "alkylthioalkyl" indicates the substitution of alkylthio on alkyl. Representative examples of “alkylthioalkyl” include -CH2SCH2, -CH2SCH2CH2, CH3CH2SCH2, CH3CH2CH2CH2SCH2 and CH3CH2SCH2CH2. "Alkylthioalkoxy" indicates the substitution of alkylthio on alkoxy. The term "cycloalkylalkylamine" indicates the substitution of cycloalkyl on alkylamino. The terms alkoxyalkoxyalkyl, alkylaminoalkyl, dialkylaminoalkyl, cycloalkylaminoalkyl, cycloalkylaminocarbonyl and the like are defined analogously to “alkylthioalkyl” or cycloalkylalkylamine. The term “alkoxycarbonyl” is an alkoxy group attached to a backbone through a carbonyl group (-CO-). This definition also applies to alkoxycarbonyl as part of a substituent compound, for example, cycloalkylalkoxycarbonyl and the like, unless specifically defined elsewhere. The term "alkoxycarbonylalkylamino" indicates the substitution of alkoxycarbonyl on alkylamino. "Alkylcarbonylalkylamino" indicates the substitution of alkylcarbonyl on alkylamino. The terms alkylthioalkoxycarbonyl, cycloalkylalkylaminealkyl and the like are defined analogously. Examples of “alkylsulfinyl” include, but are not limited to, methylsulfinyl, ethylsulfinyl, propylsulfinyl, 1-methylethylsulfinyl, butylsulfinyl, 1-methylpropylsulfinyl, 2-methylpropylsulfinyl, 1,1-dimethylethylsulfinyl, pentylsulfinyl, 1-methylbutylsulfinyl, 2-methylbutylsulfinyl, 3-methyl butylsulfinyl, 2,2 -dimethylpropylsulfinyl, 1-ethylpropylsulfinyl, hexylsulfinyl, 1,1 -dimethylpropylsulfinyl, 1,2-dimethylpropylsulfinyl, 1-methylpentylsulfinyl, 2-methylpentylsulfinyl, 3-methylpentylsulfinyl, 4-methylpentylsulfinyl, npfcCLn / Lznz / e / YiAi 1,1-dimethylbutylsulfinyl, 1,2-dimethylbutylsulfinyl, 1,3-dimethylbutylsulfinyl, 2,2-dimethylbutylsulfinyl, 2,3-dimethylbutylsulfinyl, 3,3-dimethylbutylsulfinyl, 1-ethylbutylsulfinyl, 2-ethylbutylsulfinyl, 1,1,2-trimethylpropylsulfinyl, 1,2,2-trimethylpropylsulfinyl, 1-ethyl-1methylpropylsulfinyl and 1-ethyl-2-methylpropylsulfinyl and the different isomers. The term "arylsulfinyl" includes Ar-S(O), where Ar can be any carbocycle or heterocycle. This definition also applies to alkylsulfinyl as part of a compound substituent, for example, haloalkylsulfinyl, etc., unless specifically defined elsewhere. Examples of “alkylsulfonyl” include, but are not limited to, methylsulfonyl, ethylsulfonyl, propylsulfonyl, 1-methylethylsulfonyl, butylsulfonyl, 1-methylpropylsulfonyl, 2methylpropylsulfonyl, 1,1-dimethylethylsulfonyl, pentylsulfonyl, 1-methylbutylsulfonyl, 2methylbutylsulfonyl, 3-methyl butylsulfonyl, 2,2 -dimethylpropylsulfonyl, 1-ethylpropylsulfonyl, hexylsulfonyl, 1,1-dimethylpropylsulfonyl, 1,2-dimethylpropylsulfonyl, 1-methylpentylsulfonyl, 2-methylpentylsulfonyl, 3-methylpentylsulfonyl, 4-methylpentylsulfonyl, 1,1-dimethylbutylsulfonyl, 1,2-dimethylbutyls sulfonyl, 1,3-dimethylbutylsulfonyl, 2,2 -dimethylbutylsulfonyl, 2,3-dimethylbutylsulfonyl, 3,3-dimethylbutylsulfonyl, 1-ethylbutylsulfonyl, 2-ethylbutylsulfonyl, 1,1,2-trimethylpropylsulfonyl, 1,2,2-trimethylpropylsulfonyl, 1-ethyl-1-methylpropylsulfonyl and l-ethyl-2- methylpropylsulfonyl and the different isomers. The term "arylsulfonyl" includes Ar-S(O)2, where Ar can be any carbocycle or heterocycle. This definition also applies to alkylsulfonyl as part of a compound substituent, for example, alkylsulfonylalkyl etc., unless defined elsewhere. “Alkylamino”, “dialkylamino”, and the like, are defined analogously to the previous examples. The term “carbocycle” includes “aromatic carbocyclic ring system” and “non-aromatic carbocyclic ring system” or polycyclic or bicyclic ring compounds (spiro, fused, bridged, non-fused), in which the ring may or may not be aromatic. aromatic (where the aromatic term indicates that Huckel's rule holds and the non-aromatic term indicates that Huckel's rule does not hold). The term “hetero” in relation to rings refers to a ring in which at least one ring atom is not carbon and which may contain 1 to 4 npfrCLn / Lznz / e / YiAi heteroatoms independently selected from the group consisting of nitrogen. , oxygen and sulfur, provided that each ring contains no more than 4 nitrogens, no more than 2 oxygens and no more than 2 sulfurs. The term “aromatic” indicates that Huckel's rule holds and the term “non-aromatic” indicates that Huckel's rule does not hold. The term "heterocycle" or "heterocyclic" includes "aromatic heterocycle" or "heteroaryl ring system" and "non-aromatic heterocyclic ring system" or polycyclic or bicyclic ring compounds (spiro, fused, bridged, non-fused) in which The ring may be aromatic or non-aromatic, wherein the heterocycle ring contains at least one heteroatom selected from N, O, S(0)o-2, and / or the ring member C of the heterocycle may be replaced by C(=O), C(=S), C(=CR*R*) and C=NR*, * indicates integers. The term "non-aromatic heterocycle" or "non-aromatic heterocyclic" means 3 to 15 membered, possibly 3 to 12 membered, saturated or partially unsaturated heterocycle containing one to four heteroatoms from the oxygen, nitrogen and sulfur group: mono heterocycles , bi-tricyclics containing, in addition to a carbon ring, one to three nitrogen atoms and / or one oxygen or one sulfur atom or one or two oxygen atoms and / or sulfur atoms; if the ring contains more than one oxygen atom, they are not directly adjacent; for example, (among others) oxetanil, oxiranil, aziridinyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tetrahydrothienyl, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-isoxazolidinyl, 4-isoxazolidinyl, 5isoxazolidinyl, 3 -isothiazolidinyl , 4-isothiazolidinyl, 5-isothiazolidinyl, 1-pyrazolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5oxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 1-imidazolidinyl, 2 imidazolidinyl , 4-imidazolidinyl, 1,2,4-oxadiazolidin-3-yl, l,2,4-oxadiazolidin-5-yl, l,2,4-thiadiazolidin-3-yl, 1,2, 4-thiadiazolidin-5-yl, l,2,4-triazolidin-1-lio, l,2,4triazolidin-3-yl, l,3,4-oxadiazolidin-2-yl, l,3,4-thiadiazolidin- 2-yl, 1,3,4-triazolidin1 -yl, 1,3,4-triazolidín-2-yl, 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl , 2,4-dihydrofur2-lo, 2,4-dihydrofur-3-lo, 2,3-dihydrofur-2-lo, 2,3-dihydrofur-3-lo, 2,4-dihydrothien -2-yl, 2,4-dihydrothien-3-yl, pyrrolinyl, 2-pyrrolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 2-soxazolin-3-yl, 3-soxazolin-3-yl, 4-soxazolin-3yl, 2-soxazolin-4-yl, 3-soxazolin-4-yl, 4-soxazolin-4-yl yl, 2-¡soxazolin-5-yl, 3npfrCLn / Lznz / e / YiAi isoxazolin-5-yl, 4-¡soxazolin-5-yl, 2-¡sothiazolín-3-yl, 3-¡sothiazolín -3-yl, 4-isothiazolin-3-yl, 2-isothiazolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2isothiazolin-5-yl, 3- ¡sothiazol¡n-5-yl, 4-¡sothiazol¡n-5-yl, 2,3-dihydropyrazol-l-yl, 2,3npfrCLn / Lznz / e / YiAi dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydropyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol-l-yl, 3,4- dihydropyrazol-3-yl, 3,4-dihydropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-l-yl, 4,5-dihydropyrazol-3-yl , 4,5-dihydroxazol-4-yl, 4,5-dihydroxazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-3-yl, 2, 3-dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, 3, 4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4- dihydrooxazol-3-yl, 3,4-dihydrooxazol-4-yl, piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, pyrazinyl, morpholinyl, thiomorphlinyl, l,3-dioxan-5-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 2-tetrahydropyrimidinyl, 3-hexahydropyridazinayl, 4-hexahydropyridazinayl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazinyl, 1,3,5-hexahydrotriazin-2-yl, 1,2,4-hexahydrotriazinyl n-3 -yl, cycloserines, 2,3,4,5-tetrahydro[1 H]azepin-1 - or -2- or -3- or 4- or -5- or -6- or -7- lo, 3, 4,5,6-tetra-hydro[2H]azepine-2- or -3- or -4- or -5- or -6- or -7yl, 2,3,4,7-tetrahydro[1H] azepin-1- or -2- or -3- or -4- or -5- or -6- or-7- lo, 2,3,6,7tetrahydro[1 H]azepin-1 - or - 2- or -3- or -4- or -5- or -6- or -7- lo, hexahydroazepin-1- or -2- or -3- or -4- lo, tetra- and hexahydrooxepinil, such as 2,3,4,5-tetrahydro[1 H]oxepin-2 Ó3Ó4Ó5Ó6Ó 7-ílo, 2,3,4,7-tetrahydro[1 H]oxepin-2- or -3- or -4- or 5 - or -6- or -7-yl, 2,3,6,7-tetrahydro[1 H]oxepin-2- or -3- or -4- or -5- or -6- or -7- , hexahydroazepin-1- or -2- or -3- or -4-yl, tetra- and hexahydro-1,3-diazepinyl, tetray hexahydro-1,4-diazepinyl, tetra- and hexahydro-1,3-oxazepinyl , tetra- and hexahydro1,4-oxazepinyl, tetra- and hexahydro-1,3-dioxepinyl, tetra- and hexahydro-1,4-dioxepinyl. This definition also applies to heterocyclyl as part of a compound substituent, for example, heterocyclylalkyl, etc., unless specifically defined elsewhere. The term “heteroaryl” or “aromatic heterocyclic” means a fully unsaturated, 5- or 6-membered monocyclic ring system containing one to four heteroatoms from the oxygen, nitrogen, and sulfur group; if the ring contains more than one oxygen atom, they are not directly adjacent; 5-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur atom or one oxygen atom: 5-membered heteroaryl groups that, in addition to carbon atoms, may contain from one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom as ring members, for example (among others), furyl, thienyl, pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, oxazolyl, thiazolyl, imidazolyl, 1, 2,4-oxadiazolyl, 1,2,4-thiadiazolyl, 1,2,4-triazolyl, 1,3,4-oxadiazolyl, 1,3,4-thiadiazolyl, 1,3,4-triazolyl, tetrazolyl; nitrogen-linked 5-membered heteroaryl containing one to four nitrogen atoms, or benzomolten nitrogen-linked 5-membered heteroaryl containing one to three nitrogen atoms: 5-membered heteroaryl groups that, in addition to carbon atoms, can contain one to four nitrogen atoms or one to three nitrogen atoms as ring members and in which two adjacent carbon ring members or one nitrogen and one adjacent carbon ring member may be linked by a buta-group. 1,3diene-1,4-diyl in which one or two carbon atoms can be replaced by nitrogen atoms, in which these rings are attached to the skeleton through one of the nitrogen ring members, for example (among others) 1-pyrrolyl, 1-pyrazolyl, 1,2,4-triazol-l-yl, 1-imidazolyl, 1,2,3-triazol-l-yl and 1,3,4triazol-l- ilo. A 6-membered heteroaryl containing one to four nitrogen atoms: 6-membered heteroaryl groups that, in addition to carbon atoms, may contain, respectively, one to three and one to four nitrogen atoms as ring members, for example (among others) 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinayl, 4-pyridazinayl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, l,3,5-thazin-2- lo, l,2,4-tnaz¡n-3-yl and l,2,4,5-tetrazin-3-yl; a 5-membered benzofused heteroaryl containing one to three nitrogen atoms or one nitrogen atom and one oxygen or sulfur atom: for example (among others) indol-l-yl, indol-2-yl, indol-3 -yl, indol-4-yl, indol-5-yl, indol-6-yl, indol-7-yl, benzimidazol-l-yl, benzimidazol-2-yl, benzimidazol-4-yl, benzimidazol-5-yl , indazol-l-yl, indazol-3-yl, indazol-4-yl, indazol-5-yl, indazol6-yl, indazol-7-yl, indazol-2-yl, l-benzofuran-2-yl, l-benzofuran-3-yl, Ibenzofuran-4-yl, l-benzofuran-5-yl, 1-benzofuran-6-yl, l-benzofuran-7-yl, Ibenzothiophen-2-yl, l-benzothiophen-3 -yl, l-benzothiophen-4-yl, 1-benzothiophen-5-yl, I npfrCLn / Lznz / e / YiAi benzothiophen-6-yl, l-benzothiophen-7-yl, l,3-benzothiazol-2-yl , 1,3-benzothiazol-4-yl, l,3-benzothiazol-5-yl, l,3-benzothiazol-6-yl, l,3-benzothiazol-7-yl, l,3-benzoxazol-2yl, l ,3-benzoxazol-4-yl, l,3-benzoxazol-5-yl, 1,3-benzoxazol-6-yl and l,3-benzoxazol-7-yl; a 6-membered benzofused heteroaryl containing one to three nitrogen atoms: for example (but not limited to) quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6 -yl, quinolin-7-yl, quinolin8-yl, isoquinolin-l-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl. This definition also applies to heteroaryl as part of a compound substituent, for example, heteroarylalkyl, etc., unless specifically defined elsewhere. The term Trialkylsilyl includes 3 straight or branched chain alkyl radicals linked and linked through a silicon atom, such as trimethylsilyl, triethylsilyl and t-butyl-dimethylsilyl. Halotrialkylsilyl indicates that at least one of the three alkyl radicals is partially or completely substituted with halogen atoms that may be the same or different. The term alkoxytrialkylsilyl indicates that at least one of the three alkyl radicals is substituted with one or more alkoxy radicals which may be the same or different. The term trialkylsilyloxy indicates a trialkylsilyl moiety linked through oxygen. Examples of alkylcarbonyl include, but are not limited to, C(O)CH3, C(O)CH2CH2CH3 and C(O)CH(CH3)2. Examples of alkoxycarbonyl include, but are not limited to, CH3OC(=O), CH3CH2OC(=O), CH3CH2CH2OC(=O), (CH3)2CHOC(=O) and the different butoxy- or pentoxycarbonyl isomers. Examples of alkylaminocarbonyl include, but are not limited to, CH3NHC(=O), CH3CH2NHC(=O), CH3CH2CH2NHC(=O), (CH3)2CHNHC(=O) and the different isomers of butylamino or pentylaminocarbonyl. Examples of dialkylaminocarbonyl include, but are not limited to, (CH3)2NC(=O), (CH3CH2)2NC(=O), CH3CH2(CH3)NC(=O), ΟΗ3ΟΗ2ΟΗ2(ΟΗ3)ΝΟ(=Ο) and (CH3) 2CHN(CH3)C(=O). Examples of alkoxyalkylcarbonyl include, but are not limited to, CH3OCH2C(=O), CH3OCH2CH2C(=O), ΟΗ3ΟΗ2ΟΟΗ2Ο(=Ο), CH3CH2CH2CH2OCH2C(=O) and CH3CH2OCH2CH2C(=O). Examples of alkylthioalkylcarbonyl include, but are not limited to, CH3SCH2C(=O), npfrCLn / Lznz / e / YiAi CH3SCH2CH2C(=O), CH3CH2SCH2C(=O), CH3CH2CH2CH2SCH2C(=O) and CH3CH2SCH2CH2C(=O). The term haloalkylsulfonylaminocarbonyl, alkylsulfonylaminocarbonyl, alkylthioalkoxycarbonyl, alkoxycarbonylalkyl amino and the like are defined analogously. Examples of alkylaminoalkylcarbonyl include, but are not limited to, CH3NHCH2C(=O), CH3NHCH2CH2C(=O), CH3CH2NHCH2C(=O), CH3CH2CH2CH2NHCH2C(=O), and CH3CH2NHCH2CH2C(=O). The term "amide" means A-R'C=ONR-B, where R' and R indicate substituents and A and B indicate any group. The term "thioamide" means A-R'C=SNR-B, where R' and R indicate substituents and A and B indicate any group. The total number of carbon atoms in a substituent group is indicated by the prefix “C1-Cj”, where i and j are numbers from 1 to 21. For example, C1-C3 alkylsulfonyl indicates methylsulfonyl through propylsulfonyl; C2alkoxyalkyl indicates CH3OCH2; C3alkoxyalkyl denotes, for example, CH3CH(OCH3), CH3OCH2CH2 or CH3CH2OCH2; and C4 alkoxyalkyl indicates the various isomers of an alkyl group substituted with an alkoxy group containing a total of four carbon atoms, examples of which include CH3CH2CH2OCH2 and CH3CH2OCH2CH2. In any of the above citations, when a compound of Formula I is composed of one or more heterocyclic rings, substituents can be attached to these rings through any available carbon or nitrogen by substitution of a hydrogen on said carbon or nitrogen. When a compound is substituted with a substituent carrying a subscript indicating that the number of said substituents may exceed 1, said substituents (when they exceed 1) are selected independently from the group of defined substituents. Furthermore, when the subscript m in (R)m indicates an integer ranging from, for example, 0 to 4, then the number of substituents can be selected from the integers between 0 and 4 inclusive. npfrCLn / Lznz / e / YiAi When a group contains a substituent that may be hydrogen, then when this substituent is taken as hydrogen, said group is recognized to be unsubstituted. The embodiments herein and the various advantageous features and details thereof are explained with reference to the non-limiting embodiments in the description. Descriptions of well-known components and processing techniques have been omitted in order not to unnecessarily obscure the embodiments of this document. The examples used herein are intended simply to facilitate understanding of the ways in which the embodiments herein may be practiced and further to enable those skilled in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein. The description of the specific embodiments will fully disclose the general nature of the embodiments herein that, applying current knowledge, others will be able to easily modify and / or adapt such specific embodiments for various applications without departing from the generic concept and, therefore, such adaptations and modifications must and are intended to be understood within the meaning and range of equivalents of the described embodiments. It should be understood that the phraseology or terminology used in this document is for the purpose of description and not limitation. Therefore, although embodiments of the present invention have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein may be practiced with modification within the spirit and scope of the embodiments as described herein. document. Any discussion of documents, acts, materials, devices, articles and the like that has been included in this specification is for the sole purpose of providing context for the invention. It should not be assumed that any or all of these matters form part of the basis of the prior art or that they were common general knowledge in the field relevant to the invention as it existed anywhere prior to the priority date of this application. npfrCLn / Lznz / e / YiAi However, the numerical values ​​mentioned in the description and claims above may form a critical part of the present invention, and any deviation from such numerical values ​​will still be within the scope of the present invention if that deviation follows the same scientific principle as the of the present invention. The inventive compound of the present invention may be present, if appropriate, as mixtures of different possible isomeric forms, especially of stereoisomers, for example, E and Z, threo and entro, and also optical isomers, but also of tautomers, if appropriate. appropriate. Both E and Z isomers, as well as threo and erythro isomers, and optical isomers, any desired mixture of these isomers and possible tautomeric forms are described and claimed. The term pest for the purpose of the present invention includes, but is not limited to, fungi, estrogens (oomycetes), bacteria, nematodes, mites, ticks, insects and rodents. Also pest is an animal or plant that is detrimental to humans or human concerns, including crops, livestock and forestry. The term plant as used herein is understood to refer to all plants and plant populations, such as desired and unwanted wild plants or crop plants (including naturally occurring crop plants). Crop plants may be plants that can be obtained by conventional breeding or optimization methods or by genetic and biotechnological engineering methods or combinations of these methods, including transgenic plants and plant cultivars that are protectable and non-protectable by copyright. the breeders. For the purpose of the present invention, the term plant includes a living organism of the type exemplified by trees, shrubs, herbs, ferns and mosses, which typically grows in a location, absorbs water and necessary substances through its roots, and synthesizes nutrients. in its leaves through photosynthesis. Examples of plants for the purposes of the present invention include, but are not limited to, agricultural crops such as wheat, rye, barley, triticale, oats or rice; beet, for example sugar beet or fodder beet; fruits and fruit trees, such as pome fruits, stone fruits or soft fruits, for example apples, pears, plums, peaches, almonds, cherries, strawberries, raspberries, blackberries or currants; leguminous plants, such as lentils, peas, alfalfa or soybeans; oilseed plants, such as rapeseed, mustard, olives, sunflowers, coconut, cocoa beans, castor oil plants, palm oil, ground nuts or soybeans; cucurbits, such as pumpkins, cucumber or melons; fiber plants, such as cotton, flax, hemp or jute; citrus and citrus trees, such as oranges, lemons, grapefruits or tangerines; any horticultural plant, vegetables, such as spinach, lettuce, asparagus, cabbage, carrots, onions, tomatoes, potatoes, cucurbits or paprika; lauraceae plants, such as avocados, cinnamon or camphor; cucurbits; oil plants; energy and raw material plants, such as cereals, corn, soybeans, other leguminous plants, rapeseed, sugar cane or oil palm; tobacco; walnuts; coffee; tea; cocoa; bananas peppers; vines (table grapes and juice grapes); hop; grass; sweet leaf (also called Stevia); natural rubber plants or ornamental and forest plants, such as flowers, shrubs, broadleaf trees or evergreen trees, for example, conifers, and on plant propagation material, such as seeds, and growing material of these plants. Preferably, for the purposes of the present invention, the plant includes, but is not limited to, cereals, corn, rice, soybeans and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, horticultural plants , cucurbits, oil plants, tobacco, coffee, tea, cocoa, sugar beet, sugar cane, cotton, potato, tomato, onion, peppers and vegetables, ornamental plants, flower plants and other plants for use by humans and animals. The term plant parts is understood to mean all parts and organs of plants above and below ground. For the purpose of the present disclosure, the term plant parts includes, but is not limited to, cuttings, leaves, twigs, tubers, flowers, seeds, branches, roots, including primary roots, lateral roots, root hairs, root apex, root cap, rhizomes, shoots, fruits, fruit bodies, bark, stem, buds, auxiliary shoots, meristems, nodes and internodes. npfrCLn / Lznz / e / YiAi The term plant site includes the soil, the environment of the plants or parts and the equipment or tools used before, during or after the sowing / planting of a plant or a plant part. The application of a compound or compounds of the present invention or the compound of the present invention in a composition optionally comprising at least one other active compound compatible to a plant or a plant material or to the place where it is found includes application by a technique known to one skilled in the art including, but not limited to, spraying, coating, dipping, fumigation, impregnation, injection and dusting. The term applied means attached to a plant or plant part, whether physically or chemically, including impregnation. In one embodiment, the present invention provides a compound of Formula (I), (X)m Formula (I) npfrCLn / Lznz / e / viAi in which, R1 is selected from the group consisting of Ci-Ce-alkyl, C2-C6alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl and Cs-Cs-cycloalkyl-Ci -Ce-alkyl; Y is selected independently from O or NRY; RY is selected from the group consisting of hydrogen, cyano, C1C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-haloalkyl, C2-C4haloalkenyl, Cs-Cs-cycloalkyl and Cs-Cs-cycloalkyl. -Ci-Cs-alkyl; A represents N or CR2; G represents N or C; as long as the two Gs are not nitrogen simultaneously; R2 is selected from the group consisting of hydrogen, halogen, cyano, Ci-Ce-alkyl, C2-C6-alkenyl, Cz-Ce-alkynyl, Ci-Ce-haloalkyl, C2C6-haloalkenyl, Cs-Cs-cycloalkyl, OR4 , CR4=NR5, NR5R6, S(O)0-2R7, C(=O)R8, S(0)o-iR9=NR10, N=S(O)0-i(R9)2, P(=O )(OR')2, Yes(R')3, C6-Cio-aryl, Cy-Cu-aralkyl and Cs-Cw-heterocyclyl; wherein each aliphatic group may be optionally substituted with one or more groups of R2a and the cyclic groups of R2 may be optionally substituted with one or more groups of R2b; R2ase is selected from the group consisting of halogen, cyano, C-iCe-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cscycloalkyl, OR4, CR4=NR5, NR5R6, S (O)0-2R7, C(=O)R8, S(0)o-iR9=NR10, N=S(O)d-i(R9)2, Yes(R')3, Ce-C-io-aryl , C7-Ci4-aralkyl and Cs-Cw-heterocyclyl; R2b is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6haloalkenyl, Cs-Cs-cycloalkyl, OR4, CR4=NR5 , NR5R6, S(O)0-2R7, C(=O)R8, Si(R')3, S(0)o-iR9=NR10y N=S(O)0-i(R9)2; or two R2a or two R2b substituents together with the atom to which they are attached or together with other atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group that consists of C(=O), C(=S), S(0)o-2 and Si(R')2, they can form a ring with 3 to 7 members, which in turn can be replaced by one or more R2ab groups; R2ab is selected from the group consisting of halogen, cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, OR4, NR5R6 , S(0)o-2R7, S(O)0-iR9=NR10, N=S(O)q-i(R9)2, Si(R')s, C6-Cw-aryl, Cz-Cu- aralkyl and Cs-Cw-heterocyclyl; Q represents a partially saturated or unsaturated 5- to 12-membered heterocyclic ring system that may optionally be substituted by one or more R3 groups; wherein said heterocyclic ring system represents neither unsubstituted benzothiazolyl nor unsubstituted N-methyl benzimidazolyl; npfrCLn / Lznz / e / YiAi R3 is selected from the group consisting of halogen, cyano, Ci-Cealkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, OR4, CR4 =NR5, NR5R6, S(0)o-2R7, C(=O)R8, S(O)ciR9=NR10, N=S(O)0-i(R9)2, P(=O)(OR' )2, Yes(R')3, C6-Cio-aryl, C7-Ci4-aralkyl and Cs-Cio-heterocyclyl; wherein each aliphatic group may be optionally substituted with one or more groups of R3a and the cyclic groups of R3 may be optionally substituted with one or more groups of R3b; R3ase is selected from the group consisting of halogen, cyano, CiCe-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cscycloalkyl, OR4, CR4=NR5, NR5R6, S(O )0-2R7, C(=O)R8, S(0)o-iR9=NR10, N=S(O)q-i (R9)2, Yes(R')3, Ce-Cio-aryl, C7-Ci4 -aralkyl and C3-C10heterocyclyl; R3b is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6haloalkenyl, Cs-Ce-cycloalkyl, OR4, C (R')2-NR5R6, C(R')2-OR4, CR4=NR5, NR5R6, S(0)o-2R7, C(=O)R8, S(O)0-iR9=NR10, N=S(O)q-i(R9)2, Yes(R')3, Ce-Cio-aryl, C7-Ci4-aralkyl and Cs-Cio-heterocyclyl; two R3a or two R3b substituents together with the atom to which they are attached or together with other atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting in C(=O), C(=S), S(O)m and Si(R')2, they can form a ring with 3 to 7 members, which in turn can be replaced by one or more R3ab groups; wherein R3ab is selected from the group consisting of hydrogen, halogen, cyano, Ci-Ce-alkyl, Ci-Ce-haloalkyl, Cs-Ce-cycloalkyl, OR4, NR5R6 and S(O)0-2R7; two R3 together with the atom to which they are attached or together with other atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C( =O), C(=S), S(O)m and Si(R')2 can form a ring of three to seven members, which in turn can be replaced by one or more groups selected from the group consisting in halogen, cyano, R3c, OR3c, SR3c, NR3c2, Si(R3c)3, COOR3c and CONR3c2; npfrCLn / Lznz / e / YiAi R3c is selected from the group consisting of hydrogen, halogen, Ci-Ce-alkyl and Cs-8-straight chain or branched cyclic alkyl; wherein each R3c group is optionally substituted by one or more halogens; ring E represents a 5- or 6-membered heterocyclic ring fused to ring D in which ring E is optionally substituted by one or more R11 groups; R11 is selected from the group consisting of halogen, cyano, CiCe-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6haloalkenyl, Cs-Ce-cycloalkyl, OR4, CR4=NR5 , NR5R6, S(0)o-2R7, C(=O)R8, S(O)0-iR9=NR10, N=S(O)0-i(R9)2, P(=O)(OR' )2, Yes(R')3, C6-Cio-aryl, C7-C14aralkyl and Ca-Cio-heterocyclyl; wherein each aliphatic group may be optionally substituted with one or more R11 groups and the cyclic R11 groups may be optionally substituted with one or more R11b groups; R11ase is selected from the group consisting of halogen, cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Cehaloalkyl, Cs-Ce-cycloalkyl, OR4, CR4=NR5, NR5R6, S (O)0-2R7, C(=O)R8, S(O)0-iR9=NR10, N=S(O)0-i(R9)2, Si(R')3, C6-Cio-aryl , C7Cu-aralkyl and Cs-Cio-heterocyclyl; R11b is selected from the group consisting of halogen, cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, OR4, C (R')2NR5R6, C(R')2-OR4, CR4=NR5, NR5R6, S(O)q-2R7, C(=O)R8, S(O)diR9=NR10, N=S(0) o-i(R9)2, Yes(R')3, C6-Cio-aryl, C7-Ci4-aralkyl and C3-Cio-heterocyclyl; R4 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2Ce-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, C3-C8cycloalkyl, S(O)2R7, Si (R')3, Ce-Cio-aryl, C7-Ci4-aralkyl and Cs-Cw-heterocyclyl; wherein each aliphatic group may be optionally substituted with R4a and the cyclic groups of R4 may be optionally substituted with one or more groups of R4b; npfrCLn / Lznz / e / YiAi R4ase is selected from the group consisting of halogen, cyano, CiCe-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cscycloalkyl, OR', NR'R, S(O) c-2R', C(=O)R', Si(R')3, Ce-Cw-aryl, C7-C14aralkyl and Cs-Cw-heterocyclyl; R4b is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6haloalkenyl, Cs-Cs-cycloalkyl, OR', NR' R, S(O)q-2R', C(=O)R', Si(R')3, Ce-Cw-aryl, Cz-Cu-aralkyl and Cs-Cw-heterocyclyl; R5 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2Ce-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cscycloalkyl, OR4, NR'R, S (0)o-2R7, C(=O)R8, Yes(R')3, Ce-Cw-aryl, Cz-Cw-aralkyl and Cs-Cw-heterocyclyl; wherein each aliphatic group may be optionally substituted with R5a and the cyclic groups of R5 may be optionally substituted with one or more groups of R5b; R5ase is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cscycloalkyl, OR', NR'R, S(O) q-2R', C(=O)R', Si(R')s, Ce-Cw-aryl, C7-C14aralkyl and Cs-Cw-heterocyclyl; R5b is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6haloalkenyl, Cs-Cs-cycloalkyl, OR', NR' R, S(O)d-2R', Si(R')3, C(=O)R', Ce-Cw-aryl, C7-Ci4-aralkyl and Cs-Cw-heterocyclyl; R6 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2Ce-alkenyl, C2-Ce-alkyl, Ci-Ce-haloalkyl, C2-Ce-haloalkenyl, Ci-Cecycloalkyl and C(= O)R8; R7 is selected from the group consisting of Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, NR5R6, Ce-Cw-aryl , Cz-Ci4-aralkyl and Cs-Cw-heterocyclyl; wherein each aliphatic group may be optionally substituted with one or more groups of R7a and the cyclic groups of R7 may be optionally substituted with one or more groups of R7b; npfrCLn / Lznz / e / YiAi R7ase is selected from the group consisting of halogen, cyano, CiCe-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Cs-haloalkyl, Cs-Cscycloalkyl, OR', NR'R, S(0) o-2ñ', C(=O)R', Ce-Cio-aryl, C7-Ci4-aralkyl and Cs-Cio-heterocyclyl; R7b is selected from the group consisting of halogen, cyano, CiCe-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6haloalkenyl, Cs-Cs-cycloalkyl, OR', NR' R, S(0)o-2ñ', C(=O)R', C6-C10aryl, Cz-Cu-aralkyl and Ca-Cio-heterocyclyl; R8 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2Ce-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cscycloalkyl, OR4, NR5R6, N=S (O)q-i(R9)2, Ce-Cio-aryl, C7-Ci4-aralkyl and C3-C10heterocyclyl; wherein each aliphatic group may be optionally substituted with one or more groups of R8a and the cyclic groups of R8 may be optionally substituted with one or more groups of R8b; R8ase is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cscycloalkyl, OR', NR'R, S(0) o-2R', C(=O)R', Ce-Cio-aryl, C7-Ci4-aralkyl and Cs-Cio-heterocyclyl; R8b is selected from the group consisting of halogen, cyano, C1Ce-alkyl, Cp-Cs-alkenyl, Cp-Ce-alkynyl, Ci-Ce-haloalkyl, C2-C6haloalkenyl, Cs-Cs-cycloalkyl, OR', NR' R, S(0)o-2R', C(=O)R', Ce-Cioaryl, C7-Ci4-aralkyl and Cs-Cio-heterocyclyl; R9 is selected from the group consisting of Ci-Ce-alkyl, C2-C6alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl and C(=O)R8; R10 is selected from the group consisting of hydrogen, cyano, Ci-Csalkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cs-haloalkenyl, Cs-Cs-cycloalkyl, Si(R ')3, S(O)0-2R7and C(=O)R8; R' is selected from the group consisting of halogen, cyano, R, OR, N(R)2, S(0)o-2R, C(=O)R, C(=O)OR and C(= O)N(R)2R8; npfrCLn / Lznz / e / YiAi R is selected from the group consisting of hydrogen, Ci-Cealkyl, Cz-Ce-alkenyl, Cz-Ce-alkynyl, Ci-Ce-haloalkyl and Cs-Cscycloalkyl; wherein each may be optionally substituted with halogen; each group of R1a R11, R2a, R2b, R2ab, R3a, R3b, R3ab, R3c, R4a, R4b, R5a, R5b, R7a, R7b, R8a and R8b may be optionally replaced by one or more groups selected from the group consisting of halogen, cyano, R', OR', SR', N(R')2, COOR'and CON(R')2; m is an integer that ranges from 0 to 2; or their agrochemically acceptable salts, structural isomers / isomers, stereoisomers, diastereoisomers, enantiomers, tautomers, polymorphs, metal complexes or N-oxides. In another embodiment, the compound of Formula (I) is represented by the compound of Formula (IA); npfrCLn / Lznz / e / YiAi Formula (AI) In yet another embodiment, the compound of Formula (I) is represented by the compound of Formula (IB); Formula (IB) In one embodiment, Q is selected from the group consisting of the Formulas Qi to Qw: Q1 02 Q3 Q5 npfrCLn / Lznz / e / viAi Q6 Q8# Q9 Q10 in which, Gi, G2, G4 and Gs independently represent N or CR3; Gs is NR6, O or S; Z is O or S; and n is an integer that varies from 0 to 4. In a preferred embodiment, Q is selected from the group consisting of Q1aaQ10b: Q4a Q4b Q1e Q5a Q5b Q7a Q9b Q6b EITHER Q10a EITHER QlOb in which # indicates the point of attachment to the D ring, R6 is selected from the group consisting of hydrogen, Ci-Ce-alkyl and cyclic Cs-w-alkyl; wherein each group of R6 is optionally substituted by one or more halogens and n is an integer ranging from 0 to 4. In one embodiment, the present invention provides a compound of Formula (I), wherein at least one nitrogen is present in the DE fused 5-ring system. npfrCLn / Lznz / e / YiAi In another embodiment, the fused ring system DE is selected from the group consisting of DE-1 to DE-15: in which # indicates the point of attachment to the Q ring and · indicates the point of attachment to the S(Y)mR1-group. In a preferred embodiment, the present invention provides a compound of Formula (I) wherein, Q is selected from Q1 a, Q1 b, Q1 c, Q1 h, Q2b, Q3a, Q5b, Q5d, Q6a Q6b, Q9a, Q9b Q7a or Q8a; Q1b Q7a Q8a Q9a npirCLn / Lznz / e / YiAi where # indicates the attachment point to the D ring; R3 is selected from the group consisting of halogen, cyano, Ci-Cealkyl, Ci-Ce-haloalkyl, Cs-Cs-cycloalkyl and S(Y)o-2R7; R6 is selected from the group consisting of hydrogen, Ci-Cs-alkyl and Cs-Cio-cycloalkyl; R7 is selected from the group consisting of Ci-Ce-alkyl, C2-C6alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl; The fused rings DE are selected from the group consisting of in which # indicates the point of attachment to the Q ring and · indicates the point of attachment to the -S(Y)mR1 group; R2 is selected from the group consisting of halogen, cyano, Ci-Csalkyl, Ci-Ce-haloalkyl, Cs-Cs-cycloalkyl, Ce-Cs-aryl, Cz-Cg-aralkyl and Cs-Ce15 heterocyclyl; wherein each aliphatic group may be optionally substituted with one or more groups of R2a and the cyclic groups of R2 may be optionally substituted with one or more groups of R2b; m is an integer that ranges from 0 to 2; n is an integer ranging from 0 to 4; R11 is selected from the group consisting of halogen, cyano, Ci-Cealkyl, Ci-Ce-haloalkyl, Cs-Cs-cycloalkyl, OR4, NR5R6, Ce-Cio-aryl, C7-C14aralkyl and Cs-Cio-heterocyclyl; wherein each aliphatic group may be optionally substituted with one or more groups of R11a and the cyclic groups of R11 may be optionally substituted with one or more groups of R11b. In a preferred embodiment, the compound of Formula I is selected from 2-(1-(3,5-dichlorophenyl)-2-(ethylsulfonyl)indolyzin-3-lo) -3-methyl-6(trifluoromethyl)-3H-imidazole[4,5-b]pyridine; 2-(2-(ethylsulfonyl)imidazole[1,2a]pyrdina-3-ílo)-3-methyl-6-(thfluoromethyl)-3H-ímídazole[4 ,5-b]p¡r¡d¡na; 6-(1bromo-2-(ethylsulfonyl)indolizin-3-yl)-7-methyl-3-(trifluoromethyl)-7H-midazol[4,5c]pyridazine; 2-(2-(ethylsulfonyl)imidazole[1,2-a]pyridine-3-yl)-5(trifluoromethyl)benzo[d]oxazole; 2-(2-(ethylsulfonyl)-7-(trifluoromethyl)indolizin-3yl)-3-methyl-6-(trifluoromethyl)-3H-midazole [4,5-b]pyridine; 2-(8-(3,5dichlorophen¡lo)-2-(ethylsulfon¡lo)indol¡zín-3-¡lo)-3-methyl-6-(thfluoromethyl)- 3Himidazol[4,5-b]pyridine; 2-(1-(3,5-dichlorophenyl)-2-(ethylsulfonyl)-7(tnfluoromethyl)indolyzin-3-yl)-3-methyl-6- (trifluoromethyl)-3H-midazol[4,5b]pyridine; 2-(6-(3,5-dichlorophenyl)-2-(ethylsulfonyl)indolizin-3-yl)-3-methyl-6(trifluoromethyl)-3H-imidazole [4,5-b]pindina; 2-(2-(ethylthio)-5,7-dimethylpyrazol[1,5a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)-3H -midazol[4,5-b]pyridine; 2-(2(ethylsulfonyl)-5,7-dimethylpyrazole[1,5-a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl )3H-imidazole[4,5-b]pyridine; 2-(2-(ethylthio)-5,7-dimethylpyrazol[1,5-a]pyrimidine-3-yl)3-methyl-6-(trifluoromethyl)-3H-m dazolo[4,5-c]pyridine; 2-(2-(ethylsulfonyl)-5,7dimethylpyrazole[1,5-a]pyrimidena-3-lo)-3-methyl-6-(trifluoromethyl)-3H -imidazole[4,5c]pyridine; 2-(2-(ethylthio)-5,7-dimethylpyrazol[1,5-a]pyrimidine-3-yl)-5((trifluoromethyl)thio)benzo[d] oxazole; 2-(2-(ethylthio)pyrazol[1,5-a]pyrimidina-3-yl)-3methyl-6-(trifluoromethyl)-3H-midazole [4,5-b]p¡r¡dina; 2-(2-(ethylsulfonyl)-5,7dimethylpyrazol[1,5-a]pyrimidina-3-yl)-5-((trifluoromethyl)sulfonyl)benzo[d ]oxazole; 2-(2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)-3Hymidazole[4,5-b ]p¡r¡dina; 2-(2-(Ethylthio)pyrazol[1,5-a]pyrimidine-3-yl)-5((trifluoromethyl)thio)benzo[d]oxazole; 2-(2-(ethylsulfonyl)pyrazole[1,5-a]pyrimidina-3ílo)-5-((trifluoromethyl)sulfonílo)benzo[d]oxazole; 2-(2-(ethylthio)-7-(4fluorophenyl)pyrazole[1,5-a]pyrimidina-3-lo)-3-methyl-6-(trifluoromethyl )-3Hímidazol[4,5-b]pyridine; 2-(2-(ethylthio)-7-(4-fluorophenyl)pyrazol[1,5-a]pyrimidine-3 npfrCLn / Lznz / e / YiAi yl)-3-methyl-6-( trifluoromethyl)-3H-imidazole[4,5-c]pyridine; 2-(2-(ethylsulfonyl)-7(4-fluorophenyl)pyrazole[1,5-a]pyrimídina-3-ílo)-3-methyl-6-(trifluoromethyl)-3Hímidazole[4 ,5-c]pyridine; 2-(2-(ethylthio)pyrazol[1,5-a]pyrimidine-3-ílo)-3-methyl-6(trifluoromethyl)-3H-imídazole[4,5 -c]pyridine; 2-(2-(ethylsulfonyl)pyrazole[1,5a]pyrithidine-3-yl)-3-methyl-6-(trifluoromethyl)-3H-midazole[4,5 -c]p¡r¡d¡na; 2-(7(3,5-dichlorophenyl)-2-(Ethylthio)pyrazol[1,5-a]pyrimidine-3-yl)-3-methyl-6 (trifluoromethyl)-3H-imidazole[4,5-c]pyridine; 2-(2-(ethylsulfonyl)-7-(4fluorophenyl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl-6-(trifluoromethyl) -3H¡midazol[4,5-b]pyridine; 2-(7-(3,5-dichlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5a]pyrimidin-3-yl)-3-methyl-6-( trifluoromethyl)-3H-midazol[4,5-b]pindine; 2-(2(ethylthio)-7-(4-(trifluoromethoxy)phenyl)pyrazol[1,5-a]pyrimidena-3-yl)-3- methyl-6(trifluoromethyl)-3H-imidazole[4,5-b]pyridine; 2-(2-(Ethylthio)-7-(4(trifluoromethoxy)phenyl)pyrazol[1,5-a]pyrmidine-3-yl)-3-methyl 6-(tnfluoromethyl)3H-imidazole[4,5-c]pyridine; 2-(2-(ethylsulfonyl)-7-(4(trifluoromethoxy)phenyl)pyrazol[1,5-a]pyrimidina-3-yl)-3-methyl 6-(trifluoromethyl)3H-imidazole[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-7-(4(trifluoromethoxy)phenyl)pyrazol[1,5-a]pyrmidina-3-lo)-3-methyl lo-6-(trifluoromethyl)3H-imidazole[4,5-c]pyridine; 2-(2-(ethylthio)-7-(4-(trifluoromethoxy¡)phenyl)p¡razol[1,5a]pyryrTidine-3-¡lo)-5-((trifluoromethyl)t¡ o)benzo[d]oxazole; 2-(2-(ethylsulfonyl)-7-(4(trifluoromethoxy¡)phenyl)pyrazole[1,5-a]pyrimidina-3-¡lo)-5((trifluoromethyl)sulfonyl) benzo[d]oxazole; 2-(2-(ethylthio)-7-(4fluorophenyl)pyrazole[1,5-a]pyrimidena-3-yl)-5-((trifluoromethyl)thio)benzo[d ]oxazole; 2-(2-(ethylsulfonyl)-7-(4-fluorophenyl)pyrazol[1,5-a]pyrimidine-3-yl)-5((trifluoromethyl)sulfonyl)benzo[d]oxazole; 2-(7-(4-chlorophenyl)-2-(ethylthio)pyrazol[1,5a]pyrimidine-3-yl)-3-methyl-6-(trifluoromet ¡lo)-3H-¡m¡dazol[4,5-c]pyr¡dina; 2-(7-(4chlorophenyl)-2-(Ethylthio)pyrazol[1,5-a]pyramidane-3-yl)-3-methyl-6-(tr fluoromethyl)-3Himidazol[4,5-b]pyridine; 2-(7-(4-chlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidina3-yl)-3-methyl-6-(trifluoromethyl )-3H-¡m¡dazol[4,5-c¡r¡dina; 2-(7-(4-chlorophenyl)-2(ethylthio)pyrazole[1,5-a]pyrimidine-3-yl)-5-((trifluoromethyl)thio)benzo[d]oxazole; 2-(7(4-chlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidine-3-yl)-3-methyl-6(trifluoromethyl)- 3H-midazol[4,5-b]pyridine; 2-(7-(4-chlorophenyl)-2(ethylsulfonyl)pyrazole[1,5-a]pinmidina-3-ílo)-5((trifluoromethyl)sulfonílo)benzo[d]oxazole; 2-(7-(3,5-dichlorophenyl)-2(ethylsulfonyl)pyrazol[1,5-a]pinmadine-3-yl)-3-methyl-6-(tnfluoromethyl )-3HnpfrCLn / Lznz / e / YiAi im¡dazo[4,5-c]pyridine; 2-(7-(3,5-dichlorophenyl)-2-(Ethylthio)pyrazol[1,5-a]pyrimidina3-yl)-5-((trifluoromethyl) thio)benzo[d]oxazole; 2-(7-(3,5-dichlorophenyl)-2(ethylsulfonyl)pyrazol[1,5-a]pinmidine-3-yl)-5((trifluoromethyl)sulfonyl)benzo[d] oxazole; 2-(2-(ethylthio)-5-phenylpyrazole[1,5a]pyrithidine-3-yl)-3-methyl-6-(trifluoromethyl)-3H-midazole[ 4,5-c]p¡r¡d¡na; 2-(2(ethylthio)-5-phenylpyrazole[1,5-a]pyrimidine-3-yl)-3-methyl-6-(tnfluoromethyl)-3Himidazole[ 4,5-c]p¡nd¡na; 2-(2-(ethylsulfonyl)-5-phenylpyrazol[1,5-a]pyrimidine-3-yl)-3methyl-6-(trifluoromethyl)-3H-imidazole [4,5-b]pyridine; 2-(2-(ethylsulfonyl)-5phenylpyrazole[1,5-a]pyrimidina-3-lo)-3-methyl-6-(trifluoromethyl)-3H- mídazo[4,5c]pyridine; 2-(6-chloro-2-(ethylthio)pyrazol[1,5-a]pinmidine-3-yl)-3-methyl-6(tnfluorornetyl)-3H-midazole[ 4,5-b]p¡nd¡na; 2-(2-(ethylthio)-6-phenlprazol[1,5a]pyrmidine-3-lo)-3-methyl-6-(trifluoromethyl)-3H -midazol[4,5-b]pyridine; 2-(6chloro-2-(ethylsulfonyl)pyrazole[1,5-a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)3H-im dazolo[4,5-b]pyridine; 2-(2-(Ethylthio)-5-(4-(trifluoromethoxy)phenyl)pyrazol[1,5a]pyrmidina-3-yl)-3-met lo-6-(trifluoromethyl)-3H-midazol[4,5-c]pyridine; 2-(6chloro-2-(eth¡lt¡o)pyrazole[1,5-a]pyrim¡dina-3-¡lo)-3-methyl-6-(trifluoromethyl )-3Hímidazol[4,5-c]pyridine; 2-(6-chloro-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidina-3-lo)-3methyl-6-(trifluoromethyl)-3H- imidazole[4,5-c]pyridine;2-(2-(ethylsulfonyl)-6phenylpyrazole[1,5-a]pyrmádina-3-ílo)-3-methyl-6-(trifluoromethyl)-3H -midazol[4,5b]pyridine; 2-(2-(ethylthio)-5-(4-(trifluoromethoxy¡)phenyl)pyrazol[1,5-a]pyrimidina-3-lo)3-methyl -6-(trifluoromethyl)-3H-midazol[4,5-b]pine; 2-(2-(ethylsulfonyl)-5-(4(trifluoromethoxy)phenyl)pyrazol[1,5-a]pyrimidina-3-yl)-3-methyl 6-(trifluoromethyl)3H-imidazole[4,5-c]pyridine; 2-(2-(ethylthio)-5-(4-fluorophenyl)pyrazol[1,5-a]pinmidine3-yl)-3-methyl-6-(tnfluorornetyl)- 3H-¡m¡dazol[4,5-b]pindine; 2-(6-(4-chlorophenyl)-2(ethylthio)pyrazole[1,5-a]pyrimidine-3-ílo)-3-methyl-6-(trifluoromethyl)-3H-í midazol[4,5b]pyridine; 2-(2-(ethylsulfonyl)-5-(4-(trifluoromethoxy)phenyl)pyrazol[1,5-a]pyrimidina3-yl)-3-methyl -6-(trifluoromethyl)-3H-midazol[4,5-b]pyridine; 2-(2-(ethylthio)-5-(4fluorophenyl)pyrazole[1,5-a]pyrimidine-3-lo)-3-methyl-6-(trifluoromethyl )-3Hímidazol[4,5-c]pyridine; 2-(2-(ethylsulfonyl)-5-(4-fluorophenyl)pyrazol[1,5a]pyryrthidine-3-yl)-3-methyl-6-(trifluoromethyl)- 3H-¡m¡dazol[4,5-c¡r¡dina; 2-(2(ethylsulfonyl)-5-(4-fluorophenyl)pyrazol[1,5-a]pyrimidina-3-yl)-3-methyl-6(tr ¡fluoromethyl)-3H-im¡dazo[4,5-b]pind¡na; 2-(6-(4-chlorophenyl)-2(ethylsulfonyl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl-6-(trifluoromethyl)-3H midazol[4,5-b]pyridine; 2-(2-(ethylthio)-6-phenylpyrazol[1,5-a]pyrimidine-3-lo)-3-methylonpfrCLn / Lznz / e / YiAi; 6-(trifluoromethyl)-3H-midazol[4,5-c]pyridine; 2-(5-(3,5-dichlorophenyl)-2(ethylthio)pyrazole[1,5-a]pyrimidine-3-ílo)-3-methyl-6-(trifluoromethyl) -3H-¡m¡dazol[4,5b]pyridine; 2-(2-(ethylsulfonyl)-6-phenylpyrazol[1,5-a]pyrimidine-3-yl)-3-methyl-6(trifluoromethyl)-3H-im dazolo[4,5-c]pyridine; 2-(5-(3,5-dichlorophenyl)-2(ethylsulfonyl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl-6-(trifluoromethyl) -3Hímidazol[4,5-b]pindin; 2-(5-(3,5-dichlorophenyl)-2-(Eth¡lt¡o)pyrazol[1,5-a]pyrimidina3-¡lo)-3-methyl-6- (trifluoromethyl)-3H-midazol[4,5-c]pyridine; 2-(5-(3,5dichlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidine-3-yl)-3-methyl-6 (tnfluoromethyl)-3H-imidazole[4,5-c]pyridine; 2-(6-bromo-2-(ethylthio)pyrazol[1,5a]pyrmidin-3-yl)-3-methyl-6-(trifluoromethyl)-3H -midazol[4,5-b]pindine; 2-(6bromo-2-(ethylsulfonílo)pyrazol[1,5-a]pyrimína-3-ílo)-3-methyl-6-(trifluoromethyl )3H-imidazole[4,5-b]pyridine; 2-(6-(3,5-dichlorophenyl)-2-(eth¡lt¡o)pyrazol[1,5a]pyrmidina-3-¡lo)-3-met¡lo- 6-(trifluoromethyl)-3H-¡m¡dazo[4,5-b]pind¡na; 2-(6-(4chlorophenyl)-2-(ethylthio)pyrazol[1,5-a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)- 3Himidazol[4,5-c]pyridine; 2-(6-(4-chlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidine3-yl)-3-methyl-6-(trifluoromet ¡lo)-3H-im¡dazo[4,5-c]pyr¡dina; 2-(2-(ethylthio)-5-(4(1,1,2,2-tetrafluoroethoxy)phenyl)pyrazol[1,5-a]pyrimádina-3-yl)-3 -methyl-6(trifluoromethyl)-3H-imidazole[4,5-c]pyridine; 2-(6-(3,5-dichlorophenyl)-2(ethylsulfonyl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl-6-(trifluoromethyl) -3Hímidazol[4,5-b]pindin; 2-(2-(ethylthio)-5-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazole[1,5-a]pyrimidina-3-lo)-3-met lo-6-(trifluoromethyl)3H-imidazole[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-5-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazol[1,5-a]pyrimidena-3-ilo)-3 -methyl-6-(trifluoromethyl)3H-imidazole[4,5-c]pyridine; 2-(2-(ethylsulfonyl)-5-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazole[1,5-a]pyrimídina-3-ílo)-3-met lo-6-(trifluoromethyl)3H-imidazole[4,5-b]pyrdina; 2-(6-(3,5-dichlorophenyl)-2-(ethyllitho)pyrazol[1,5a]pyrimidina-3-yl)-3-methyl-6 -(trifluoromethyl)-3H-midazol[4,5-c]pyridine; 2-(6(3,5-dichlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidine-3-yl)-3-methyl-6 (trifluoromethyl)-3H-imidazole[4,5-c]pyridine; 2-(2-(ethylthio)-6-(4(trifluoromethoxy)phenyl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl 6-(trifluoromethyl)3H-imidazole[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-6-(4(trifluoromethoxy)phenyl)pyrazol[1,5-a]pyrimidina-3-yl)-3-methyl 6-(trifluoromethyl)3H-imidazole[4,5-b]pyridine; 2-(5-(4-chlorophenyl)-2-(ethylthio)pyrazol[1,5-a]pyrimidine-3yl)-3-methyl-6-(trifluoromet lo)-3H-¡m¡dazol[4,5-b]pyr¡dina; 2-(5-(4-chlorophenyl)-2 npfrCLn / Lznz / e / YiAi (Ethylthio)pyrazol[1,5-a]pyrimidina-3-lo)-3-met lo-6-(trifluoromethyl)-3H-midazol[4,5c]pyridine; 2-(2-(Ethylthio)-6-(4-(trifluoromethoxy)phenyl)pyrazol[1,5-a]pyrimidine-3-yl)3-methyl- 6-(trifluoromethyl)-3H-midazol[4,5-c]pyridine; 2-(2-(ethylthio)-7-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazole[1,5-a]pyrimidina-3-lo)-3-met lo-6-(trifluoromethyl)3H-imidazole[4,5-b]pyrdina; 2-(5-(4-chlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5a]pyrimidina-3-¡lo)-3-methyl-6-(tr fluoromethyl)-3H-midazol[4,5-b]pyridine; 2-(5-(4chlorophenyl)-2-(ethylsulfonyl)pyrazole[1,5-a]pyrimidine-3-yl)-3-methyl-6(trifluoromethyl)-3H-imidazole [4,5-c]pyridine; 2-(2-(ethylsulfonyl)-7-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazol[1,5-a]pyrimidina-3-ilo)-3 -methyl-6-(trifluoromethyl)3H-imidazole[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-7-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazole[1,5-a]pyrimídina-3-ílo)-3-met lo-6-(trifluoromethyl)3H-imidazole[4,5-c]pyridine; 3-(7-(3,5-dichlorophenyl)-2-(Ethylthio)pyrazole[1,5a]pyrimidine-3-yl)-7-(trifluoromethyl )-[1,2,4]triazolo[4,3-a]pyridine; 2-(2-(ethylthio)-7(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyrazole[1,5-a]pyrimidin-3-yl)-3-methyl -6(trifluoromethyl)-3H-imidazole[4,5-c]pyridine; 3-(7-(3,5-dichlorophenyl)-2(ethylsulfonyl)pyrazol[1,5-a]pyrimidina-3-yl)-7-(trifluoromethyl )-[1,2,4]triazolo[4,3a]pyridine; 2-(2-(ethylthio)-6-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyrazole[1,5a]pyrimidin-3-yl)-3-methyl-6 -(trifluoromethyl)-3H-midazol[4,5-b]pyridine; 2-(2(ethylsulfonyl)-6-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyrazole[1,5-a]pyrimidine-3-yl)-3methyl-6- (trifluoromethyl)-3H-midazol[4,5-b]pyridine; 2-(7-(3-chlorophenyl)-2(Ethylthio)pyrazole[1,5-a]pyrimidina-3-lo)-3-methyl-6-(trifluorometh) lo)-3H-¡m¡dazol[4,5b]py ridine; 2-(7-(3,5-difluorophenyl)-2-(Eth¡lt¡o)pyrazol[1,5-a]pyrimidina-3-yl)-3-methyl6 -(trifluoromethyl)-3H-midazol[4,5-b]pyridine;2-(7-(3-chlorophenyl)-2(ethylsulfonyl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl-6-(trifluoromethyl)-3Himidazole [4,5-b]p¡r¡d¡na; 2-(2-(ethylsulfonyl)-6-(4-(trifluoromethoxy)phenyl)pyrazol[1,5a]pyramidine-3-yl)-3-methyl-6 -(trifluoromethyl)-3H-midazol[4,5-c]pyridine; 2-(7(3,5-difluorophenyl)-2-(ethylsulfonyl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl-6(tr fluoromethyl)-3H-midazol[4,5-b]pyridine; 2-(7-(3-chloro-5-fluorophenyl)-2(ethylthio)pyrazole[1,5-a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)-3H -midazol[4,5b]pyridine; 2-(7-(3-chloro-5-fluorophenyl)-2-(ethylsulfonyl)pyrazole[1,5-a]pyrimidina-3¡lo)-3-methyl-6-( trifluoromethyl)-3H-midazol[4,5-b]pyrdina; 2-(7-(3,4dichlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidina-3-yl)-3-methyl-6 (trifluoromethyl)-3H-imidazole[4,5-b]pyridine; 7-(3,5-dichlorophenyl)-2-(ethylthio)-3-(1 methyl-5-(trifluoromethyl)-1 H-benzo[d]imidazole-2-lo)py razole[1,5-a]pyrimidine; 2 npfrCLn / Lznz / e / YiAi (ethylthio)-3-(1 -methyl-5-(trifluoromethyl)-1 H-benzo[d]midazol-2-yl)pyrazole[1,5a]pyrim dyne; 7-(3,5-dichlorophenyl)-2-(ethylsulfonyl)-3-(1-methyl-5-(trifluoromethyl)1 H-benzo[d]imidazole-2-yl) pyrazol[1,5-a]pyrimidine; 2-(ethylsulfonyl)-3-(1-methyl-5(trifluoromethyl)-1 H-benzo[d]imidazol-2-ilo)pyrazole[1,5-a]pinmidine; 2-(2(ethylsulfonyl)-6-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyrazole[1,5-a]pyrimidina-3-yl)-3methyl-6- (trifluoromethyl)-3H-midazol[4,5-c]pyridine; 3-(7-(3,5-dichlorophenyl)-2(ethylthio)pyrazole[1,5-a]pinmidine-3-yl)-6-(trifluoromethyl)-[1,2,4] triazolo[4,3ajpyridine; 3-(7-(3,5-dichlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidine-3-yl)-6(trifluoromethyl)-[1, 2,4]triazolo[4,3-a]pyridine; 2-(7-(2,3-dichlorophenyl)-2(ethylthio)pyrazole[1,5-a]pyrimidin-3-yl)-3-methyl-6-(trifluoromethyl)- 3H-¡m¡dazol[4,5b]pyridine; 2-(2-(ethylthio)-7-phenylpyrazol[1,5-a]pyramidane-3-yl)-3-methyl-6(trifluoromethyl)-3H -imidazole[4,5-b]pyridine; 2-(7-(2,3-dichlorophenyl)-2(ethylsulfonyl)pyrazole[1,5-a]pinm¡dina-3-yl)-3-methyl-6-(tnfluoromethyl)- 3Hímidazol[4,5-b]pindina; 2-(2-(ethylsulfonyl)-7-phenylpyrazol[1,5-a]pyrimidine-3-yl)-3methyl-6-(trifluoromethyl)-3H-imidazole [4,5-b]pyridine; 2-(7-(4-chloro-3-fluorophenyl)2-(Ethylthio)pyrazole[1,5-a]pyrimidena-3-lo)-3-methyl -6-(trifluoromethyl)-3Himidazol[4,5-b]pindina; 2-(7-(3,5-dichlorophenyl)-2-(Eth¡lt¡o)pyrazol[1,5-a]pyrimidina3-ílo)-3-methyl-6-(tr fluoromethyl)-3H-midazol[4,5-b]pyridine; 2-(7-(4-chloro-3fluorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidina-3-yl)-3-rethylyl- 6(trifluoromethyl)-3H-midazol[4,5-b]pindine; 2-(7-(4-chloro-3-fluorophenyl)-2(ethylthio)pyrazole[1,5-a]p¡nmidina-3-ílo)-3-methyl-6-(tr¡ fluoromethyl)-3H-midazol[4,5c]pyridine; 2-(7-(2,4-dichlorophenyl)-2-(Et¡lt¡o)pyrazol[1,5-a]pyrimidina-3-¡lo)-3methyl-6- (tnfluoromethyl)-3H-imidazole[4,5-b]pyridine; 2-(7-(2,4-dichlorophenyl)-2(ethylsulfonyl)pyrazole[1,5-a]pinm¡dina-3-yl)-3-methyl-6-(tnfluoromethyl)-3H¡ midazol[4,5-b]pindina; 2-(7-(2,4-dichlorophenyl)-2-(Eth¡lt¡o)pyrazol[1,5-a]pyrimidina3-ílo)-3-methyl-6-(tr fluoromethyl)-3H-iTiidazole[4,5-c]pyridine; 2-(7-(3-chloro-5fluorophenyl)-2-(ethylthio)pyrazole[1,5-a]pyrimidena-3-yl)-3-methyl-6- (trifluoromethyl)3H-imidazole[4,5-c]pyridine; 2-(7-(3-chloro-5-fluorophenyl)-2(ethylsulfonyl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl-6-(trifluoromethyl) -3H¡m¡dazol[4,5-c]pyrádine; 2-(7-(3,5-bis(trifluoromethyl)phenyl)-2-(ethylthio)pyrazol[1,5a]pyrmidine-3-lo )-3-methyl-6-(trifluoromethyl)-3H-midazol[4,5-b]pine; 2-(2(ethylthio)-7-(3-(trifluoromethyl)phenyl)pyrazol[1,5-a]pinmidin-3-yl)-3-methyl-6 (trifluoromethyl)-3H-imidazole[4,5-b]pyridine; 2-(2-(ethylthio)-7-(3fluorophenyl)pyrazole[1,5-a]p¡nm¡na-3-yl)-3-methyl-6-(trifluoromethyl) -3HnpfrCLn / Lznz / e / YiAi ¡midazol[4,5-b]pyr¡dina; 2-(7-(3,5-bis(trifluoromethyl)phenyl)-2(ethylsulfonyl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl-6 -(trifluoromethyl)-3Himidazol[4,5-b]pine; 2-(2-(ethylsulfonyl)-7-(3-(trifluoromethyl)phenyl)pyrazol[1,5a]pyrmidin-3-yl)-3-methyl-6 -(trifluoromethyl)-3H-midazol[4,5-b]pyridine; 2-(2(ethylsulfonyl)-7-(3-fluorophenyl)pyrazol[1,5-a]pyrimidine-3-yl)-3-methyl-6(trifluoromethyl)- 3H-im¡dazo[4,5-b]pyr¡dina; 2-(2-(ethylthio)-7-methylpyrazol[1,5a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)-3H-m dazolo[4,5-b]pyridine; 2-(2(ethylthio)-7-(3-fluorophenyl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl-6(tnfluoromethyl) -3H-imidazole[4,5-c]pyridine; 2-(2-(ethylsulfonyl)-7-methyllprazole[1,5a]pyrmidin-3-yl)-3-methyl-6-(trifluoromethyl) -3H-midazol[4,5-b]pyridine;2-(2(ethylthio)-7-(3-(trifluoromethyl)phenyl)pyrazol[1,5-a]pyrimidine-3-yl)-3-methyl -6(tnfluoromethyl)-3H-imidazole[4,5-c]pyridine; (7-(3,5-dichlorophenyl)-3-(3-methyl-6(trifluoromethyl)-3H-imidazole[4,5-b]pyridine-2-! lo)pyrazol[1,5-a]pyrimidina-2ílo)(ethyl)(imíno)-6-sulfanone; 2-(2-(ethylsulfonyl)-7-(3(trifluoromethyl)phenyl)pyrazol[1,5-a]pyrimidina-3-yl)-3-methyl 6-(trifluoromethyl)3H-imidazole[4,5-c]pyridine; 2-(2-(ethylsulfonyl)-7-(3-fluorophenyl)pyrazol[1,5a]pyrmidina-3-yl)-3-methyl-6- (trifluoromethyl)-3H-¡m¡dazo[4,5-c]pyr¡dina; 2-(2(ethyl¡t¡o)-7-met¡lp¡razole[1,5-a]p¡rim¡dina-3-¡lo)-3-met¡lp¡razol-6-(tr fluoromethyl)-3Hímídazo[4,5-c]pyridine; 2-(7-(3-chloro-4-fluorophenyl)-2-(ethylthio)pyrazol[1,5a]pyrimidina-3-lo)-3-met lo-6-(trifluoromethyl)-3H-midazol[4,5-b]pine; 2-(2(ethylthio)-5,7-bis(trifluoromethyl)pyrazol[1,5-a]pyrimidina-3-yl)-3-methyl-6 (trifluoromethyl)-3H-imidazole[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-5,7bis(trifluoromethyl)pyrazole[1,5-a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)-3Hymidazole[4 ,5-b]pind¡na; 2-(ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-midazol[4,5b]pyridine-2-lo)pyrazol[1,5 -a]p¡rim¡d¡na-7(4H)-one; 2-(7-bromo-2(ethylthio)pyrazol[1,5-a]pyrmidine-3-lo)-3-methyl-6-(trifluoromethyl)-3H -¡m¡dazo[4,5b]pyridine; 2-(ethylsulfonyl)-N-methyl-3-(7-(trifluoromethyl)-[1,2,4]triazolo[1,5c]pyrimidena-2-yl) pyrazole[1,5-a]pyrimidine-7-amine; 6-(8-(4-chloro-3-fluorophenyl)-2(ethylsulfonyl)indolizin-3-yl)-7-methyl-3-(trifluoromethyl)-7H-midazole[4, 5c]pyridazine; 2-(2-(ethylsulfonyl)-7-(5-methyl-3-(trifluoromethyl)-1 H-pyrazol-1yl)pyrazole[1,5-a]pyrmidine-3- ¡lo)-3-methyl¡-6-(trifluoromethyl)-3H-¡midazol[4,5b]pyridine; 2-(ethylthio)-N-methyl-3-(3-methyl-6-(trifluoromethyl)-3H-midazol[4,5b]pyridine-2-yl)pyrazole[ 1,5-a]pyrim¡dina-7-am¡na; 2-(2-(ethylsulfonyl)-7-(3fluorophenoxy)pyrazole[1,5-a]p¡nm¡dina-3-¡lo)-3-methyl-6-(trifluoromethyl)- 3HnpfrCLn / Lznz / e / YiAi ¡midazol[4,5-b]p¡nd¡na; 6-(8-(4-chloro-3-fluorophenyl)-2-(ethylsulfonyl)midazol[1,2a]pyridine-3-methyl)-7-methyl -3-(trifluoromethyl)-7H-¡m¡dazo[4,5-c]pyrádaz¡ne; 2-(6(3,5-dichlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidine-3-yl)-6(trifluoromethyl)m dazolo[1,2-a]pyrazine; 4-(2-(ethylsulfonyl)-3-(7-methyl-3(trifluoromethyl)-7H-imidazole[4,5-c]pyridazine-6-yl)andol z(n-8-yl)-2fluorobenzonitrile; 2-(8-(cyclopropylmethyl)-2-(ethylsulfonyl)imidazole[1,2-a]pyridine3-yl)-3-methyl-6-(tnfluoromet ¡lo)-3H-¡m¡dazole[4,5-b]pyridine; 2-(7-(4-chloro-1Hpyrazol-1-yl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyramidane-3-yl)-3 -methyl-6(trifluoromethyl)-3H-imidazole[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-7-(5-methyl-1 H1,2,4-triazol-1 -i lo)pyrazole[1,5-a]pyrimidine-3-ilo)- 3-methyl-6-(trifluoromethyl)-3Hímidazol[4,5-b]pine; 2-(2-(ethylsulfonyl)-7-(1 -methyl-1 H-pyrazol-5yl)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl -6-(trifluoromethyl)-3H-midazol[4,5b]pyridine; 2-(2-(ethylsulfonyl)-7-(1-methyl-3-(trifluoromethyl)-1 H-pyrazol-5yl)pyrazole[1,5-a]pyramidine-3-yl )-3-methyl-6-(trifluoromethyl)-3H-midazol[4,5b]pyridine; 2-(7-cyclopropyl-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidine-3-yl)-6(trifluoromethyl)-[1,2,4] triazolo[1,5-a]pyrazine; 2-(2-(ethylsulfonyl)-7-(1 -methyl-3(trifluoromethyl)-l H-pyrazol-5-ílo)pyrazol[1,5-a]pyrimádina-3 -ílo)-7(trifluoromethyl)ímidazol[1,2-c]pínmidina; 4-(2-(ethylsulfonyl)-3-(7(trifluoromethyl)midazol[1,2-a]pyridine-2-yl)pyrazol[1,5-a]pyrimidine-7yl) morpholine; 2-(7-(4-chloro-3-fluorophenyl)-2-(ethylsulfonyl)pyrazole[1,5-a]pyrimidina3-yl)-7-(trifluoromethyl)-[1,2 ,4]triazolo[1,5-c]pyrimide; 2-(2-(ethylsulfonyl)-7-(1 H1,2,4-triazol-1 -i lo) pyrazole[ 1,5-a]pyrimidin-3-yl)-7-(tnfluoromet¡ lo)[1,2,4]triazolo[1,5-c]pyrimidine; 2-(2-(ethylsulfonyl)-5,7bis(trifluoromethyl)pyrazole[1,5-a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)-3Himidazole [4,5-b]pyridina; 6-(1-bromo-2-(ethylsulfonyl)-8-methylindolízina-3-ílo)-7methyl-3-(trifluoromethyl)-7H-imidazole[4,5-c ]p¡r¡dazine; 6-(8-bromo-2(ethylsulfonyl)indolizin-3-yl)-3-(difluoromethyl)-7-methyl-7H-midazole[4.5c ]pyridazine; 2-(2-(ethylsulfonyl)-7-methoxypyrazolo[1,5-a]pyrimidine-3-yl)-3-methyl6-(trifluoromethyl)-3H-m dazolo[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-7(methylthio)pyrazol[1,5-a]pinmídine-3-ílo)-3-methyl-6-(tnfluoromethyl)-3Hímidazole[4 ,5-b]p¡r¡d¡na; 2-(ethylsulfonyl)-3-(3-methyl-6-(trifluoromethyl)-3Hímidazol[4,5-b]pindin-2-yl)pyrazole [1,5-a]pyrimidine-7(4H)-thione; 2-(2(ethylsulfonyl)-7-(1,1,2,2-tetrafluoroethoxy)pyrazole[1,5-a]p¡nm¡na-3-ílo)-3-methyl-6(tr fluoromethyl)-3H-midazol[4,5-b]pyridine;2-(7-ethoxy-2-(ethylsulfonyl)pyrazol[1,5npfrCln / Lznz / e / YiAi; a]pyrámidina-3-ílo)-6-(trifluoromethyl)ímídazo[1,2-a]pyrazine; diethyl((2(ethylsulfonílo)-3-(6-(trifluoromethyl)ímídazo[1,2-a]pyrazine-2-yl)pyrazol[1,5a]pyrámide ¡na-7-¡lo)im¡no)-A6-sulfanone; 2-(ethylsulfon¡lo)-N,N-dimethyl-3-(3-methyl-6(trifluoromethyl)-3H-im¡dazole[4,5-b]pyrid¡ na-2-yl)midazol[1,2-a]pyridine-8-amine; 6-(2-(ethylsulfonyl)-7-(5-(trifluoromethyl)pyridine-2-lo)pyrazol[1,5-a]pyrimidine-3 lo)-7-methyl-3-(trifluoromethyl)-7H-ímídazo[4,5-c]pyrádazíne; 2-(7-(4-chloro-3fluorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidena-3-yl)-3,5-dimethyl- 6(trifluoromethyl)-3,5-dihydro-4H-midazol[4,5-c]pyridine-4-one; 2-(2-(ethylsulfonyl)7-(3-(trifluoromethyl)-1 H-1,2,4-triazol-1 -yl)pyrazole[1,5-a]pyrimidina-3-yl) -3,5dimethyl-6-(trifluoromethyl)-3,5-dihydro-4H-midazol[4,5-c]pyridine-4-one; 2-(7-(3chloro-5-fluorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidine-3-yl)-6(trifluoromethyl)-[1,2, 4]triazolo[1,5-a]pyrazine; 2-(7-(3,5-dichlorophenyl)-2(ethylsulfonyl)pyrazole[1,5-a]pyrimidena-3-lo)-7-(thfluoromethyl) dazole[1,2c]pyrimidine; 2-(7-(4-chloro-3-fluorophenyl)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidine3-yl)-6-methyl-7-(trifluoromethyl )-[1,2,4]triazolo[1,5-c]primidine-5(6H)-one; 2-(7(5-chloropyridina-2-ílo)-2-(ethylsulfonyl)pyrazol[1,5-a]pyrimidina-3-ílo)-6( trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyridine; 2-(2-(ethylsulfonyl)-7-(5-methyl-3(trifluoromethyl)-1 H-pyrazol-1-yl)pyrazole[1,5-a]pyrimidine-3-yl )-6-methyl-7(trifluoromethyl)-[1,2,4]triazolo[1,5-c]pyrimidine-5(6H)-one; 2-(2-(ethylsulfonyl)-7(3-(trifluoromethyl)-1 H-1,2,4-triazol-1 -i lo)pyrazole[1,5-a]pyrimidine-3-! lo)-7(trifluoromethyl)-[1,2,4]triazolo[1,5-c]pyrimidine; ethyl(3-(3-methyl-6(trifluoromethyl)-3H-imidazole[4,5-c]pyridine-2-lo)pyrazole[1,5-a]pyr midina-2ilo)(methylimino)-A6-sulfanone. The compounds of the present invention may exist as one or more stereoisomers. The various stereoisomers include enantiomers, diastereomers, atropisomers, and geometric isomers. One skilled in the art will appreciate that a stereoisomer may be more active and / or have beneficial effects when enriched relative to another isomer(s) or when separated from the other isomer(s). Furthermore, the person skilled in the art knows how to selectively separate, enrich and / or prepare said stereoisomers. The compounds of the present invention may be present as a mixture of stereoisomers, individual stereoisomers or as an optically active form. npfrCLn / Lznz / e / YiAi In case the compound of Formula I is cationic or capable of forming a cation, an anion portion of the salt may be organic or inorganic. Alternatively, in case the compound of Formula I is anionic or capable of forming an anion, a cation portion of the salt may be organic or inorganic. Examples of the inorganic anion part of the salt include, but are not limited to, chloride, bromide, iodide, fluoride, sulfate, phosphate, nitrate, nitrite, hydrogen carbonates, and hydrogen sulfate. Examples of organic anions that are part of the salt include, but are not limited to, formate, alkanoates, carbonates, acetates, trifluoroacetate, trichloroacetate, propionate, glycolate, thiocyanate, lactate, succinate, malate, citrates, benzoates, cinnamates, oxalates, alkyl sulfates, alkylsulfonates, arylsulfonates, aryldisulfonates, alkylphosphonates, arylphosphonates, aryldiphosphonates, p-toluenesulfonate and salicylate. Examples of the inorganic cation part of the salt include, but are not limited to, alkali and alkaline earth metals. Examples of organic cationic part of the salt include, but are not limited to, pyridine, methylamine, imidazole, benzimidazole, hitidine, phosphazene, tetramethylammonium, tetrabutylammonium, choline and trimethylamine. The metal ions in metal complexes of the compound of the general Formula (I) are especially the ions of the elements of the second main group, especially calcium and magnesium, of the third and fourth main group, especially aluminum, tin and lead, and also of the first to the eighth transition group, especially chromium, manganese, iron, cobalt, nickel, copper, zinc and others. Particular preference is given to metal ions of the elements of the fourth period and the first to eighth transition groups. Here, metals can be present in the various valences they can assume. In one embodiment, the present invention provides a compound of General Formula (I), its agriculturally acceptable salts, metal complexes, constitutional isomers, stereoisomers, diastereoisomers, enantiomers, chiral isomers, atropisomers, conformers, rotamers, tautomers, optical isomers, polymorphs, geometric isomers, or N-oxides thereof, the composition with the excipient, inert vehicle or any other essential ingredient such as surfactants, additives, solid diluents and liquid diluents. Compounds selected from General Formula (I), (including all stereoisomers, N-oxides and salts thereof), typically exist in more than one form, and General Formula (I) includes all crystalline and non-crystalline forms of the compounds represented by General Formula (I). Non-crystalline forms include embodiments that are solids, such as waxes and gums, as well as embodiments that are liquids, such as solutions and melts. Crystal forms include embodiments that essentially represent a single crystal type and embodiments that represent a mixture of polymorphs (e.g., different crystal types). The term polymorph refers to a particular crystalline form of a chemical compound that can crystallize into different crystalline forms, these forms having different arrangements and / or conformations of the molecules in the crystal lattice. Although polymorphs may have the same chemical composition, they may also differ in composition due to the presence or absence of cocrystallized water or other molecules, which may be weakly or strongly bound in the crystal lattice. Polymorphs can differ in chemical, physical and biological properties, such as crystalline form, density, hardness, color, chemical stability, melting point, hygroscopicity, suspensibility, dissolution rate and biological availability. . One skilled in the art will appreciate that a polymorph of a compound represented by General Formula (I) may exhibit beneficial effects (e.g., suitability for the preparation of useful formulations, improved biological performance) relative to another polymorph or a mixture of polymorphs. of the same compound represented by the general Formula (I). The preparation and isolation of a particular polymorph of a compound represented by General Formula (I) can be achieved by methods known to those skilled in the art, including, for example, crystallization using selected solvents and temperatures. In one embodiment, the present invention provides a process for preparing the compound of Formula (I) or its agriculturally acceptable salts. The compound of Formula (I) can be prepared according to Schemes: 1-23 or in the Examples described herein. The process for preparing the compound of Formula (I), more specifically, compound of Formula (la) or the compound of Formula (Ib) wherein Q is Q1 or Q2 comprises the reaction of the compound of Formula (2 ), with the npfrCLn / Lznz / e / YiAi compound of Formula (3) or (4), where M is O, S, NR' to obtain the compound of Formula (la) and (Ib). The process is summarized in Scheme 1: npfrCLn / Lznz / e / YiAi Outline: 1 wherein, R1, R3, A, G, Gi,G2, Gs,G4, Gs, E, m and n have the meanings described above. The compound of Formulas (3) and (4) are commercially available or can be prepared using methods known or analogously described in US200369257, WO200665703, WO2009131237, WO2010125985, WO2011043404, WO2011040629, WO201208684 8, WO2013018928 and WO201500071 5. In Scheme 1, the carboxylic acid group present in the compound of Formula (2) can be converted to a more reactive functional group, such as acyl halide, mixed anhydride, acyl azide, N-acylbenzotriazoles, active esters, or by an in situ activation by peptide coupling reagents such as Bis(2-oxo-3-oxazolidin¡l) phosphinic chloride (ΒΟΡ-Cl); dicyclohexyl carbodiimide (DCC) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDO), followed by the formation of amide bonds with the compound of Formula (3) in solvents such as dichloromethane, dichloroethane, Ν,Ν-dimethylacetamide, tetrahydrofuran, acetonitrile or a mixture thereof to obtain the compound of Formula (5). Non-nucleophilic organic bases such as triethylamine, ethyldiisopropylamine, pyridine, N-methylpyrrolidine, 1,8 can be used. Diazabicyclo[5.4.0]undec-7-ene. The reaction can be carried out at a temperature ranging between approximately 0aC and 150aC. The compound of Formula (5) can be converted to a compound of Formula (la) by dehydration, following conventional conditions or under microwave conditions, in the presence of an acid catalyst, for example, methanesulfonic acid or para-toluenesulfonic acid, in an inert solvent such as N-methylpyrolidine at a temperature ranging between approximately 25aC and 185aC. Such processes have been previously described in documents WO2009131237, WO2010125985, WO2011043404, WO2011040629, WO2012086848, WO2013018928, WO2015000715 and WO2015121136. Alternatively, the compound of Formula (5) can be converted to a compound of Formula (la) wherein M is oxygen under Mitsunobu conditions, well known to those skilled in the art using di-isopropyl azodicarboxylate or triphenyl phosphine. in an inert solvent, such as diethyl ether or tetrahydrofuran, at a temperature varying between approximately 25aC and 50aC. This process has been previously described in document WO2009131237. Application of the methods of Scheme 1 in the reaction of the compound of Formula (2) with the compound of Formula (4) can lead to the compound of Formula (Ib). A process for the synthesis of the compound of Formula (I) represented by the compound of Formula (le and Id) is described in Scheme 2. The compound of Formula (le) or (Id) can be prepared by reacting the compound of Formula (6) with the compound of Formula (3) or (4) to obtain the compound of Formula (7) or (8). Furthermore, the compound of Formulas (7) and (8) (where X is a halogen, for example, fluorine, chlorine or bromine) can be reacted with a compound of Formula (9) or with a compound of Formula (10), wherein Mi is, for example, sodium or potassium, optionally in the presence of a suitable base, such as alkali metal carbonates, for example, sodium carbonate or potassium carbonate, or alkali metal hydrides such as sodium hydride, or alkali metal hydroxides such as npfrCLn / Lznz / e / YiAi sodium hydroxide and potassium hydroxide, in an inert solvent at temperatures varying between approximately 25eC and 110eC, to obtain the compound of the Formula (le) or (Id). npfrCLn / Lznz / e / YiAi Outline: 2 wherein, R1, R3, A, G, Gi,G2,Gs,G4, Gs, E, m and n have the meanings described above. Alternatively, the above reaction can also be carried out in the presence of a palladium catalyst, such as tris(dibenzyldenacetone)dipalladium(0), in the presence of a ligand, such as xanthos, in an inert solvent, e.g. , toluene or xylene, at temperatures varying between approximately 100eC and 150θO, as described in Tetrahedron, 2005, 61, 5253. The compound of Formula (I), in which Y=O, m=1 (sulfoxide ) and / or m=2 (sulfone), can be obtained by oxidation of the corresponding sulfide compound of Formulas (le) and (Id) while applying appropriate oxidizing agents and conditions well known to those skilled in the art. Oxidizing agents, such as mchloroperoxybenzoic acid (mCPBA), hydrogen peroxide / glacial acetic acid, hydrogen peroxide / trifluoroacetic acid, hydrogen peroxide / potassium permanganate, hydrogen peroxide / p-tulenesulfonylimidazole, urea hydrogen peroxide / acid trifluoroacetic acid, oxone, sodium periodate, sodium hypochlorite and other organic peracids and the like can be used for this. Examples of the solvents used in this reaction include aliphatic halogenated hydrocarbons, such as dichloromethane and chloroform, alcohols such as methanol and ethanol, and mixtures thereof. The compound of Formula (I) in which m= 1 or 2 and Y=NRYy / or Y=O, can be obtained by sulfoximination / sulfilimination of the corresponding sulfur compound 5 of Formula (le) and (Id) using the procedure analogous to that described in Chem. Commun., 2017,53, 2064-2067; Tetrahedron Lett., 2005, 46, 8007-8008 and WO2015071180A1. The compound of Formula (2) is selected from the group consisting of Formula (2a), (2b) and (2c); npfrCLn / Lznz / e / YiAi (2a) (2b) (2c) X = Halogen, -S(O)mR, n = 0-2 in which, R1 and R11 have the same meanings as described above. The synthesis of the compounds of Formulas (2a), (2b) and (2c) is described in Scheme 3 to Scheme 9. Outline: 3 o o RiiAjARn R11 (15) |_j Step 3 OMe θ' i RL R11—^-OMe H2NZ R O ? O (12) ñ 7 R° N u Rl1______ RiiAA / (14) z-\ R 1 1 --------- N J K d Rn 1 Step 1 K R =lower alkyl 'K / n Ste <11> ( 13) Step2 (16) R1 or 1 Hcr / N ---N, p 4 ' / n (2a) wherein, R1, R11yn have the meanings described above. The reaction of the compound of Formula (11) with the compound of Formula (12) can be carried out in an appropriate solvent at temperatures ranging between 50-2003C to obtain the dielectrophilic compound of Formula (13). Examples of the solvents include, but are not limited to, Ν,Ν-dimethylformamide, dimethylacetamide, 1,4-dioxane, 1,2-dichloromethane, toluene, xylene and the like. In pyrimidine formation, Step 2, the pyrazole-derived compound of Formula (14) can undergo a cyclocondensation reaction when treated with a dielectrophilic compound of Formula (13) or the 1,3-diketone compound of Formula ( 15) (for example, a 1,3-dialdehyde or a 3(dialkylamino)-prop-2-enal) in the presence or absence of a base to obtain a bicyclic compound of Formula (16). The preparation of a compound of Formula (14) has been described in published material (Acta Chimica Sinica, 2003, 63, 855; Organic & Biomolecular Chemistry, 2010, 8, 3394). Examples of the bases include, but are not limited to, piperidine, morpholine, N-methylpiperazine, diethylamine, triethylamine and the like. Examples of solvents include, but are not limited to, methanol, ethanol, isopropanol, ethylene glycol and the like. The reaction can be carried out at temperatures varying between approximately 50sC and 150sC. When one or both electrophilic centers are present in compounds of Formulas (13) and (15) are protected / masked (for example, aldehyde masked as a ketal), condensation can be carried out in a solvent in the presence of an acid. Examples of acid include acetic acid, sulfonic acid (e.g. PTSA), sulfuric acid, hydrochloric acid, which releases the reactive functional group. Examples of solvents include, but are not limited to, methanol, ethanol, isopropanol, ethylene glycol and the like. The reaction can be carried out at temperatures varying between approximately 0°C and 150°C. Hydrolysis of a compound of Formula (16) can be achieved using a base, such as sodium hydroxide, potassium hydroxide, lithium hydroxide, bis(tributyltin) oxide and the like, or in solvents such as tetrahydrofuran, water, methanol , ethanol or a mixture thereof, to obtain a compound of Formula (2a). The reaction can be carried out at temperatures varying between approximately 50sC and 150sC. npfcCLn / Lznz / e / YiAi Alternatively, the compound of Formula (2a) can also be prepared following Scheme 4: npfrCLn / Lznz / e / YiAi Outline: 4 (17) R' = lower alkyl Step 1 OMe R11-^-OMe NMe2(12) (18) (twenty) (2a) R11B(OR')j (22) Step 5 Step 4 1' (23) (R' =H; or R', Rmpinacolate) wherein, X is halogen, R1 and R11 have the meanings described above. The compound of Formula (19) can be obtained from the compound of Formula (18) in the same manner as described in Step 1 of Scheme 3. The reaction of the compound of Formula (18) can be carried out in the same manner as described in Step 2 of Scheme 3. Furthermore, the compound of Formula (20) can be obtained without performing Step 3, when Step 2 is performed in the presence of acetic acid. The conversion of the compound of Formula (20) to the compound of Formula (21) can be carried out in a solvent in the presence of a halogenating agent and in the presence or absence of a base. Examples of solvents include, but are not limited to, acetonitrile, chloroform, tetrahydrofuran, 1,4dioxane, toluene, Ν,Ν-dimethylformamide and the like. Examples of halogenating agents include, but are not limited to, phosphorus oxychloride, thionyl chloride, phosphorus pentachloride, oxalyl chloride and the like. Examples of base include, but are not limited to, N,N-dimethylaniline, diisopropylethylamine, N-methylmorpholine and the like. The reaction can be carried out at temperatures ranging between 50-2002C. The compound of Formula (21) can be conveniently coupled under standard Suzuki cross-coupling conditions with boronic acids or with a boronic ester compound of Formula (22) to obtain the compound of Formula (23). The Suzuki cross-coupling reaction can be catalyzed by a palladium-based catalyst, including, but not limited to, 1,r-Bis(diphenylphosphino)ferrocene]dichloropalladium(ll) or tetrakis(tr phenylphosphine)palladium(0) in a suitable solvent, for example, tetrahydrofuran (THF), Λ / ,Λ / '-dimethylformamide (DMF), 1,2-dimethoxyethane, 1,4dioxane, or a solvent system, such as a mixture of tetrahydrofuran (THF) / water, 1,2-dimethoxyethane / water, 1,4-dioxane / water, or the like. The reaction is usually carried out in the presence of a base, for example potassium carbonate, cesium carbonate or potassium phosphate. The reaction temperature may vary, preferably, between room temperature (20°C) to the boiling point of the reaction mixture, according to published material (see, for example, Chem. Soc. Rev. 2014, 43, 412- 443 or document WO2014070978). Hydrolysis of a compound of Formula (23) can be achieved using a base, such as sodium hydroxide, potassium hydroxide, lithium hydroxide, bis(tributyltin) oxide and the like; in solvents such as tetrahydrofuran, water, methanol, ethanol, toluene or mixtures thereof, to obtain a compound of Formula (2a). The reaction can be carried out at temperatures varying approximately between 50sC and 150eC. npfrCLn / Lznz / e / YiAi The compound of Formula (2aa) can be prepared according to the following Scheme 5: Outline: 5 wherein, R1 and R11 have the meanings described above. The pyrazole derivative compound of Formula (14) can be subjected to cyclocondensation with the 1,3-dimethyluracil compound of Formula (24) or with alkoxyacrylate derivatives of Formula (25) in the presence of a base to obtain pyrimidine derivative -5-one from Formula (26). Examples of the bases include sodium ethoxide, sodium methoxide, potassium tert-butoxide, potassium carbonate, sodium carbonate, cesium carbonate, potassium phosphate and the like. Examples of solvents include methanol, ethanol, isopropanol, ethylene glycol, N,N-dimethylacetamide, N,N-dimethylformamide and the like. The reaction can be carried out at temperatures varying between approximately 50eC and 150eC. Such a reaction is well known in the published material, as well as alternative reactions, which are also widely described in the published material, for example, J. Org. Chem 2007, 72, 1046, or document WO2018081417. Halogenation of the compound of Formula (26) with phosphorus oxychloride or phosphorus oxybromide can obtain a compound of Formula (28) as described in WO201108689, for example. The compound of Formula (27) can be conveniently coupled under standard Suzuki cross-coupling conditions to obtain the compound of Formula (28), as described in Step 5 of Scheme 4. Subsequent alkaline hydrolysis of the compound of Formula Formula (28), as described in Step 6 of Scheme 4, can obtain a compound of Formula (2aa). A process for the synthesis of the compound of Formula (2ab) is described in Scheme 6: npfrCLn / Lznz / e / YiAi Outline: 6 npfrCLn / Lznz / e / YiAi in which, R1 and R11 have the meanings described above. The bisacetal-protected malonaldehyde compound of Formula (29) can be activated by halogenation with a halogenating agent, such as bromine, iodine or chlorine, or N-bromosuccinimide, N-iodosuccinimide or N-chlorosuccinimide under acidic conditions, which can be generated using a selected acid independently from hydrochloric acid, sulfuric acid, methanesulfonic acid, trifluoroacetic acid, tetrafluoroboric acid or p-toluenesulfonic acid in a suitable solvent, for example, water, to obtain a halogenated aldehyde, such as chlorine, iodine or bromomalonaldehyde of the Formula ( 30). Following Step 2, the compound of Formula (30) can be reacted with the pyrazole derivative of Formula (14) under suitable condensation conditions to obtain the compound of Formula (31). Examples of solvents include, but are not limited to, N-dimethylsulfoxide, N-dimethylacetamide, N,N-dimethylformamide and the mixture thereof. The reaction can be carried out at temperatures varying between approximately 50sC and 150sC. The compound of Formula (31) can be conveniently coupled under standard Suzuki cross-coupling conditions to obtain the compound of Formula (32) as described in Step 5 of Scheme 4. Subsequent alkaline hydrolysis of the compound of Formula (32), as described in Step 6 of Scheme 4, can obtain a compound of Formula (2ab). Alternatively, the compound of Formula (31) can also be prepared by cyclization of the pyrazole derivative of Formula (14) with commercially available 2-halomalonaldehydes of Formula (33) under acid-catalyzed conditions. Examples of acid include, but are not limited to, acetic acid, sultanic acid (e.g. PTSA), sulfuric acid, hydrochloric acid. Examples of solvents include, but are not limited to, methanol, ethanol, isopropanol, ethylene glycol and the like. The reaction can be carried out at temperatures ranging between approximately 0aC and 150aC. The pyrazole[1,5ajpyrimidine derivative of Formula (32) can also be prepared after cyclocondensation of pyrazole derivatives of Formula (14) with a commercially available malonaldehyde (34) or its equivalent (35). Derivatives (35) can be prepared by the methods described in J. Het. Chem., 1974, 44, 51. npirCLn / Lznz / e / YiAi A process for the synthesis of the compound of Formula (2b) is described in Scheme 7: Outline: 7 X = Halogen ^o) in which, R11yn have the meanings described above. The compound of Formula (38) can be prepared in a two-step procedure from the 2-aminopyridine derivatives of Formula (36), in which the first step involves the condensation reaction of the 2-aminopyridine derivatives of Formula (36) with haloacetic acid (37) under basic conditions in a suitable solvent. Examples of suitable bases include, but are not limited to, tertiary amines such as trimethylamine and diisopropylethylamine. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol, isopropanol and mixtures thereof. The reaction can be carried out at temperatures varying between approximately 50aC and 150°C. Intramolecular cyclization of the compound of Formula (38) in the presence of phosphorus oxychloride or phosphorus oxybromide at elevated temperature in a suitable solvent (e.g., toluene) can provide 2haloimidazole[1,2-a]pyridine analogous to that of Formula (39). Alkoxycarbonylation of the compound of Formula (38) using alkyl chlorocarbonate of Formula (40), as a carbon source, can be carried out using organometallic reagents such as n-butyl lithium and the like in ether solvents such as tetrahydrofuran, diethyl ether, methyl tert-butyl ether and the like to obtain the compound of Formula (41). The reaction can be carried out at temperatures ranging between -78sC and approximately 25sC (WO2011163355). Subsequent alkaline hydrolysis of the compound of Formula (41), as described in Step 6 of Scheme 4, can obtain a compound of Formula (2b). npfrCLn / Lznz / e / YiAi A process for the synthesis of the compound of Formula (2c) is described in Scheme 8: Outline: 8 (46) (2c) (43) Step-1 X = Halogen R' = lower alkyl (44) in which, R2, R11and n have the meanings described above. The compound of Formula (44) can be prepared by allowing the substituted pyridine compound of Formula (42) to react with the alkyl 2-haloacetate of Formula (43) in an inert solvent, including, but not limited to, ethyl acetate, acetone, diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dichloroform, chloroform, N, N-dimethylformamide, toluene, xylene, methanol, ethanol, a mixture thereof and the like. Bases such as trimethylamine, pyridine, N, N-diisopropyl ethylamine, 2,6-lutidine can be used in the reaction. The reaction can be carried out at temperatures ranging from 0eC to reflux temperature, and the reaction time generally ranges from 30 minutes to 48 hours and varies depending on the starting material, the solvent used and the reaction temperature or the like. Indolizine derivatives of Formula (46) can be prepared by allowing the compound of Formula (44) to react with the halo alkenyl tosylates of Formula (45). The preparation of a compound of Formula (45) has been described in published material (Tetrahedron 2018, 74, 5295; Organic Letters, 2010, 12, 5518). As inert solvents, ethyl acetate, acetone, diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane, dichloroform, chloroform, N, N-dimethylformamide, toluene, xylene, methanol, ethanol or a mixture can be used. of them in the reaction. As a base, potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, potassium fluoride, lithium hydroxide, trimethylamine, pyridine, N, N-diisopropyl ethylamine, 2,6-lutidine can be used in the reaction. The reaction can be carried out at temperatures varying between 0-C and reflux temperature. The reaction time is usually 1 hour and 48 hours and varies depending on the starting material, the solvent used and the reaction temperature or the like. Said reaction is disclosed in the published material and is well described, for example, in Tetrahedron, 2004, 60, 5487. Subsequent alkaline hydrolysis of the compound of Formula (46), as described in Step 6 of Scheme 4, can obtain a compound of Formula (2c). A process for the synthesis of the compound of Formula (2ca) is described in Scheme 9: npfrCLn / Lznz / e / YiAi Outline: 9 npfrCLn / Lznz / e / YiAi Step 4 Π (O)* ^R1 mS (50) wherein, R1, R2, R11 and n have the meanings described above. The indolizine derivatives of Formula (47) can be prepared by allowing the compound of Formula (44) to react with the halo alkenyl tosylates of Formula (45a) following Step 2, as described in Scheme 8. The compound of Formula (47) can be reacted with the compound of Formula (9) or with a compound of Formula (10), followed by oxidation, to obtain the compound of Formula (48). The compound of Formula (49) can be prepared from a compound of Formula (48) by halogenation with a halogenating agent, such as N-bromosuccinimide, N-chlorosuccinimide, N-iodosuccinimide. The reaction can be carried out in an inert solvent selected from dichloromethane, 2-dichloromethane, chloroform, carbon tetrachloride, acetic acid, acetonitrile, methanol, N, Ndimethylformamide, the like or a mixture thereof. The reaction can be carried out at temperatures varying between 0°C and reflux temperature. The reaction time is usually 30 minutes to 48 hours and varies depending on the starting material, the solvent used, and the reaction temperature. The compound of Formula (49) can be conveniently coupled under standard Suzuki cross-coupling conditions to obtain the compound of Formula (50), as described in Step 5 of Scheme 4. Subsequent alkaline hydrolysis of the compound of Formula Formula (50) as described in Step 6 of Scheme 4 can obtain a compound of Formula (2ca). The subgroup of the compound of Formula (I), wherein Q is Q3 and Gs is CR3; R=H may be represented by a compound of Formula (52) and may be prepared by reacting the compound of Formula (6b) with the compound of Formula (51) to obtain the compound of Formula (52), in which that Gs is CR3, R3= H, Outline: 10 npfrCLn / Lznz / e / YiAi X = halogen (6b) (52) in which, R3, R7, A, G, Gi, G2, G4, GS, E and N have the meanings described above. Cyclization to obtain the compound of Formula (52) can be carried out in the presence of a Lewis acid, such as indium (III) triflate or zinc (II) iodide, in solvents such as 1,2-dichlorobenzene, chlorobenzene, in presence of catalytic copper(II) salts, such as copper(II) acetate, or under an atmosphere of oxygen or air. The reaction can be carried out at temperatures ranging between approximately 100aC and 180aC. This reaction has precedents in published material (see, for example, Adv. Synth. Catalysis, 2013, 355, 1741; J. Org. Chem, 2013, 78, 12494). The synthesis of the compound of Formula (51) has been described in WO2015000715. The compound of Formula (52) can be reacted with a compound of Formula (9) or with a compound of Formula (10) to obtain the compound of Formula (53). The compound of Formula (53A) can be prepared according to the synthesis process described in Chem. Commun., 2017,53, 2064-2067; Tetrahedron Lett., 2005, 46, 8007-8008 and document WO2015071180A1. Scheme: 11 χ (52) npfrCLn / Lznz / e / YiAi wherein, R1, R3, A, G, Gi, G2, G4, Gs, E, m and n have the meanings described above. The compound represented by Formula (54) in which m=1 (sulfoxide) and / or m=2 (sulfone), can be obtained by oxidation of the corresponding sulfide compound of Formulas (53) while applying appropriate oxidizing agents and conditions well known to experts in the field. Oxidizing agents, such as m-chloroperoxybenzoic acid (mCPBA), hydrogen peroxide / glacial acetic acid, hydrogen peroxide / trifluoroacetic acid, hydrogen peroxide / potassium permanganate, hydrogen peroxide / p-tulenesulfonylimidazole, urea hydrogen peroxide / trifluoroacetic acid, oxone, sodium periodate, sodium hypochlorite and other organic peracids and the like can be used for oxidation. Examples of the solvents used in this reaction include aliphatic halogenated hydrocarbons, such as dichloromethane and chloroform, alcohols such as methanol and ethanol, and mixtures thereof. Halogenation of the compound of Formula (54) wherein Gs = CR3; R3= H, with a halogenating agent such as N-chlorosuccinamide, N-bromorosuccinamide, N-iodorosuccinamide, in a polar aprotic solvent such as acetonitrile or N, Ndimethylformamide, at room temperature, can lead to compounds of the Formula (lei), Outline: 12 wherein, R1, R3, A, G, Gi, G2, G4, Gs, E, m and n have the meanings described above. Compounds of Formula (lei) can be reacted with compounds R3-B(OR')2 (R'= H or R' = pinacolato); in the presence of a palladium catalyst to provide the compounds of Formula (le), wherein Gs = GR3; R3= alkyl, cycloalkyl, aryl, hetroaryl. Such Suzuki reactions are well preceded in published material (see, for example, WO2012133607). A process for the synthesis of the compound of Formula (6b) is described in Scheme 12a: Scheme: 12a X = Halogen, wherein, G, E and A have the meanings described above. The carboxylic acid of Formula (6) can be converted to the Weinreb amide of Formula (55) upon reaction with N,O-dimethylhydroxylamine by methods known to those skilled in the art analogously to the procedures described in the documents WO201175643 and EP2671582. Subsequent treatment of the Weinreb amide of Formula (55) with Grignard reagents of Formula (R7CH2MgHal), according to the methods described in Tetrahedron Letters, 1981,22, 3815, can obtain a compound of Formula (6b). The process for the synthesis of the compound of Formula (1d) is described in Scheme 13, in which Q is Q4 and Gs is nitrogen, G4 is GR3, then the compound of Formula (1d) can be prepared by reacting the compound of Formula (1d) Formula (56) with a compound of Formula (57), optionally in the presence of a suitable base in an inert solvent. Alternatively, when G4 is nitrogen, the compound of Formula (Id) can be prepared by reacting a compound of Formula (58), where X' is a halide or mesitylsulfonate ion with a compound of Formula (59), optionally in the presence of a suitable base in an inert solvent. npfrCLn / Lznz / e / YiAi Outline: 13 X = halogen in which, R1, R3, A, G, Gi, G2, G4, Gs, E, m and n have the meanings described above. The synthesis of the compound of Formula (56) has been described in document WO2015000715. The synthesis of the compound of Formula (57) can be obtained, for example, in a manner analogous to that described in document EP1371638. The compound of Formula (58) can be prepared by Namination by reacting the compound of Formula (56) with Omesitylenesulfonylhydroxylamine (MSH) as an amination reagent or one of its equivalents, as described, for example, in J. Heterocyclic Chem. , 1975, 12, 107, and Synthesis, 1977, 1,17. The subgroup of compounds of Formula (I), where Q is Qs and Gs is CR3, may be represented by the compounds of Formula (le). The compound of Formula (le) can be synthesized by reacting the compound of Formula (60) with a compound of Formula (6b) in a manner analogous to the preparation of the compound of Formula (le). npfrCLn / Lznz / e / YiAi Outline: 14 wherein, R1, R3, A, G, Gi, G2, Gs, E, m and n have the meanings described above. Those skilled in the art will recognize that the compound of Formula (If), where Q is Qe and G5 is CR3, can be prepared in a similar manner by reacting the compound of Formula (61) with the compound of Formula (57a ) or (6a). Outline: 15 X = leaving group R7= H where R1, R3, A, G, G1, G2, G5, E, m and n have the meanings described above. The subgroup of the compound of Formula (I), in which Q is Q3 and Gs is nitrogen, 15 may be represented by the compound of Formula (Ig) can be prepared by reacting a compound of Formula (62) with the compound of Formula (59), optionally in the presence of a suitable base in an inert solvent. Outline: 16 (ig) npfrCLn / Lznz / e / YiAi wherein, R1, R3, A, G, Gi, G2, Gs, E, m and n have the meanings described above. The compound of Formula (62) can be prepared by N-amination by reacting a compound of Formula (51) with Omesitylenesulfonylhydroxylamine (MSH) as an amination reagent or one of its equivalents, as described, for example, in J. Heterocyclic Chem., 1975, 12, 107, and Synthesis, 1977, 1, 17. The subgroup of the compound of Formula (I), in which Q is Qs and Gs is nitrogen, may be represented by the compound of Formula ( Ih), can be prepared by reacting a compound of Formula (63) with the compound of Formula (59), optionally in the presence of a suitable base in an inert solvent. The compound of Formula (63) can be prepared by N-amination by reacting a compound of Formula (60) with Omesitylenesulfonylhydroxylamine (MSH) as an amination reagent; the process is described in J. Heterocyclic Chem., 1975, 12, 107, and Synthesis, 1977, 1,17. The synthesis of the compound of Formula (60) has been described in document WO2007113558. (60) (63) wherein, R3, G1 and G2 have the meanings described above. In a further embodiment, Q is Q? and involves the reaction of the compound of Formula (64) with the compound of Formula (65) to obtain the compound of Formula (11) in which Gs is CR3o N. The process is summarized in the Scheme for the compound of the Formula (l): Outline: 17 npfrCLn / Lznz / e / YiAi wherein, R1, R3, G, A, Gi, G2, Gs, Ge, E, m and n have the meanings described above. The compound of Formula (65) are commercially available or can be prepared by methods known per se or in a manner analogous to that described in WO2017113558 and WO2011090122. In Scheme 17, N-substituted amidines of Formula (66) can be prepared by reacting the compound of Formula (64) with the compound of Formula (65) in the presence of a suitable base. Examples of suitable bases are alkali metal hydrides such as sodium hydride, alkali metal salts of hexamethyldisilazane such as sodium hexamethyldisilazane, alcoholates such as potassium or sodium tert-butoxides or lithium diisopropylamide. The reaction can be carried out in solvents, preferably inert form, under the prevailing reaction conditions such as, for example, ethereal solvents such as diethyl ether, tetrahydrofuran, 1,4-dioxane, diisopropyl ether, 1,2-dimethoxyethane, tert -butylmethyl ether; nitriles such as acetonitrile or propionitrile; aromatic hydrocarbons such as toluene, xylene; aprotic polar solvents such as N, N-dimethylformamide, N-methylpyrrolidine or dimethyl sulfoxide. The reaction can be carried out at temperatures varying between approximately 0sC and 150aC. This reaction has precedents in published material (see, for example, J. Am. Chem. Soc,. 2009, 131,15080). Intramolecular oxidative delation of the N-substituted amidines of Formula (66) in the presence or absence of a suitable base can be carried out in a manner analogous to that described in J. Org. Chem., 2015, 80, 7219; J.Org. Chem., 2014, 79, 4687. Examples of oxidants include sodium hypochlorite, lead(IV) acetate, manganese dioxide, iodine, hypervalent iodine(III) reagents such as phenylodine(III) diacetate (PIDA), and bis(trifluoroacetate). phenylodine (III) (PIFA). The reaction can be carried out in solvents, preferably inert, under the prevailing reaction conditions, for example, nitriles such as acetonitrile or propionitrile; aromatic hydrocarbons such as toluene or xylene; polar aprotic solvents such as N, N-dimethylformamide, N-methylpyrrolidine or dimethyl sulfoxide or ethyl acetate; halogenated hydrocarbons such as dichloromethane or dichloroethane; alcoholic solvents such as hexafluoroisopropanol, methanol, ethanol, trifluoroethanol, isopropanol. Suitable bases include potassium carbonate, sodium carbonate and carbonate of cesium. The reaction can be carried out at temperatures varying between approximately 25aC and 180aC. Alternatively, the compound of Formula (1i) can be synthesized following Step 3 in a single step involving the transition metal catalyzed oxidative coupling of the compound of Formula (65) with the compound of Formula (64) so analogous to that described in document WO201341472 and J. Am. Chem. Soc., 2009, 131, 15080. The transition metal catalyst includes zinc or copper salts such as copper (I) bromide, copper (I) chloride ), copper(I) iodide, copper(II) acetate, zinc chloride, zinc(II) bromide or zinc iodide. Suitable bases include, for example, 1,10-phenanthroline, cesium carbonate, sodium carbonate, potassium carbonate. The reaction can be carried out in solvents, preferably inert, under the prevailing reaction conditions, for example, aromatic hydrocarbons such as 1,2-dichlorobenzene, toluene or xylene. The reaction can be carried out at temperatures ranging from 50aC to 150aC. The compounds of Formula (64) are selected from the group consisting of Formulas (64a), (64b) and (64c) npirCLn / Lznz / e / YiAi χ (64a) Χ = Halogen, -SfOJnR, n = 0-2 npfrCLn / Lznz / e / YiAi in which, R11and n have the meanings described above. The synthesis of the compounds of Formulas (64a), (64b) and (64c) is described in Scheme 18 and Scheme 19, Outline: 18 (13) (64a) wherein, R1, R11 and m have the meanings described above. In the pyrimidine formation step, the pyrazole derivative of Formula (67) can undergo a cyclocondensation reaction when treated with a dielectrophilic compound of Formula (13) or the 1,3-diketone of Formula (15). ) (for example, a 1,3-dialdehyde or a 3-(dialkylamino)-prop-2-enal) following a procedure similar to that described in Scheme 3 to obtain the compound of Formula (64a). The preparation of a compound of Formula (67) has been described in published material (Journal of Heterocyclic Chemistry, 2016, 53, 15 1231). Outline: 19 (68)(64b) npfrCLn / Lznz / e / YiAi (41) R = Lower alkyl X = Halogen in which, R11 and n have the meanings described above. The compound of Formula (68) can be prepared from a compound of Formula (41) in an analogous manner to the method described in WO201065760 and WO2016133838 using an ammonia source. A solution of ammonium hydroxide or methanolic ammonia is generally used as the ammonia source. The synthesis of the compound of Formula (41) has been described in Scheme 7. The reaction can be carried out under the prevailing reaction conditions using ethereal solvents, such as 1,4-dioxane or tetrahydrofuran or alcoholic solvents such as methanol, ethanol and similar at temperatures varying between approximately 25aO and 100aC. The compound of Formula (64b) can be prepared in an analogous manner to the method described in documents WO201065760 and EP2740730 by reacting the compound of Formula (68) with dehydrating reagents such as phosphoryl chloride or trifluoroacetic anhydride, among others. The reaction can be carried out under the prevailing reaction conditions using ethereal solvents, such as 1,4-dioxane or tetrahydrofuran at temperatures ranging from approximately 25aC to 120aC. The compound of Formula (64c) can be prepared from the compound of Formula (46) following the reaction sequence and conditions similar to those described for the preparation of the compound of Formula (64b) as described in Scheme 19 The general synthesis of the compound of Formula (46) has been described in Scheme 8. In one embodiment, Q is Qe involves the reaction of the compound of Formula (2) or Formula (59) or Formula (69) with the compound of Formula (70) to obtain the compound of Formula (1 j) wherein G4 and Gs is N. Scheme 20 describes a method for preparing the compound of Formula (Ij). npfrCLn / Lznz / e / YiAi Outline: 20 (71) wherein, R1, R3, A, Z, G, G1, G2, E, m and n have the meanings described above. A halo derivative of the compound of Formula (71) can be obtained commercially or can be prepared by methods known in the published material or by other methods known to one skilled in the art. The reaction of a compound of Formula (71) with hydrazine can be carried out using reaction conditions known to one skilled in the art (e.g., Larock, R.C. Comprehensive Organic Transformations: A Guide a functional Group Preparations). A Guide to Functional Group Preparations), 2nd Ed., 1999, Wiley-VCH). An intermediate compound of Formula (70) in Step 2 can be reacted with an acid of the compound of Formula (2) using an appropriate set of amide coupling reagents such as N-methylmorpholine / isobutyl chloroformate, 1-Ethyl -3-(3-dimethylaminopropyl)carbodamida / hydroxybenzotriazole or other reagents described in The Practice of Peptide Synthesis, 2ndEd., Spring-Verlag , Bodanszy, Miklos (1993), can provide hydrazide intermediates of Formula (71). Furthermore, acylhydrazides of Formula (71) can also be prepared following the reaction of a compound of Formula (70) and an acid chloride of Formula (59) in the presence of an appropriate base such as Ν,Ν-diisopropylethylamine or triethylamine. . The formation of the triazole compound of Formula (Ij) can be achieved after cyclodehydration of the compound of Formula (71) using phosphorus oxychloride / phosphorus pentachloride, Lawesson's reagent, acetic acid or polyphosphoric acid at an elevated temperature, either either under conventional procedure or under microwave irradiation. Alternatively, the transformation can also be achieved by following the reaction of the compound of Formula (71) with triphenylphosphine dichloride or P(alkyl)3 / carbon tetrachloride in the presence of bases such as triethylamine or N, Ndiisopropylethylamine, or other methods known to an expert in the technique. As an alternative approach, hydrazones of Formula (72) can be prepared following Step 4, carrying out the reaction of the compound of Formula (70) with the aldehyde compound of Formula (69) by other methods known to a person skilled in the art. in the art or methods known from the published material (e.g., Larock, R.C. Comprehensive Organic Transformations: A Guide a functional Group Preparations), 2nd Ed., 1999, Wiley -VCH). Furthermore, following Step 5, the compound of Formula (Ij) can also be prepared by oxidative cyclization of the hydrazones of Formula (72) using oxidants such as diacetoxy iodobenzene, Nbromosuccinimide, chloramine T, ceric ammonium nitrate, trichlorocyanuric acid and copper (II) chloride. npfrCLn / Lznz / e / YiAi The compounds of Formula (69) are selected from the group consisting of Formulas (69a), (69b) and (69c) n = 0-2 ; X = Halogen, -3(0^^ in which, R1, R11and n have the meanings described above. The compound of Formula (69a-c) can be prepared by partial reduction of the compounds of Formulas (23), (41) and (46) by methods known in published material (e.g., Larock, R.C. Comprehensive Organic Transformations: A Guide a functional Group Preparations, 2nd Ed., 1999, Wiley-VCH). The process for preparing the compound of Formula (I), where Q is Qg, involves the reaction of the compound of Formula (6b) with the compound of Formula (73) to obtain the compound of Formula (74). , where Gs is CR3; R3= hours. Subsequently, the compound of Formula (1k) can be obtained from the compound of Formula (74), following the set of general reactions, as described for the synthesis of compound (1c) in Scheme 1. Synthesis of the compound of Formula (73) is described in WO2018206479. npfrCLn / Lznz / e / YiAi Outline: 21 X = Halogen (6b)(73) wherein, R1, R3, R6, A, G, Gi, G2, Gs, Z, E, m and n have the meanings described above. The process for preparing the compound of Formula (I), where Q is Q10, involves the reaction of the compound of Formula (2) with the compound of Formula (75) to obtain the compound of Formula (76). , in which Gs = NR6. Subsequently, the compound of Formula (IL) can be obtained from the compound of Formula (76), following the set of general reactions, as described in Scheme 1. The synthesis of the compound of Formula (75) It is described in document WO2017084879. Outline: 22 npfrCLn / Lznz / e / YiAi wherein, X is halogen, R1, R3, R6, R', A, Z, Gi, Gs, E, m and n have the meanings described above. The process for preparing the compound of Formula (I) represented by the compound of Formula (IB) is by sulfilimination / sulfoximination of the compound of Formula (IA) in which n=0 as described in Chem. Commun., 2017,53, 2064-2067, Tetrahedron Lett., 2005, 46, 8007-8008 and document WO2015071180A1 Outline: 23 wherein, Q, R1, RY, A, G, E, and n have the meanings described above. In another embodiment, the present invention provides a composition for controlling or preventing invertebrate pests. The composition comprises a biologically effective amount of the compound of the general Formula (I) and at least one additional component selected from the group consisting of surfactants and auxiliaries. In yet another embodiment, the present invention provides a compound of the general Formula (I), its N-oxides and salts, in common types of agrochemical compositions, for example, solutions, emulsions, suspensions, powders, pastes, granules, pressed, capsules and mixtures thereof. Examples for composition types are suspensions (e.g. SC, OD, FS), emulsifiable concentrates (e.g. EC), emulsions (e.g. EW, EO, ES, ME), capsules (e.g. OS, ZC), pastes, tablets, wettable powders or powders (e.g. WP, SP, WS, DP, DS), pressed (e.g. BR, TB, DT), granules (e.g. WG, SG, GR, FG , GG, MG), insecticidal articles (for example, LN), as well as gel formulations for the treatment of plant propagation materials, such as seeds (for example, GF). These and other types of compositions are defined in Catalog of pesticide formulation types and International coding system, Technical Monograph Ne2, 6th edition May 2008, CropLife International. The compositions are prepared in a known manner, as described by Mollet and Grubemann in Formulation technology, Wiley VCH, Weinheim, 2001, or Knowles in New developments in crop protection product formulation, Agrow Reports DS243, T & F Informa, London, 2005. Examples of suitable auxiliaries are solvents, liquid carriers, solid carriers or fillers, surfactants, dispersants, emulsifiers, humectants, adjuvants, solubilizers, penetration enhancers, protective colloids, adhesion agents, thickeners, humectants, repellents, attractants, feeding stimulants. , compatibilizers, bactericides, antifreeze agents, antifoaming agents, colorants, adhesives or binders. Suitable liquid solvents and vehicles are water and organic solvents, such as medium to high boiling mineral oil fractions, for example, kerosene, diesel fuel; oils of vegetable or animal origin; aliphatic, cyclic and aromatic hydrocarbons, for example, toluene, paraffin, tetrahydronaphthalene, alkylated naphthalenes; alcohols, for example, ethanol, propanol, butanol, benzyl alcohol, cyclohexanol; glycols; DMSO; ketones, for example, cyclohexanone; esters, for example, lactates, carbonates, fatty acid esters, gamma-butyrolactone; fatty acids; phosphonates; amines; amides, for example, N-methylpyrrolidone, dimethyl fatty acid amides and mixtures thereof. Suitable solid carriers or fillers are mineral earths, for example, silicates, silica gels, talc, kaolins, limestone, lime, chalk, clays, dolomite, diatomaceous earth, bentonite, calcium sulfate, magnesium sulfate, magnesium oxide ; powdered polysaccharides, eg cellulose, starch; fertilizers, for example, ammonium sulfate, ammonium phosphate, ammonium nitrate, ureas; npfrCLn / Lznz / e / YiAi products of plant origin, for example, cereal flour, bark flour, wood flour, nutshell flour and mixtures thereof. Surfactants are surface-active compounds, such as anionic, cationic, nonionic, and amphoteric surfactant agents, block polymers, polyelectrolytes, and mixtures thereof. Said surfactants can be used as emulsifiers, dispersants, solubilizers, humectants, penetration enhancers, protective colloids or adjuvants. Examples of surfactants are presented in Vol. 1: McCutcheon Emulsifiers & Detergents, McCutcheon Directories, Glen Rock, USA, 2008 (International Edition or North American Edition). Suitable anionic surfactants are alkali metal, alkaline earth metal or ammonium sulfonate salts, sulfates, phosphates, carboxylates and mixtures thereof. Examples of sulfonates are alkylaryl sulfonates, diphenyl sulfonates, alpha-olefin sulfonates, lignin sulfonates, fatty acid and oil sulfonates, ethoxylated alkylphenol sulfonates, alkoxylated arylphenol sulfonates, condensed naphthalene sulfonates, dodecyland tridecylbenzene sulfonates, naphthalene sulfonates and alkylnaphthalenes, sulfosuccinates or sulfosuccinamates. Examples of sulfates are sulfates of fatty acids and oils, of ethoxylated alkylphenols, of alcohols, of ethoxylated alcohols, or of esters of fatty acids. Examples of phosphates are phosphate esters. Examples of carboxylates are alkyl carboxylates, carboxylated alcohol or alkylphenol ethoxylates. Suitable nonionic surfactants are alkoxylates, N-substituted fatty acid amides, amine oxides, esters, sugar-based surfactants, polymeric surfactants, and mixtures thereof. Examples of alkoxylates are compounds such as alcohols, alkylphenols, amines, amides, arylphenols, fatty acids or fatty acid esters that have been alkoxylated with 1 to 50 equivalents. Ethylene oxide and / or propylene oxide may be used for alkoxylation, preferably ethylene oxide. Examples of N-substituted fatty acid amides are fatty acid glucamides or fatty acid alkanolamides. Examples of esters are fatty acid esters, glycerol esters or monoglycerides. Examples of sugar-based surfactants are sorbitans, ethoxylated sorbitans, npfrCLn / Lznz / e / YiAi sucrose esters, and glucose or alkylpolyglucosides. Examples of polymeric surfactants are homo- or copolymers of vinylpyrrolidone, vinyl alcohols, or vinyl acetate. Suitable cationic surfactants are quaternary surfactants, for example, quaternary ammonium compounds with one or two hydrophobic groups, or salts of long chain primary amines. Suitable amphoteric surfactants are alkylbetaines and imidazolines. Suitable block polymers are block polymers of type A-B or A-B-A comprising blocks of polyethylene oxide and polypropylene oxide, or of type A-B-C comprising alkanol, polyethylene oxide and polypropylene oxide. Suitable polyelectrolytes are polybases or polyacids. Examples of polyacids are alkali salts of polyacrylic acid or comb polymers of polyacids. Examples of polybases are polyvinylamines or polyethyleneamines. Suitable adjuvants are compounds that have negligible or even no pesticidal activity, and that improve the biological performance of compound I on the target. Examples are surfactants, minerals or vegetable oils and other auxiliaries. Other examples are presented in Knowles, Adjuvants and additives, Agrow Reports DS256, TandF Informa UK, 2006, chapter 5. Suitable thickeners are polysaccharides (for example, xanthan gum, carboxymethyl cellulose), inorganic clays (organically modified or unmodified), polycarboxylates and silicates. Suitable bactericides are bronopol and isothiazolinone derivatives such as alkylisothiazolinones and benzisothiazolinones. Suitable antifreeze agents are ethylene glycol, propylene glycol, urea and glycerin. Suitable antifoam agents are silicones, long chain alcohols and fatty acid salts. Suitable dyes (e.g. red, blue, green) are low water solubility pigments and water soluble dyes. Examples are inorganic dyes (for example, iron oxide, titanium oxide, iron hexacyanoferrate) and organic dyes (for example, alizarin, azo and phthalocyanine dyes). Suitable adhesives or binders are polyvinylpyrrolidone, polyvinyl acetates, polyvinyl alcohols, polyacrylates, biological or synthetic waxes, and cellulose ethers. npfrCLn / Lznz / e / YiAi Examples for types of composition and their preparation are: i) Water-soluble concentrates (SL, LS) Between 10-60% by weight of a compound I or an N-oxide or a salt thereof and 515% by weight of wetting agent (for example, alcohol alkoxylates) are dissolved in water and / or in a water-soluble solvent (e.g. alcohols) up to 100% by weight. The active ingredient dissolves after dilution with water. i) Dispersible concentrates (DC) Between 5-25% by weight of a compound in an N-oxide or its salt and 1-10% by weight of dispersant (for example, polyvinylpyrrolidone) are dissolved in 100% by weight of organic solvent (for example, cyclohexanone) . Dilution with water gives a dispersion. i) Emulsifiable concentrates (EC) Between 15-70% by weight of a compound in an N-oxide or a salt thereof and 510% by weight of emulsifiers (for example, calcium dodecyldenzenesulfonate and castor oil ethoxylate) are dissolved at up to 100% by weight of organic solvent not soluble in water (for example, aromatic hydrocarbon). Dilution with water gives an emulsion. iv) Emulsions (EW, EO, ES) Between 5-40% by weight of a compound in an N-oxide or a salt thereof and 110% by weight of emulsifiers (for example, calcium dodecylbenzenesulfonate and castor oil ethoxylate) are dissolved in 20-40% by weight of organic solvent insoluble in water (for example, aromatic hydrocarbon). This mixture is introduced into 100% by weight of water by means of an emulsifying machine and converted into a homogeneous emulsion. Dilution with water gives an emulsion. v) Suspensions (SC, OD, FS) In an agitated ball mill, 20-60% by weight of a compound is ground into an N-oxide or a salt thereof with the addition of 2-10% by weight of dispersants and wetting agents (e.g., lignosulfonate). sodium and alcohol ethoxylate), between 0.1 -2% by weight of thickener (e.g. xanthan gum) and up to 100% by weight of water to give a fine suspension of the active substance npfrCLn / Lznz / e / YiAi . Dilution with water provides a stable suspension of the active substance. For the FS type composition, up to 40% by weight of binder (for example, polyvinyl alcohol) is added. vi) Water dispersible granules and water soluble granules (WG, SG) Between 50-80% by weight of a compound I or an N-oxide or salt thereof are finely ground with the addition of up to 100% by weight of dispersants and wetting agents (for example, sodium lignosulfonate and alcohol ethoxylate) and They are prepared as water-dispersible or water-soluble granules by means of technical apparatus (for example, extrusion, spray tower, fluidized bed). Dilution with water provides a stable dispersion of the active ingredient solution. vii) Water-dispersible powders and water-soluble powders (WP, SP, WS) Between 50%-80% by weight of a compound I or an N-oxide or salt thereof are ground in a rotor-stator mill with the addition of 1%-5% by weight of dispersants (for example, sodium lignosulfonate ), 1%-3% by weight of wetting agents (for example, alcohol ethoxylate) and up to 100% by weight of solid carrier, for example, silica gel. Dilution with water provides a stable dispersion of the active ingredient solution. viii) Gel (GW, GF) In an agitated ball mill, 5%-25% by weight of a compound I or an N-oxide or salt thereof is ground with the addition of 3%-10% by weight of dispersants (for example, sodium lignosulfonate ), 1%-5% by weight of thickener (e.g. carboxymethylcellulose) and up to 100% by weight of water to give a fine suspension of the active substance. Dilution with water provides a stable suspension of the active substance. ix) Microemulsion (ME) Between 5% to 20% by weight of a compound in an N-oxide or a salt thereof is added to a mixture of 5%-30% by weight organic solvents (for example, dimethylamide and fatty acid cyclohexanone), a mixture of 10%-25% by weight of surfactant (for example, alcohol ethoxylate and arylphenol ethoxylate), and npirCLn / Lznz / e / YiAi water up to 100%. This mixture is stirred for 1 hour to spontaneously produce a thermodynamically stable microemulsion. x) Microcapsules (CS) An oil phase comprising between 5%-50% by weight of a compound I or an N-oxide or a salt thereof, 0%-40% by weight of water-insoluble organic solvent (for example, aromatic hydrocarbon), 2 %-15% by weight of acrylic monomers (for example, methyl methacrylate, methacrylic acid and dior triacrylate) are dispersed in an aqueous solution of a protective colloid (for example, polyvinyl alcohol). Radical polymerization initiated by a radical initiator results in the formation of poly(methyl acrylate) microcapsules. Alternatively, an oil phase comprising between 5%-50% by weight of a compound I according to the present invention, between 0%-40% by weight of water-insoluble organic solvent (for example, aromatic hydrocarbon), and a monomer of isocyanate (e.g. diphenylmethane). 4,4'-diisocyanates) are dispersed in an aqueous solution of a protective colloid (for example, polyvinyl alcohol). The addition of a polyamine (e.g. hexamethylenediamine) results in the formation of polyurea microcapsules. The monomers amount to 1%-10% by weight. The % by weight is related to the total composition of CS, x¡) Dusty powders (DP, DS) Between 1%-10% by weight of a compound I or an N-oxide or salt thereof are finely ground and intimately mixed with up to 100% by weight of solid carrier, for example, finely divided kaolin. xii) Granules (GR, FG) Between 0.5%-30% by weight of a compound I or an N-oxide or salt thereof is finely ground and associated with up to 100% by weight of the solid carrier (e.g., silicate). Granulation is achieved by extrusion, spray drying or fluidized bed. xiii) Ultra Low Volume Liquids (ULV) Between 1-50% by weight of a compound I or an N-oxide or salt thereof are dissolved in 100% by weight of organic solvent, for example, aromatic hydrocarbon npfrCLn / Lznz / e / YiAi. Types of compositions i) to x¡) may optionally comprise other auxiliaries, such as 0.1%-1% by weight of bactericides, 5%-15% by weight of antifreeze agents, 0.1%-1% by weight of antifoam agents, and 0.1%-1% by weight of colorants. In another embodiment of the present invention, there is provided a compound of agrochemical compositions of the general Formula (I), comprising an active substance between 0.01% and 95% by weight, usually between 0.1% and 90%, and more directly between 1% and 70%, in particular between 10% and 60% by weight of active substance. The active substances are used in a purity of 90% to 100%, preferably 95% to 100% (according to an NMR spectrum). Water-soluble concentrates (LS), suspensions (SE), fluid concentrates (FS), powders for dry treatment (DS), water-dispersible powders for sludge treatment (WS), water-soluble powders ( SS), emulsions (ES), emulsifiable concentrates (EC) and gels (GF) are generally used for the treatment of plant propagation materials, particularly seeds. The compositions in question, after a two-tenth dilution, give active substance concentrations of 0.01% to 60% by weight, possibly 0.1% to 40% by weight, in ready-to-use preparations. The application can be carried out before or during planting. Methods for applying or treating compound I and compositions thereof, respectively, to a plant propagation material, especially seeds, include dressing, dressing, granulation, dusting, soaking and in-furrow application methods of the propagation material. Preferably, compound I or compositions thereof, respectively, are applied to the plant propagation material by a method that does not induce germination, for example, by dressing, granulation, dressing and seed dusting. When used in plant protection, the amounts of active substances applied are, depending on the type of effect desired, from 0.001 to 2 kg per ha, preferably from 0.005 to 2 kg per ha, more preferably from 0.05 to 0.9 kg per ha. , in particular 0.1 to 0.75 kg per ha. npfrCLn / Lznz / e / viAi In the treatment of plant propagation materials, such as seeds, for example, by dusting, covering or soaking seeds, amounts of active substance of 0.1 to 1000 g, preferably 1 to 1000 g, more preferably 1 to 100 g, are generally required. gr and even more preferably from 5 to 100 gr per 100 kilograms of plant propagation material (preferably seeds). When used in the protection of stored materials or products, the amount of active substance applied depends on the type of application area and the desired effect. The quantities usually applied in the protection of materials are 0.001 gr to 2 kg, preferably 0.005 gr to 1 kg, of active substance per cubic meter of treated material. Various types of oils, humectants, adjuvants, fertilizers, micronutrients and other pesticides (for example, herbicides, insecticides, fungicides, growth regulators, protectants) can be added to the active substances of the compositions containing them as a premix or, if necessary appropriate, not until immediately before use (tank mix). These agents can be mixed with the compositions according to the present invention in a weight ratio of 1:100 to 100:1, preferably 1:10 to 10:1. The user can apply the composition according to the present invention generally from a pre-dosing device, a backpack sprayer, a spray tank, a spray plane or an irrigation system. Usually, the agrochemical composition is composed of water, buffer, and / or additional auxiliaries at the desired application concentration and the ready-to-use spray liquid or agrochemical composition according to the present invention is thus obtained. Typically, 20 to 2000 liters, possibly 50 to 400 liters, of the ready-to-use liquid are applied per hectare of useful agricultural area. According to one embodiment, the user himself can mix individual components of the composition according to the present invention, such as parts of a kit or parts of a conventional binary mixture in a spray tank, and other auxiliaries can be added, if appropriate. npfrCLn / Lznz / e / YiAi Therefore, the compounds and compositions of the present invention are agronomically useful in protecting field crops from phytophagous invertebrate pests, and are also non-agronomically useful in protecting other crops and horticultural plants from phytophagous invertebrate pests. This utility includes the protection of crops and other plants (i.e., both agronomic and non-agronomic) that contain genetic material introduced by genetic engineering (i.e., transgenic) or modified by mutagenesis to provide advantageous traits. The compounds of the present invention are characterized by favorable soil metabolic and / or residual patterns and exhibit activity that controls a spectrum of agronomic and non-agronomic invertebrate pests. The compounds of the present invention are valuable preventive and / or curative active ingredients in the field of pest control, even at low application rates, which can be used against pesticide-resistant pests such as insects and fungi, and / or have an effect very favorable. The biocidal spectrum is well tolerated by warm-blooded species, fish and plants. In the context of the present invention, control of invertebrate pests means inhibiting the development of invertebrate pests (including mortality) that causes a significant reduction in feeding or other injuries or damage caused by the pest; related expressions are determined analogously. As mentioned in the present invention, the term invertebrate pest includes arthropods, gastropods and nematodes of economic importance as pests. The term arthropod includes insects, mites, spiders, scorpions, centipedes, millipedes, bed bugs, and symphyla. The term gastropod includes snails, slugs and other Stylommatophora. The term nematode includes all helminths, such as roundworms, heartworms, and phytophagous nematodes (Nematoda), trematodes (Tematodá), Acanthocephala, and tapeworms (Cestoda). Those skilled in the art will recognize that not all compounds are equally effective against all pests. The compounds of the present invention show activity against agronomic, forestry, greenhouse, nursery, ornamental, turf, fiber and food, public and animal health, domestic and commercial structure, product pests npfrCLn / Lznz / e / YiAi stored and economically important. These include larvae of the order Lepidoptera, such as beetworms, cutworms, loopers, and heliothines in the family Noctuidae (e.g., autumn beetworm (Spodoptera fugiperda JE Smith), beet beetworm (Spodoptera exigua Hubner), black beetworm (Agrotis Ípsilon). Hufnagel), cabbage looper (Trichoplusia ni Hubner), tobacco worm (Heliothis virescens Fabricius); borers, net worms, cone worms, cabbage worms and skeletons of the family Pyralidae (e.g. European corn borer ( Ostrinia nubilalisHubner), orange earthworm (Amyelois transitella Walker), corn root webworm (Crambus caliginoseilus Clemens), sod webworm (Herpetogramma licarsisalis Walker); leafrohers moths, budworms, seed worms, and leafworms fruit in the family Tortricidae (e.g. codling moth (Cydia pomonella Linnaeus), grape berry moth (Endopiza viteana Clemens), oriental fruit moth (Grapholita molesta Busck); and many other economically important lepidopterans (e.g. diamondback moth (Plutella xylostella Linnaeus), pink bollworm (Pectinophora gossypiella Saunders), gypsy moth (Lymantria dispar Linnaeus); nymphs and adults of the order Blattodea, including cockroaches of the families Blattellidae and Blattidae (e.g., oriental cockroach (Blatta orientalis Linnaeus), Asian cockroach (Blatella asahinai Mizukubo), German cockroach (Blattella gemnanica Linnaeus), brown-banded cockroach (Supella longipalpa Fabricius), American cockroach (Periplaneta Americana Linnaeus), brown cockroach (Periplaneta brunnea Burmeister), Madeira cockroach (Leucophaea Madeira Fabricius); foliar-feeding larvae and adults of the order Coleoptera, including weevils of the families Anthribidae, Bruchidae, and Curculionidae (e.g., weevil (Anthonomus grandis Boheman), rice water weevil (Lissorhoptrus oryzophilus Kuschel), rice weevil (Sitophilus granarius Linnaeus), rice weevil (Sitophilus oryzae Linnaeus); flea beetles, cucumber beetles, rootworms, leaf beetles, potato beetles and mining beetles of the family Chrysomelidae, e.g. the Colorado potato beetle (Leptinotarsa ​​decemlineata Say), the rootworm of western corn (Diabrotica virgifera virgifera LeConte); parpallas and other beetles of the family Scaribaeidae, for example, Japanese beetle (Popillia japonica Newman) and European parpallas (Rhizotrogus majalis npfrCLn / Lznz / e / YiAi Razoumowsky); carpet beetles of the family Dermestidae; wireworms of the family Elateridae; bark beetles of the family Scolytidae and flour beetles of the family Tenebríonidae. It also includes: adults and larvae of the order Dermaptera, including earwigs of the family Forficulidae (e.g. European earwig (Forficula auricularia Linnaeus), black earwig (Chelisoches mono Fabricius)); adults and nymphs of the orders Hemiptera and Homoptera, such as insects of the family Mirídae, cicadas of the family Cicadidae, leafhoppers (e.g. Empoasca spp.) of the family Cicadellidae, grasshoppers of the families Fulgoroidae and Delphacidae, grasshoppers of the family Membracidae, psyllids of the family Psyllidae, whiteflies of the family Aleyrodidae, aphids of the family Aphididae, phylloxera of the family Phylloxeridae, scale insects of the family Pseudococcidae, scales of the families Coccidae, Dlaspididae and Margarodidae, lace bugs of the family Tingidae , stink bugs of the family Pentatomidae, stink bugs (e.g., Blissus spp.), and other stink bugs of the family Lygaeidae, stink bugs of the family Cercopidae, stink bugs of the family Coreidae, and red and cotton stink bugs of the family Pyrrhocoridae. Also included are adults and larvae of the order Acari (mites), such as mites and red mites of the family Tetranychidae, for example, the European red mite (Panonychus ulmi Koch), two-spotted mites (Tetranychus urticae Koch), the McDaniel mite (Tetranychus mcdanieli McGregor), flat mites of the family Tenuipalpidae, e.g. citrus flat mite (Brevipalpus lewisi McGregor), rusts and mites of the family Eriophyidae and other foliar-feeding mites and mites important for human and animal health , for example, dust mites of the family Epidermoptidae, follicular mites of the family Demodicidae, grain mites of the family Glycyphagidae, ticks of the order Ixodidae, for example, the deer tick (Ixodes scapularis Say), the Australian tick of the paralysis (Ixodes holocyclus Neumann), American dog tick (Dermacentor variabilis Say), lone star tick (Amblyomma americanum Linnaeus), and scabies and itch mites in the families Psoroptidae, Pyemotidae, and Sarcoptidae; adults and immatures of the order Orthoptera, including grasshoppers, locusts and crickets, e.g. migratory grasshoppers (e.g. Melanoplus sanguinipes Fabricius, M. differentialis Thomas), katydids (e.g. Schistocerca Americana Drury), locust npfrCLn / Lznz / e / YiAi desert (Schistocerca gregaria Forskal), migratory locust (Locusta migratoria Linnaeus), house cricket (Acheta domesticus Linnaeus), mole crickets (Gryllotalpa spp.); adults and immatures of the order Diptera, including miners, mosquitoes, fruit flies (Tephritidae), frit flies (e.g. Oscinella frit Linnaeus), soil worms, house flies (e.g. Musca domestica Linnaeus), house flies minors (e.g. Fannia canicularis Linnaeus, F. femoralis Stein), stable flies (e.g. Stomoxis calcitrans Linnaeus), face flies, horn flies, hoverflies (e.g. Chiysomya spp., Phonnia spp.) , and other pests of muscoid flies, horse flies (e.g. Tabanus spp.), flies (e.g. Gastrophilus spp., Oestrus spp.), cattle larvae (e.g. Hypoderma spp.), deer flies (e.g. Chrysops spp.), keds (e.g. Melophagus ov / 7?t / sL¡nnaeus) and other Brachycera, mosquitoes (e.g. Aedes spp., Anopheles spp., Culex spp.), black flies (e.g. for example, Prosimulium spp., Simulium spp.), bites of mosquitoes, sand flies, cyatids and other nematocerans; adults and immatures of the order Thysanoptera, including onion thrips (Thrips tabaci Lindeman) and other foliar-feeding thrips; insect pests of the order Hymenoptera, including ants (e.g. red carpenter ant (Camponotus ferrugineus Fabricius), black carpenter ant (Camponotus pennsylvanicus De Geer), pharaoh ant (Monomorium pharaonis Linnaeus), small fire ant (Wasmannia auropunctata Roger), fire ant (Solenopsis geminata Fabricius), red imported fire ant (Solenopsis invicta Burén), Argentine ant (Iridomyrmex humilis Mayr), crazy ant (Paratrechina longicornis Latreille), pavement ant (Tetramorium caespitum Linnaeus), cornfield ant (Lasius alienus Forster), odorous house ant (Tapinoma sessile Say), bees (including carpenter bees), hornets, yellow jackets and wasps; insect pests of the order Isoptera, including the eastern subterranean termite (Reticulitermes flavipes Kollar), the western subterranean (Reticulitermes hesperus Banks), the Formosan subterranean termite (Coptotermes formosanus Shiraki), West Indian drywood termites (Incisitermes inmigrans Snyder) and other economically important termites; insect pests of the order Thysanura, such as the silverfish (Lepisma saccharina Linnaeus) and the bratfish (Thermobia domestica Packard); npfrCLn / Lznz / e / YiAi insect pests of the order Mallophaga, including head louse (Pediculus humanus capitis De Geer), body louse (Pediculus humanus humanus Linnaeus), chicken body louse (Menacanthus stramineus Nitszch), dog bite louse (Trichodectes cams De Geer), fluff louse (Goniocotes gallinae De Geer), sheep body louse (Bovicola ovis Schrank), short-nosed cattle louse (Haematopinus eurystemus Nitzsch), bovine long-nosed louse (Linognathus vituli Linnaeus) and other parasitic and chewing lice that attack many animals; insect pests of the order Siphonoptera, including the eastern rat flea (Xenopsylla cfteop / sRothschild), the cat flea (Ctenocephalides felis Bouche), the dog flea (Ctenocephatides canis Curtis), the chicken flea (Ceratophyllus gallinae Schrank) , the hermetic flea (Echidnophaga gallinácea) fleas (Pulex irritans Linnaeus) and other fleas that affect mammals and birds. Additional arthropod pests covered include spiders in the order Araneae, such as the brown recluse spider (Loxosceles reclusa Gertsch and Mulaik) and the black widow spider (Latrodectus mactans Fabricius), and centipedes in the order Scutigeromorpha, such as the house centipede (Scutigera coleoptrata Linnaeus). The activity also includes members of the Classes Nematoda, Cestoda, Trematoda and Acanthocephala, including economically important members of the orders Strongylida, Ascaridida, Oxiurida, Rhabditida, Spirurida and Enoplida, among other examples, economically important agricultural pests (i.e. knot nematodes root nematodes in the genus Meloidogyne, lesion nematodes in the genus Pratylenchus, stubby root nematodes in the genus Trichodorus, etc., and animal and human health pests, i.e. all trematodes, tapeworms, and roundworms economically important, such as Strongylus vulgarís in horses, Toxocara canis in dogs, Haemonchus contortus in sheep, Dirofllaria immítis Leidy in dogs, Anoplocephala peifoliata in horses, Fasciola hepatica Linnaeus in ruminants, etc.). The compounds of the present invention show particularly high activity against pests in the order Lepidoptera, for example, Alabama argillacea Hubner (cotton leafworm), Archips argyrospila Walker (fruit tree leaf roller), A. rosana Linnaeus (European leaf roller) and other species of Archips, Chilo suppressalis Walker (npfrCLn / Lznz / e / YiAi rice stem borer), Cnaphalocrosis medinalisGuenee (rice leaf roller), Crambus caliginosellus Ciemeos (corn rootworm ), Crambus teterrellus Zincken (bluegrass worm), Cydia pomonella Linnaeus (codling moth), Earías insulana Boisduval (thorn worm), Earias vittella Fabricius (thorn worm), Helicoveipa armigera, Helicoveipa armigera, Helicoverpa, Fig tree , bigel, Helicovema, Helicoveipa zea Boddie (corn worm), Heliothis virescens Fabricius (tobacco worm), Herpetogramma licarsisalis Walker (grass worm), Lobesia botrana Denis and SchiffeTrnúller (grape worm), Pectinophora gossypiella Saunders (pink worm) ), Phyllocnístis citrella Stainton (citrus leaf miner), Pieris brassicae Linnaeus (large white butterfly), Pieris rapae Linnaeus (small white butterfly), Plutella xylostella Linnaeus (diamondback moth), Spodoptera exigua Hubner (army worm beet), Spodoptera litura Fabricius (tobacco cutworm, cluster caterpillar), Spodoptera frugiperda JE Smith (autumn armyworm), Trichoplusia n / Húbner (cabbage looper) and tomato leaf Meyrick)). The compounds of the present invention also have commercially significant activity in members of the order Homoptera, including: Acyrthisiplionpisum Harris (aphid), Aphis craccivora Koch (cowpea aphid), Aphis fabae Scopoli (black bean aphid), Aphis gossypii Glover (cowpea aphid). cotton, melon aphid), Aphis pomi De Geer (apple aphid), Aphis spiraecola patch (spirea aphid), Aulacorthum solani Kaltenbach (foxglove aphid), Chaetosiphon fragaefolii Cockerell (strawberry aphid), Diuraphis noxia Kurdjumov / Mordvilko (apple aphid Russian wheat), Dysaphis plantaginea Paaserini (rose apple aphid), Eriosoma lanigerum Hausmann (woolly apple aphid), HyalopteruspruniGeoffroy (oatmeal aphid tarnip aphid), Metopolophium dirrhodum Walker (cereal aphid), Macrosipum euphorbiae Thomas ( potato aphid), Myzus persicae Sulzer (peach and potato aphid, green peach aphid), Nasonovia ribisnigri Mosley (lettuce aphid), Pemphigus spp. (root aphids and gall aphids), Rhopalosiphum maidis Fitch (corn leaf aphid), Flhopalosiphum pad / Linnaeus (oat aphid), Schizaphis graminum Rondani (green stink bug), Sitobion gallinae Fabricius (grain aphid English), Therioaphis maculata Buckton (spotted alfalfa aphid), Toxoptera aurantii, Boyer de Fonscolombe (black citrus aphid) and Toxoptera citiicida Kirkaldy npfrCLn / Lznz / e / YiAi (brown citrus aphid); Adelges spp. (adelgids); Phylloxera devastatrix Pergande (pecan phylloxera); Bemisia tabaci Gennadius (tobacco whitefly, sweetpotato whitefly), Bemisia argentifolii Bellows and Perring (silverleaf whitefly), Dialeurodes c / Yr / Ashmead (citrus whitefly) and Trialeurodes vaporariorum Westwood greenhouse); Empoasca fabae Harris, (potato leafhopper), Laodelphax striatellus Fallen (smaller brown grasshopper), Macrolestes quadrílineatus Forbes (aster leafhopper), Nephotettix cinticeps Uhler (green leafhopper), Nephotettix nigropictus Stal (rice leafhopper), Nilaparvata lucker Peregrínus maidis Ashmead (corn grasshopper), Sogatella furcifera Horvath (white-backed grasshopper), Sogatodes orizicola Muir (rice leafhopper), Typhlocyba pomaria McAfee, white apple leafhopper, Erythroneoura spp. (grape cicada); Magicidada septendecim Linnaeus (periodical cicada); Icerya acquired Maskell (cotton mattress scale), Quadraspidiotus perniciosus Comstock (San Jose scale); Planococcus citri Risso (citrus mealybug); Pseudococcus spp. (another mealybug complex); Cacopsylla pyricola Foerster (Pear psylla), Trioza diospyri Ashmead (Persimmon psylla). These compounds also have activity in members of the order Hemiptera, including: Acrostemum hilare Say (green stink bug), Anasa tristis De Geer (bed bug), Blissus leucopterus leucopterus Say (chinch), Corythuca gossypii Fabricius (cotton lace bug), Cyrtopeltis Modesta Distante (tomato bug), Dysdercus suturellus Herrich-S chaffer (cotton spot), Euchistus servusSay (brown bug), Euchistus variolrius Palisot deBeauvois (stink bug), Graptósthetus spp. (seed bug complex), Leptoglossus corculus Say (leaf-footed pine seed bug), Lygus lineolaris Palisot de Beauvois (tarnished plant bug), Nezara viridula Linnaeus (southern green stink bug), Oebalus pugnax Fabricius ( rice stink bug), Oncopeltus fasciatus DaEas (large cotton bug), Pseudatomoscelis serietus Reuter (cotton flea). Other insects that are controlled by compounds of the General Formula (I) of the present invention include: Thysanoptera (e.g., Frankliniella occidentalis Pergande (western flower thrips), Scirthothqps citri Moulton (citrus thrips), Sericothrips variabais Beach ( soybean), and Thrips npfrCLn / Lznz / e / YiAi tabac / Lindeman (onion thrips); and the order Coleoptera (e.g., Leptinotarsa ​​decemlineata Say (Colorado potato beetle), Epilachna varivestis Mulsant (Mexican bean beetle) and wireworms of the genus Agriotes, Athous or Limonius). In particular, the compounds of the General Formula (I), their N-oxides, their isomers, their polymorphs and their salts are especially suitable for effectively combating the following pests: insects of the order Lepidoptera (Lepidoptera), for example, Agrotis ypsilon, Agrotis segetum, Alabama argillacea, Anticarsia gemmatalis, Argyresthia conjugella, Autographa gamma, Bupalus piniarius, Cacoecia murinana, Capua reticulana, Cheimatobia brumata, Chilo infuscatellus, Choristoneura fumiferana, Choristoneura occidentalis, Cirphis unipuncta, Cydia pomonella, Dendrolimus pini, Diaphania nitidalis , Diatraea grandiosella, Earías insulana, Earias vittella, Elasmopalpus lignosellus, Eupoecilia ambiguella, Evetria bouliana, Feltia subterranean, Galleria mellonella, Grapholita funebrana, Grapholita molesta, Helicoverpa armigera, Helicoverpa virescens, Helicoverpa zea, Hellula undalis, Hibernia defoliaria, Hyphantria cunea, Hyponomeuta mal inellus , Keiferia lycopersicella, Lambdina fiscellaria, Laphygma exigua, Leucoptera coffeella, Leucoptera scitella, Lithocolletis blancardella, Lobesia botrana, Loxostege sticticalis, Leucinodes orbonalis, Lymantría dispar, Lymantría monacha, Lyonetia clerkella, Malacosoma neustria, Mamestra brassicae, Orgyia pseudotsugata, Ostri nia nubilalis, Panolis flammea, Pectinophora gossypiella, Peridroma saucia, Phalera bucephala, Phthorímaea operculella, Phyllocnistis citrella, Pieris brassicae, Plathypena scabra, Plutella xylostella, Pseudoplusia includens, Rhyacionia frustrana, Scirpophaga incertulas, Scrobipalpula ABSOLUTA, Sitotroga cerealella, Sparganothis pilleríana, Spodoptera frugiperda, Spodoptera littoralis, Spodoptera litura, Spodoptera exigua, Thaumatopoea pityocampa, Tortrix viridana, Trichoplusia ni and Zeiraphera canadensis:, and Beetles (Coleoptera), e.g. Agrilus sinuatus, Agriotes lineatus, Agriotes obscurus, Amphimallus solstitiaiis, Anisandrus dispar, Anthonomus grandis, Anthonomus pomorum, Aphthona euphoridae, Athous haemorrhoídalis, Atomaria linearis, Blastophagus piniperda, Blitophaga undata, Bruchus rufimanus, Bru chus pisorum, Bruchus lentis, Byctiscus betulae, Cassida npirCLn / Lznz / e / YiAi nebulosa, Cerotoma trifurcata, Cetonia aurata, Ceuthorrhynchus assimilis, Ceuthorrhynchus napi, Chaetocnema tibialis, Conoderus vespertinus, Criocerís asparagi, Ctenicera ssp., Diabrotica longicornis, Diabrotica semipunctata, Diabrotica undecimpunctata Diabrotica speciosa, Diabrotica virgifera, Epilachna varivestis, Epitrix hirtipennis, Eutinobothrus brasiliensis, Hylobius abietis, Hypera brunneipennis, Hypera postíca, Ips typographus, Lema bilineata, Lema melanopus, Leptinotarsa ​​decemlineata, Limonius californicus, Lissorhoptrus oryzophilus, Melanotus communis, Meligethes aene us, Melolontha hippocastani, Melolontha melolontha, Oulema oryzae, Otiorrhynchus sulcatus, Otiorrhynchus ovatus, Phaedon cochleariae, Phyllobius pyri, Phyllotreta chrysocephala, Phyllophaga sp., Phyllopertha horticola, Phyllotreta nemorum, Phyllotreta striolata, Popillia japonica, Sitona lineatus and Sitophilus gran ary; flies, mosquitoes (Diptera), e.g. Aedes aegypti, Aedes albopictus, Aedes vexans, Anastrepha ludens, Anopheles maculipennis, Anopheles crucians, Anopheles albimanus, Anopheles gambiae, Anopheles freeborni, Anopheles leucosphyrus, Anopheles minimus, Anopheles quadrimaculatus, Calllphora vicina, Cerat itis capitata, Chrysomya bezziana, Chrysomya hominivorax, Chrysomya macellaria, Chrysops discalis, Chrysops silacea, Chrysops atlanticus, Cochliomyia hominivorax, Contarinia sorghicola Cordylobia anthropophaga, Culicoides furens, Culex pipiens, Culex nigripalpus, Culex quinquefasciatus, Culex tarsalis, Culiseta inornata, Culiseta melanura, Dacus cucurbitae, Dacus oleae, Dasineura brassicae, Delia antique, Delia coarctata, Delia platura, Delia radicum, Dermatobia hominis, Fannia canicularis, Geomyza Tripunctata, Gasterophilus intestinalis, Glossina morsitans, Glossina palpalis, Glossina fuscipes, Glossina tachinoides, Haematobia irritans, Haplodiplosis equestris, Hippelates spp., Hylemyia platura, Hypoderma lineata, Leptoconops torrens, Liriomyza sativae, Liriomyza trifolii, Lucilia caprina, Lucilia cuprina, Lucilia sericata, Lycoria pectoralis, Mansonia titillanus, Mayetiola destructor, Musca autumnalis, Musca domestica, Muscina stabulans, Oestrus ovis, Opomyza florum, Oscinella frit, Pegomya hysocyami, Phorbia antiqua, Phorbia brassicae, Phorbia coarctata, Phlebotomus argentipes, Psorophora columbiae, Psila rosae, Psorophora discolor, Prosimulium mixtum, Rhagoletis cerasi, Rhagoletis pomonella, Sarcophaga haemorrhoidalis, Sarcophaga spp., Simulium vitta tum, Stomoxis calcitrans , Tabanus bovinus, Tabanus atratus, Tabanus lineóla, and Tabanus npfrCLn / Lznz / e / YiAi similis, Típula olerácea, and Típula paludosa; termites (Isoptera), for example, Calotermes flavicollis, Leucotermes flavipes, Heterotermes aureus, Fleticulitermes flavipes, Reticulitermes virginicus, Reticulitermes lucifugus, Reticulitermes santonensis, Reticulitermes grassei, Termes natalensis, and Coptotermes formosanus; cockroaches (Blattaria Blattodea), for example, Blattella germánica, Blattella asahinae, Periplaneta Americana, Periplaneta japonica, Periplaneta brunnea, Periplaneta fuligginosa, Periplaneta australasiae, and Blatta orientalis; ants, bees, wasps and sawflies (Hymenoptera), for example, Athalia rosae, Atta cephalotes, Atta capiguara, Atta cephalotes, Atta laevigata, Atta robusta, Atta sexdens, Atta texana, Crematogaster spp., Hoplocampa minuta, Hoplocampa testudínea, Lasius niger, Monomorium pharaonis, Solenopsis geminata, Solenopsis invicta, Solenopsis richteri, Solenopsis xyloni, Pogonomyrmex barbatus, Pogonomyrmex californicus, Pheidole megacephala, Dasymutilla occidentalis, Bombus spp., Vespula squamosa, Paravespula vulgaris, Paravespula pennsylvanica, Paravespula germánica, Dolichovespula maculata, Vespa crabro, Polistes rubiginosa, Camponotus floridanus, and Linepithema humile; crickets, grasshoppers, locusts (Orthoptera), e.g. Acheta domestica, Gryllotalpa gryllotalpa, Locusta migratoria, Melanoplus bivittatus, Melanoplus femurrubrum, Mexican melanoplus, Melanoplus sanguinipes, Melanoplus spretus, Nomadacris septemfasciata, Schistocerca Americana, Schistocerca gregaria, Dociostaurus maroccanus, Ta chycines asynamorus , Oedaleus senegalensis, Zonozerus variegatus, Hieroglyphus daganensis, Kraussaria angulifera, Calliptamus italicus, Chortoicetes terminifera, and Locustana pardalina; Araneida, for example, Latrodectus mactans, and Loxosceles reclusa; fleas (Siphonaptera), e.g. Ctenocephalides felis, Ctenocephalides canis, Xenopsylla cheopis, Pulex irritans, Tunga penetrans, and Nosopsyllus fasciatus, silverfish, firebrat (Thysanura), e.g. , Scutigera oleoptrata, millipedes (Diplopoda), e.g. Narceus spp., Earwigs (Dermaptera), e.g. forficula auricularia, lice (Phthiraptera), e.g. Pediculus humanus capitis, Pediculus humanus corporis, Pthirus pubis, Haematopinus eurysternus, Haematopinus suis, Linognathus vituli, Bovicola bovis, Menopon allinae, npfrCLn / Lznz / e / YiAi. Menacanthus stramineus and Solenopotes capillatus. Collembola (springtails), e.g. Onychiurus ssp. The compounds of Formula (I) of the present invention are also suitable for controlling nematodes: plant parasitic nematodes such as root knot nematodes, Meloidogyne hapla, Meloidogyne incognita, Meloidogyne javanica, and other Meloidogyne species; cyst-forming nematodes, Globodera rostochiensis and other Globodera species; Heterodera Avenae, Heterodera glycines, Heterodera schachtii, Heterodera trifolli, and other Heterodera species; Seed gall nematodes, Anguina species; stem and leaf nematodes, Aphelenchoides species; Sting nematodes, Belonolaimus longicaudatus and other Belonolaimus species; Pine nematodes, Bursaphelenchus xylophilus and other Bursaphelenchus species; Ring nematodes, Criconema species, Criconemella species, Criconemoides species, Mesocriconema species; Stem and bulb nematodes, Ditylenchus destructor, Ditylenchus dipsaci and other Ditylenchus species; Awl nematodes, Dolichodorus species; Spiral nematodes, Heliocotylenchus multicinctus and other Helicotylenchus species; Sheath and sheathoid nematodes, Hemicycliophora species and Hemicriconemoides species; Hirshmanniella species; Lance nematodes, Hoploaimus species; false rootknot nematodes, Nacobbus species; Needle nematodes, Longidorus elongatus and other Longidorus species; Lesion nematodes, Pratylenchus neglectus, Pratylenchus penetraos, Pratylenchus curvitatus, Pratylenchus goodeyi and other Pratylenchus species; Burrowing nematodes, Radopholus similis and other Radopholus species; Reniform nematodes, Rotylenchus robustus and other Rotylenchus species; Scutellonema species; Stubby root nematodes, Trichodorus primitivus and other Trichodorus species, Paratrichodorus species; Stunt nematodes, Tylenchorhynchus claytoni, Tylenchorhynchus dubius and other Tylenchorhynchus species; Citrus nematodes, Tylenchulus species; Dagger nematodes, Xiphinema species; and other species of plant parasitic nematodes. The compounds of the General Formula (I) and their salts are also useful for controlling arachnids (Arachnoidea), such as mites (Acariña), for example, of the families Argasidae, Ixodidae and Sarcoptidae, such as Amblyomma americanum, Amblyomma variegatum, Argas persicus, Boophilus annulatus, npfrCLn / Lznz / e / YiAi Boophilus decoloratus, Boophilus microplus, Dermacentor silvarum, Hyalomma truncatum, Ixodes ricinus, Ixodes rubicundus, Omithodorus moubata, Otobius megnini, Dermanyssus gallinae, Psoroptes ovis, Rhipicephalus appendiculatus, Rhipicephalus evertsi, Sarcoptes scabiei, and Eriophyidae spp. such as Aculus schlechtendali, Phyllocoptrata oleivora and Eriophyes sheldoni; Tarsonemidae spp. such as Phytonemus pallidus and Polyphagotarsonemus latus; Tenuipalpidae spp. such as Brevipalpus phoenicis; Tetranychidae spp. such as Tetranychus cinnabarinus, Tetranychus kanzawai, Tetranychus pacificus, Tetranychus telarius and Tetranychus urticae, Panonychus ulmi, Panonychus citri, and oligonychus pratensis. In one embodiment of the present invention, there is provided the compound of General Formula (I) that is useful for controlling insects selected from selected sucking or boring insects, such as insects of the genera Thysanoptera, Diptera and Hemiptera, particularly the following species: Thysanoptera: Frankliniella fusca, Frankliniella occidentalis, Frankliniella tritici, Scirtothrips citri, Thrips oryzae, Thrips palmi and Thrips tabaci, Diptera: Aedes aegypti, Aedes albopictus, Aedes vexans, Anastrepha ludens, Anopheles maculipennis, Anopheles crucians, Anopheles albimanus, Anopheles gambiae, Anopheles freeborni, Anopheles leucosphyrus, Anopheles minimus, Anopheles quadrimaculatus, Calliphora vicina, Ceratitis capitata, Chrysomya bezziana, Chrysomya hominivorax, Chrysomya macellaria, Chrysops discalis, Chrysops silacea, Chrysops atlanticus, Cochliomyia hominivorax, Contarinia sorghicola Cordylobia anthropophaga, Culicoides furens, Culex pipiens, Culex nigripalpus, Culex quinquefasciatus, Culex tarsalis, Culiseta inornata, Culiseta melanura, Dacus cucurbitae, Dacus oleae, Dasineura brassicae, Delia antique, Delia coarctata, Delia platura, Delia radicum, Dermatobia hominis, Fannia canicularís, Geomyza Tripunctata, Gasterophilus intestinalis, Glossina morsitans, Glossina palpalis, Glossina fuscipes, Glossina tachinoides, Haematobia írritans, Haplodiplosis equestris, Hippelates spp., Hylemyia platura, Hypoderma lineata, Leptoconops torrens, Liriomyza sativae, Liriomyza trifolii, Lucilia caprina, Lucilia caprina, Lucilia sericata, Lycoria pectoralis, Mansonia titillanus, Mayetiola destructor, Musca autumnalis, Musca domestica, Muscina stabulans, Oestrus ovis, Opomyza florum, Oscinella frit, Pegomya hysocyami, npfrCLn / Lznz / e / YiAi Ancient Phorbia, Phorbia brassicae, Phorbia coarctata, Phlebotomus argentipes, Psorophora columbíae, Psila rosae, Psorophora discoior, Prosimulium mixtum, Rhagoletis cerasi, Rhagoletis pomonella, Sarcophaga haemorrhoidalis, Sarcophaga spp., Simulium vittatum, Stomoxis calcitrans, Tabanus bovinus, Tabanus atratus, Tabanus lineola, and Tabanus similis, Típula oleracea, and Típula paludosa; Hemiptera, particularly aphids: Acyrthosiphon onobrychis, Adelges laricis, Aphidula nasturtil, Aphis fabae, Aphis forbesi, Aphis pomi, Aphis gossypii, Aphis grossulariae, Aphis schneideri, Aphis spiraecola, Aphis sambuci, Acyrthosiphon pisum, Aulacorthum solani, Brachycaudus cardui, Brachy caudus helichrysi, Brachycaudus persicae, Brachycaudus prunicola, Brevicoryne brassicae, Capitophorus horni, Cerosipha gossypii, Chaetosiphon fragaefolii, Cryptomyzus ribis, Dreyfusia nordmannianae, Dreyfusia piceae, Dysaphis radicóla, Dysaulacorthum pseudosolani, Dysaphis plantaginea, Dysaphis pyri, Empoasca fabae, Hyalopterus pruni, Hyperomyzus lactucae, Macrosiphum gallinae , Macrosiphum euphorbiae, Macrosiphon rosae, Megoura viciae, Melanaphis pyrarius, Metopolophium dirhodum, Myzodes persicae, Myzus ascalonicus, Myzus cerasi, Myzus varians, Nasonovia ribis-nigri, Nilaparvata iugens, Pemphigus bursarius, Perkinsiella saccharicida, Phorodon humuli, Psylla mail, P sylla piri , Rhopaiomyzus ascalonicus, Rhopalosiphum maidis, Rhopalosiphum padi, Rhopalosiphum insertum, Sappaphis mala, Sappaphis mali, Schizaphis graminum, Schizoneura lanuginosa, Sitobion gallinae, Trialeurodes vaporariorum, Toxoptera aurantiiand and Viteus vitifolii. In one embodiment, the present invention provides a composition comprising a biologically effective amount of the compound of General Formula (I) and at least one additional biologically active compatible compound selected from fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers and nutrients. The compounds used in the composition and in combination with the compound of the general Formula (I) are also called active compatible compounds. The known fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics and nutrients and npfrCLn / Lznz / e / YiAi described can be combined with at least one compound of the General Formula (I) of the present description. For example, fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers and nutrients disclosed and described in WO2016156129 and / or WO2017153200 can be combined with at least one compound of the General Formula (I) of this description. The fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers and nutrients described in WO2016156129 and / or WO2017153200 are incorporated herein by reference as non-limiting examples that can be combined with at least one compound of the general Formula (I) of the present description. In particular, the compounds of the present invention can be mixed with at least one additional biologically active compatible compound including, among others, fungicides, nematocides, bactericides, acaricides, growth regulators such as rooting stimulants, chemosterylants, semiochemicals, repellents, attractants. , pheromones, feeding stimulants, other biologically active compounds or entomopathogenic bacteria, viruses or fungi to form a multicomponent pesticide that provides an even broader spectrum of agricultural utility. Examples of such compounds or biologically active agents / mixing partners with which the compound of Formula (I) of the present invention can be combined / formulated are described in WO2019072906A1 (pages 27 to 37). In one embodiment, biological agents for mixing with the compounds of the present invention include Bacillus thuringiensis, delta endotoxin from Bacillus thuringiensis, as well as naturally occurring and genetically modified viral incecticides, including members of the Baculoviridae family, as well as entomophagous fungi. . In certain instances, combinations with other invertebrate pest control compounds or agents that have a similar control spectrum, but a different mode of action, may be particularly advantageous for resistance management. Thus, the compositions of the present invention may further comprise a biologically effective amount of at least one additional invertebrate pest control compound or agent having a similar control spectrum, but a different mode of action. Contacting a genetically modified plant with an instantaneous plant protection compound (e.g., protein) or the site of the plant with a biologically effective amount of a compound of the invention can also provide a broader spectrum of plant protection and be advantageous for resistance management. In one embodiment of the present invention, the biologically effective amount of the compound of the general Formula (I) in the compositions ranges from 0.1% to 99% by weight with respect to the total weight of the composition, preferably from 5% to 50% by weight. weight with respect to the total weight of the composition. The present invention further provides a method for combating invertebrate pests, which comprises contacting the invertebrate pests, their habitat, the breeding ground, food supply, plant, seed, soil, area, material or environment in which the invertebrates grow or can grow. invertebrate pests, or the materials, plants, seeds, soils, surfaces or spaces must be protected from pest attack or infestation with a biologically effective amount of the compound or composition of the present invention. Invertebrate pests are controlled and the protection of agronomic, horticultural and specialty crops, animal and human health is achieved by applying one or more of the compounds of the present invention, in an effective amount, to the pest environment. , including the agronomic and / or non-agronomic place of infestation, to the area to be protected, or directly on the pests to be controlled. Therefore, the present invention further comprises a method for the control of soil- and leaf-dwelling invertebrates and the protection of agronomic and / or non-agronomic crops, comprising contacting the invertebrates or their environment with a biologically effective amount of one or more of the compounds of the present invention, or with a composition comprising at least one such compound or a composition comprising at least one such compound and an effective amount of at least one compound or agent npfrCLn / Lznz / e / YiAi additional biologically active. A preferred method of contact is by spraying. Alternatively, a granular composition comprising a compound of the present invention can be applied to plant foliage or soil. The compounds of the present invention are effective in their performance through the absorption of the plant when it comes into contact with a composition that comprises a compound of the present invention applied by soaking the soil with a liquid formulation, applying a granular formulation in the soil, a nursery box treatment or a transplant dip. Other contact methods include application of a compound or composition of the present invention by direct residual aerosols, aerosols, seed coatings, microencapsulations, systemic uptake, baits, spikes, boluses, nebulizers, fumigants, aerosols, powders and many others. The compounds of the present invention can be incorporated into baits that are consumed by invertebrates or within devices such as traps and the like. Granules or baits comprising between 0.01-5% active ingredient, 0.05-10% moisture retention agent(s) and 40-99% vegetable flour are effective in controlling soil insects with a very low application, particularly a dose of active ingredient that is lethal by ingestion and not by direct contact. The compounds of the present invention can be applied in their pure state, but most of the time it will be a formulation comprising one or more compounds with suitable carriers, diluents, surfactants and possibly in combination with a food, depending on the expected end use. A preferred method of application involves spraying the compounds in a water dispersion or refined oil solution. Combinations with aerosol oils, aerosol oil concentrations, spreading adhesives, adjuvants, other solvents, and synergists, such as piperonyl butoxide, often improve the effectiveness of the compound. The application rate required for effective control (i.e., “biologically effective amount”) will depend on factors such as the invertebrate species to be controlled, the life cycle of the pest, its life stage, its size, location, time of year, crop or host animal, feeding behavior, mating behavior, environmental humidity, temperature, and the like. Under normal circumstances, application rates of approximately 0.01 to 2 kg of active ingredient per hectare are sufficient to control pests in agronomic ecosystems, but as little as 0.0001 kg / hectare may be sufficient or up to 8 kg / hectare may be needed. hectare. For non-agronomic applications, effective use rates will range from approximately 1.0 to 50 mg / square meter, but as little as 0.1 mg / square meter may be sufficient or as much as 150 mg / square meter may be necessary. One skilled in the art can easily determine the biologically effective amount necessary for the desired level of invertebrate pest control. The animal pest, that is, insects, arachnids and nematodes, the plant, the soil or the water in which the plant grows may come into contact with compounds of the General Formula (I), their N-oxides and salts or compositions that They contain any application method known in the art. As such, “coming into contact” includes both direct contact (applying the compounds / compositions directly to the animal or plant pest, usually on the foliage, stem or roots of the plant) and indirect contact (applying the compounds / compositions). compositions in the place where the animal or plant pest is found). The compounds of the present invention or the pesticide compositions containing them can be used to protect growing plants and crops from attack or infestation by animal pests, especially insects, mites or arachnids, by placing the plant / crop in contact with a quantity effective as a pesticide of at least one compound of the present invention. The term “crop” refers to both growing and harvested crops. In one embodiment, the present invention provides a method for protecting crops from infestation attack by invertebrate pests, comprising contacting the crop with a biologically effective amount of the compound or composition of the present invention, isomer, polymorph, Noxide or get out of it. The compounds of the present invention are used as such or in the form of compositions by treating insects or plants, plant propagation materials, such as seeds, soil, surfaces, materials or rooms to protect from insect attack, with an effective insecticidal amount of the active compounds. The application can be carried out before or after infection of plants, plant propagation materials such as seeds, soil, surfaces, materials or rooms by insects. In one embodiment, the present invention provides a method of protecting seeds from soil insects and protecting the roots and shoots of soil seedlings from foliar insects comprising contacting the seeds before sowing and / or after sowing. prior germination with the compound or composition of the present invention, N-oxide or salt thereof. Furthermore, the present invention provides a method of treating or protecting animals against parasite infestation or infection comprising orally, topically or parenterally administering or applying to animals a biologically effective amount of the compound or composition of the present invention. invention, isomer, polymorph, N-oxide or acceptable veterinary salt thereof. For use in the treatment of crop plants, the application rate (effective dose application) of the compound of the present invention can be in the range of 1 gai to 5000 gai per hectare in agricultural or horticultural crops, preferably 25 g to 600 gr per hectare, more preferably from 50 gr to 500 gr per hectare. The compounds and compositions of the present invention are particularly useful in the control of a multitude of insects on various cultivated plants, such as cereals, tubers, oil crops, vegetables, spices, ornamental plants, for example, seeds of durum wheat and other wheat. , barley, oats, rye, corn (feed corn and sweet corn), soybeans, oil crops, cruciferous, cotton, sunflowers, bananas, rice, rapeseed, turnip, sugar beet, fodder beet, eggplant, potatoes, grass, lawn, lawn , fodder grass, tomatoes, leeks, pumpkin, cabbage, iceberg lettuce, pepper, cucumbers, melons, Brassica species, melons, beans, peas, garlic, onion, carrots, tuberous plants such as potatoes, sugar cane, tobacco, grapes, petunias, geraniums / pelargoniums, pansies and impatiens. npfrCLn / Lznz / e / YiAi Particularly, the compound or composition of the present invention is useful for protecting agricultural crops such as cereals, corn, rice, soybeans and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, plants horticultural crops, cucurbits, oil plants, tobacco, coffee, tea, cocoa, sugar beet, sugar cane, cotton, potato, tomato, onion, peppers and other vegetables and ornamental plants. The compounds of the present invention are effective both by contact (through the floor, glass, wall, bedding net, carpet, plant parts or animal parts), and by ingestion (bait or plant parts). The compounds of the present invention can also be applied against non-crop invertebrate pests, such as ants, termites, wasps, flies, mosquitoes, crickets, or cockroaches. For use against such non-crop pests, the compounds of the present invention are specifically used in a bait composition. The bait may be a liquid, a solid, or a semi-solid preparation (e.g., a gel). Solid baits can be formed into various forms suitable for the respective application, for example, pellets, blocks, rods or discs. Liquid baits can be filled into various devices to ensure proper application, for example, open containers, spray devices, drip sources, or evaporation sources. Gels can be based on aqueous or oil matrices and can be formulated according to particular needs in terms of adhesion, moisture retention or aging characteristics. The bait used in the composition is a product attractive enough to encourage insects such as ants, termites, wasps, flies, mosquitoes, crickets or cockroaches, etc., to eat it. Attractiveness can be manipulated using food stimulants or sexual pheromones. Food stimulants are chosen, for example, among others, from animal and / or vegetable proteins (meat, fish or blood meal, insect parts, egg yolk), from fats and oils of animal and / or vegetable origin. , or mono, oligo or polyorganosaccharides, especially sucrose, lactose, fructose, dextrose, glucose, starch, pectin or even molasses or honey. Fresh or decomposed parts of fruits, crops, plants, animals, insects or specific parts thereof can also serve as feeding stimulants. Sex pheromones are known to be more specific to insects. Specific pheromones are described in the published material and are known to those skilled in the art. For bait compositions, the typical content of an active ingredient is between 0.001% to 15% by weight, desirably between 0.001% to 5% by weight of the active compound. The compound formulations of the present invention, such as aerosols (e.g., aerosol cans), oil aerosols or pump aerosols, are well suited for the non-professional user to control pests such as flies, fleas, ticks, mosquitoes or cockroaches. Aerosol recipes are preferably composed of the active compound, solvents such as lower alcohols (e.g. methanol, ethanol, propanol, butanol), ketones (e.g. acetone, methyl ethyl ketone), paraffin hydrocarbons (e.g. kerosenes). with boiling ranges of approximately 50θ to 250eC, dimethylformamide, N-methylpyrrolidone, dimethyl sulfoxide, aromatic hydrocarbons such as toluene, xylene, water, as well as auxiliaries such as emulsifiers, such as sorbitol monooleate, oleyl ethoxylate with 3-7 mol of ethylene oxide, fatty alcohol ethoxylate, perfume oils such as ethereal oils, esters of medium fatty acids with lower alcohols, aromatic carbonyl compounds, if applicable, stabilizers such as sodium benzoate, amphoteric surfactants, lower epoxides, triethyl orthoformate and, if necessary, propellants such as propane, butane, nitrogen, compressed air, dimethyl ether, carbon dioxide, nitrous oxide, or mixtures of these gases. Oil spray formulations differ from aerosol formulations in that no propellants are used. For use in aerosol compositions, the content of the active ingredient is 0.001 to 80% by weight, preferably 0.01 to 50% by weight and even more preferably 0.01 to 15% by weight. The compounds of the present invention and their respective compositions can also be used in mosquito fumigation coils, smoke cartridges, vaporizer plates or long-term vaporizers and also in moth papers, moth pads or other heat-independent vaporizer systems. Methods of controlling infectious diseases transmitted by insects (for example, malaria, dengue and yellow fever, lymphatic filariasis, leishmaniasis) with compounds of the General Formula (I) and their respective compositions also comprise the treatment of surfaces of cabins and houses, air spraying and impregnation of curtains, tents, articles of clothing, mosquito nets, tsetse fly traps or similar. Insecticidal compositions for application to fibers, fabrics, knitted fabrics, nonwovens, meshes or sheets and canvas preferably comprise a mixture that includes the insecticide, optionally a repellent and at least one binder. Suitable repellents are, for example, Ν,Ν-diethyl-meta-toluamide (DEET), N,N-diethylphenylacetamide (DEPA), 1 -(3-cyclohexan-1-ílo-carbonílo)-2-methylpiñna , (2hydroxymet¡lc¡clohex¡l) acetic acid lactone, 2-ethyl-1, 3-hexandiol, indalone, methylneodecanamide (MNDA), a pyrethroid not used for insect control, such as {(+ / -)- 3-allylo-2-methyl4-oxocyclopent-2-(+)-enyl-(+)-transchrysanthemate (Esbiotrin), a repellent derived from or identical to plant extracts such as limonene, eugenol, (+)- Eucamalol (1), (-)-l-epi-eucamalol or crude plant extracts of plants such as Eucalyptus maculata, Vitex rotundifolia, Cymbopogan martinii, Cymbopogan citratus (lemongrass), Cymopogan nartdus (citronella). Suitable binders are selected, for example, from polymers and copolymers of vinyl esters of aliphatic acids (such as vinyl acetate and vinyl versatate), acrylic and methacrylic esters of alcohols, such as butyl acrylate, 2-ethylhexyl acrylate, and methyl acrylate. , mono- and di-ethylenically unsaturated hydrocarbons, such as styrene, and aliphatic hydrocarbons, such as butadiene. The impregnation of curtains and mosquito nets is generally carried out by dipping the textile material in emulsions or dispersions of the insecticide or by spraying them on the nets. The compounds of the present invention and their compositions can be used to protect wooden materials such as trees, wooden fences, sleepers, etc., and buildings such as houses, outbuildings, factories, but also construction materials, furniture, leather, fibers, vinyl articles, npfrCLn / Lznz / e / YiAi electrical cables and wires, etc., from ants and / or termites, and to control that ants and termites do not damage a crop or human (for example, when pests invade housing and public facilities). The compounds of the present invention are applied not only to the surrounding floor surface or subfloor to protect wood materials, but can also be applied to heavy items such as subfloor concrete surfaces, niche posts, beams, plywood, furniture, etc., wooden items such as particle board, half boards, etc. and vinyl items such as covered electrical cables, vinyl sheets, thermal insulating material such as styrene foams, etc. In case of application against ants that damage crops or humans, a compound of the present invention is applied to the surrounding soil crops, or applied directly to the ant nest, or the like. Seed treatment The present invention further provides seed treatment comprising the compounds of the present invention, particularly in an amount ranging from approximately 0.0001% to 1% by weight of the seed before treatment. The compounds of the present invention are also suitable for treating seeds to protect them against insect pests, in particular soil-dwelling insect and mite pests, and also to protect plant roots and shoots. resulting against soil pests and foliar insects. The compounds of the present invention are particularly useful for protecting the seeds and roots of the resulting plants against soil pests (white grubs, termites, wireworms), as well as for protecting shoots against soil pests and foliar insects. Preference is given to protecting the roots and resulting shoots of the plant. Most preferred is the protection of resulting plant shoots from piercing and sucking insects, wherein protection against aphids, jassids, thrips and whiteflies is most preferred. npirCLn / Lznz / e / YiAi Therefore, the present invention comprises a method for protecting seeds from insects, particularly soil insects, and protecting seedlings, roots and shoots from insects, particularly soil and foliar insects. This method comprises contacting seeds before sowing or after pregermination with a compound of the present invention. Particularly preferable is a method in which the roots and shoots of the plant are protected; More preferable is a method in which the plant shoots are protected from piercing and sucking insects and, even more preferable is a method in which the plant shoots are protected from aphids. The term seed encompasses seeds and propagules of plants of all types, including, but not limited to, true seeds, seed pieces, shoots, corms, bulbs, fruits, tubers, grains, cuttings, cut shoots and the like, and in a preferred embodiment means true seeds. The term seed treatment encompasses all suitable seed treatment techniques known in the art, such as coating, coating, dusting, soaking and granulating seeds. The present invention also comprises seeds coated or containing the active compound. Seeds may be coated with seed coating compositions containing the compounds of the present invention. For example, seed coating compositions are disclosed in EP3165092, EP3158864, WO2016198644, WO2016039623, WO2015192923, CA2940002, US2006150489, US2004237395, WO2011028115, EP2229808, WO2007067042, EP1 795071, EP1273219, WO200178507, EP1 247436, NL1012918 and CA2083415. The term “coated with and / or containing” generally means that the active ingredient is mostly on the surface of the spread product at the time of application, although more or less of the ingredient may penetrate the spread product, depending on the Application Method. When the propagation product is (re)planted, it can absorb the active ingredient along with moisture. npfrCLn / Lznz / e / YiAi 100 Suitable seeds are seeds of cereals, tubers, oil crops, vegetables, spices, ornamental plants, for example, seeds of durum wheat and other varieties of wheat, barley, oats, rye, corn (fodder corn and sweet corn), soybeans, oilseeds, cruciferous, cotton, sunflowers, bananas, rice, rapeseed, turnip, sugar beet, fodder beet, eggplant, potatoes, grass, lawn, fodder grass, tomatoes, leeks, pumpkins, cabbage, iceberg lettuce, pepper, cucumbers, melons, Brassica species, melons, beans, peas, garlic, onions, carrots, tuberous plants such as potatoes, sugar cane, tobacco, grapes, petunias, geraniums / pelargoniums, pansies and impatiens. Furthermore, the compounds of the present invention can be used to treat seeds of plants that tolerate the action of herbicides or fungicides or insecticides due to genetic improvement, including genetic engineering methods. For example, the compound of the present invention can be used in the treatment of seeds of plants that are resistant to herbicides of the group consisting of sulfonylureas, imidazolinones, glufosinate ammonium or isopropylammonium glyphosate and analogous active substances (see, for example, documents EP242236, EP242246) (WO92 / 00377) (EP257993, US5013659) or in transgenic crop plants, for example, cotton, with the ability to produce Bacillus thuringiensis toxins (Bt toxins) that make the plants resistant to certain pests (documents EP142924, EP193259). The term “coated with and / or containing” generally means that the active ingredient is mostly on the surface of the spread product at the time of application, although more or less of the ingredient may penetrate the spread product, depending on the Application Method. When the propagation product is (re)planted, it can absorb the active ingredient. Suitable seeds are seeds of cereals, tubers, oil crops, vegetables, spices, ornamental plants, for example, seeds of durum wheat and other varieties of wheat, barley, oats, rye, corn (fodder corn and sweet corn), soybeans, oilseeds, cruciferous, cotton, sunflowers, bananas, rice, rapeseed, turnip, sugar beet, fodder beet, eggplant, potatoes, grass, lawn, fodder grass, tomatoes, leeks, pumpkin, npfrCLn / Lznz / e / YiAi 101 cabbage, iceberg lettuce, pepper, cucumbers, melons, Brassica species, melons, beans, peas, garlic, onions, carrots, tuberous plants such as potatoes, sugar cane, tobacco, grapes, petunias, geraniums / pelargoniums, pansies and impatience Furthermore, the compounds of the present invention can be used to treat seeds of plants, which tolerate the action of herbicides or fungicides or insecticides due to genetic improvement, including genetic engineering methods. For example, the compound of the present invention can be used in the treatment of seeds of plants that are resistant to herbicides of the group consisting of sulfonylureas, imidazolinones, glufosinate ammonium or isopropylammonium glyphosate and analogous active substances (see, for example, documents EP242236, EP242246) (WO92 / 00377) (EP257993, US5013659) or in transgenic crop plants, for example, cotton, with the ability to produce Bacillus thuringiensis toxins (Bt toxins) that make the plants resistant to certain pests (documents EP142924, EP193259). Furthermore, the compound of the present invention can be used for the treatment of plant seeds, which have modified characteristics compared to existing plants, which can be generated, for example, by traditional breeding methods and / or the generation of mutants, or through recombinant procedures. For example, several cases of recombinant modifications of crop plants have been described in order to modify the starch synthesized in plants (see, for example, WO92 / 11376, WO92 / 14827, WO91 / 19806) or of transgenic crops having a modified fatty acid composition (WO91 / 13972). Application of the seed treatment of the compound of the present invention is carried out by spraying or dusting the seeds before sowing and before the plants emerge. Compositions that are especially useful for seed treatment are, for example,: A. Soluble concentrates (SL, LS) npfrCLn / Lznz / e / YiAi 102 B. Emulsions (EW, EO, ES) C. Suspensions (SC, OD, FS) D. Water dispersible granules and water soluble granules (WG, SG) E. Water dispersible powders and water soluble powders (WP, SP, WS) F. Gel formulations (GF) G. Dusting powders (DP, DS) H. Conventional seed treatment formulations include, for example, flowable concentrates FS, solutions LS, dry treatment powders DS, water-dispersible sludge treatment powders WS, water-soluble powders SS and emulsions ES and EC and formulations of GF gel. These formulations can be applied to the seed diluted or undiluted. The application of the seeds is carried out before sowing, either directly on the seeds or after they have pre-germinated. I. In one embodiment, an FS formulation is used for seed treatment. Generally, an FS formulation may comprise from 1 to 800 g / l of active ingredient, from 1 to 200 g / l of surfactant, from 0 to 200 g / l of antifreeze agent, from 0 to 400 g / l of binder, from 0 to 200 gr / l of a pigment and up to 1 liter of solvent, preferably water Especially, FS formulations of compounds of the present invention for seed treatment usually comprise from 0.1 to 80% by weight (1 to 800 gr / 1) of the active ingredient, from 0.1 to 20% by weight (1 to 200 gr / 1) l) of at least one surfactant, for example, 0.05 to 5% by weight of a humidifier and from 0.5 to 15% by weight of a dispersing agent, up to 20% by weight, for example, from 5 to 20% of a antifreeze agent, from 0 to 15% by weight, for example, from 1 to 15% by weight of a pigment and / or a dye, from 0 to 40% by weight, for example, 1 to 40% by weight of a binder (adhesive / bonding agent), optionally up to 5% by weight, for example, 0.1 to 5% by weight of a thickener, optionally 0.1 to 2% of an antifoam agent, and optionally a preservative such as a biocide, antioxidant or similar, for example, in an amount of 0.01 to 1% by weight and a load / vehicle up to 100% by weight. npfrCLn / Lznz / e / YiAi 103 The seed treatment formulations may additionally comprise binders and optionally colorants. Binders can be added to improve the adhesion of the active materials on the seeds after treatment. Suitable binders are homo- and copolymers of alkylene oxides, such as ethylene oxide or propylene oxide, polyvinyl acetate, polyvinyl alcohols, polyvinylpyrrolidones and copolymers thereof, ethylene-vinyl acetate copolymers, acrylic homo- and copolymers, polyethylneamines, polyethylneamides and polyethylpyrimidines. , polysaccharides such as celluloses, tylose and starch, polyolefin homo- and copolymers, such as olefin / maleic anhydride copolymers, polyurethanes, polyesters, polystyrene homo- and copolymers. Optionally, colorants can also be included in the formulation. Suitable colorants or dyes for seed treatment formulations are Rhodamin B, C.L Red Pigment 1 12, C.L Red Solvent 1, Blue Pigment 15:4, Blue Pigment 15:3, Blue Pigment 15:2, Blue Pigment 15:1 , Blue Pigment 80, Yellow Pigment 1, Yellow Pigment 13, Red Pigment 1 12, Red Pigment 48:2, Red Pigment 48:1, Red Pigment 57:1, Red Pigment 53:1, Orange Pigment 43, Orange Pigment 34, Pigment Orange 5, Pigment Green 36, Pigment Green 7, Pigment White 6, Pigment Brown 25, Basic Violet 10, Basic Violet 49, Acid Red 51, Acid Red 52, Acid Red 14, Acid Blue 9, Acid Yellow 23, Basic Red 10, Basic Red 108. An example of a gelling agent is carrageenan (Satiagel®). In seed treatment, application rates of the compounds of the present invention are generally from 0.1 g to 10 kg per 100 kg of seed, preferably from 1 g to 5 kg per 100 kg of seed, more preferably from 1 g to 1000 gr per 100 kg of seed and in particular from 1 gr to 200 gr per 100 kg of seed. Therefore, the present invention also provides a seed comprising a compound of the general Formula (I), or an agriculturally useful salt of I, as defined herein. The amount of compound I or the agriculturally useful salt thereof will generally vary from 0.1 g to 10 kg per 100 kg of seed, preferably from 1 g to 5 kg per 100 kg of seed, in particular from 1 g to 1000 g per 100 kg of seed. For specific crops, such as lettuce, the rate may be higher. npfrCLn / Lznz / e / YiAi 104 Animal health The present invention also provides a veterinary and / or agricultural composition comprising at least one compound of the present invention. The present invention further relates to a use of the compound, N-oxide or veterinarily acceptable salt thereof or the composition of the present invention, for the preparation of a medicament for the treatment or protection of animals against infestation or infection by pests. invertebrates or parasites. The compounds of the general Formula (I), their N-oxides and / or their veterinaryly acceptable salts, in particular, are also suitable for combating parasites in and on animals. Therefore, an object of the present invention is to provide new methods for controlling parasites in animals. Another object of the present invention is to provide safer pesticides for animals. Another object of the present invention is to provide pesticides for animals that can be used at lower doses than existing pesticides. Another object of the present invention is to provide animal pesticides with long residual parasite control. The present invention also relates to compositions containing a parasitically effective amount of at least one compound of the general Formula (I), N-oxide or veterinarily acceptable salt thereof and an acceptable vehicle, for combating parasites in animals. The present invention also provides a method for treating, controlling, preventing and protecting animals against infestation and infection by parasites, comprising applying or administering orally, topically or parenterally to animals a parasitically effective amount of a compound of the present invention or a composition comprising it. The present invention also provides a process for the preparation of a composition for treating, controlling, preventing or protecting animals against parasite infestation or infection comprising a parasitically effective amount of a compound of the present invention or a composition comprising it . npfrCLn / Lznz / e / YiAi 105 The activity of the compounds against agricultural pests does not suggest their suitability for the control of endo- and ectoparasites in animals, which requires, for example, low doses, non-emetic in the case of oral application, metabolic compatibility with the animal, low toxicity and safe handling. Surprisingly, it has now been found that the compounds of the present invention are suitable for combating endo and ecto parasites in animals. The compounds of the present invention and their component compositions are used to control and prevent animal infestations and infections, including warm-blooded animals (including humans) and fish. For example, they are suitable for controlling and preventing infestations and infections in mammals such as cattle, sheep, pigs, camels, deer, horses, pigs, poultry, rabbits, goats, dogs and cats, water buffalo, donkeys, fallow deer and reindeer. , and also in animals with fur such as mink, chinchilla and raccoon, birds such as chickens, geese, turkeys and ducks and fish, such as fresh saltwater fish, such as trout, carp and eel. The compounds of the present invention and the compositions comprising them are used to control and prevent infestations and infections in domestic animals, such as dogs or cats. Infestations in warm-blooded animals and fish include, but are not limited to, lice, ticks, nasal bots, keds, biting flies, muscoid flies, flies, myasitic fly larvae, chiggers, mosquitoes, midges, and fleas. The compounds of the present invention and the compositions comprising them are suitable for the systemic and / or non-systemic control of ecto- and / or endo-parasites. They may be active in some or all stages of development. The compounds of the present invention are especially useful for combating ectoparasites. The compounds of the present invention are especially useful for combating parasites of the following orders and species, respectively: fleas (Siphonaptera), for example, Ctenocephalides felis, Ctenocephalides cams, Xenopsylla cheopis, Pulex irritans, Tunga penetrans, and Nosopsyllus fasciatus, cockroaches ( Blattaria Blattodea), e.g. Blattella germánica, Blattella nobcini zoz / e / yiai 106 asahinae, Periplaneta Americana, Periplaneta japonica, Periplaneta brunnea, Periplaneta fuligginosa, Periplaneta australasiae, and Blatta orientalis, flies and mosquitoes (Diptera), for example, Aedes aegypti, Aedes albopictus, Aedes vexans, Anastrepha ludens, Anopheles maculipennís, Anopheles crucians, Anopheles albimanus, Anopheles gambiae, Anopheles freeborni, Anopheles leucosphyrus, Anopheles minimus, Anopheles quadrimaculatus, Calliphora vicina, Chrysomya bezziana, Chrysomya hominivorax, Chrysomya macollaria, Chrysops discalis, Chrysops silacea, Chrysops atlanticus, Cochliomyia hominivorax, Cordylobia anthropophaga, Culicoides furens, Culex pi pi ens, Culex nigripalpus, Culex quinquefasciatus, Culex tarsalis, Culiseta inornata, Culiseta melanura, Dermatobia hominis, Fannia canicularis, Gasterophilus intestinalis, Glossina morsitans, Glossina palpalis, Glossina fuscipes, Glossina tachinoides, Haematobia írritans, Haplodiplosis equestris, Hippelates spp ., Hypoderma lineata, Leptoconops torrens, Lucilia caprina, Lucilia cuprina, Lucilia sericata, Lycoria pectoralis, Mansonia spp., Musca domestica, Muscina stabulans, Oestrus ovis, Phlebotomus argentípes, Psorophora columbiae, Psorophora discolor, Prosimulium mixtum, Sarcophaga haemorrhoidalis, Sarcophaga sp., Simulium vittatum, Stomoxis calcitrans, Tabanus bovinus, Tabanus atratus, Tabanus lineóla, and Tabanus similis, lice (Phthiraptera), e.g. Pediculus humanus capitis, Pediculus humanus corporis, Pthirus pubis, Haematopinus eurysternus, Haematopinus suis, Linognathus vituli, Bovicola bovis, Menopon gallinae, Menacanthus stramineus and Solenopotes capillatus. ticks and parasitic mites (Parasitiformes): ticks (Ixodida), for example, Ixodes scapularis, Ixodes holocyclus, Ixodes pacificus, Rhiphicephalus sanguineus, Dermacentor andersoni, Dermacentor variabilis, Amblyomma americanum, Ambryomma maculatum, Ornithodorus hermsi, Ornithodorus turicata and parasitic mites (Mesos tigmata ), for example, Ornithonyssus bacoti and Dermanyssus gallinae, Actinedida (Prostigmata) and Acaridida (Astigmata) for example, Acarapis spp., Cheyletiella spp., Ornithocheyletia spp., Myobia spp., Psorergates spp., Demodex spp., Trombicula spp. , Listrophorus spp., Acarus spp., Tyrophagus spp., Caloglyphus spp., Hypodectes spp., Pterolichus spp., Psoroptes spp., Chorioptes spp., Otodectes spp., Sarcoptes spp., Notoedres spp., Knemidocoptes spp., Cytodites spp., and Laminosioptes spp, Bugs (Heteropterida): Cimex lectularius, Cimex hemipterus, Reduvius senilis, Triatoma spp., Rhodnius npfrCLn / Lznz / e / YiAi 107 ssp., Panstrongylus ssp. and Arilus critatus, Anoplurida, e.g., Haematopinus spp., Linognathus spp., Pediculus spp., Phtirus spp., and Solenopotes spp, Mallophagida (suborders Arnblycerina and Ischnocerina), e.g., Trimenopon spp., Menopon spp., Trinoton spp. ., Bovicola spp., Werneckiella spp., Lepikentron spp., Trichodectes spp., and Felicola spp. Nematode worms: Whipworms and trichinosis (Trichosyringida), e.g., Trichinellidae (Trichinella spp.), (Tríchuridae,) Trichuris spp., Capillaria spp, Rhabditida, e.g., Rhabditis spp, Strongyloides spp., Helicephalobus spp, Strongylida, e.g., Strongylus spp. ., Ancylostoma spp., Necator americanus, Bunostomum spp. (Hookworm), Trichostrongylus spp., Haemonchus contortus., Ostertagia spp., Cooperia spp., Nematodirus spp., Dictyocaulus spp., Cyathostoma spp., Oesophagostomum spp., Stephanurus dentatus, Ollulanus spp., Chabertia spp., Stephanurus dentatus, Syngamus trachea, Ancylostoma spp., Uncinaria spp., Globocephalus spp., Necator spp., Metastrongylus spp., Muellerius capillaris, Protostrongylus spp., Angiostrongylus spp., Parelaphostrongylus spp. Aleurostrongylus abstrusus, and Dioctophyma renale; Intestinal worms (Ascaridida), e.g. Ascaris lumbricoides, Ascaris suum, Ascaridia galli, Parascaris equorum, Enterobius vermicularis (Threadworm), Toxocara canis, Toxascaris leonine, Skrjabinema spp., and Oxiuris equi, Camallanida, e.g. Dracunculus medinensis (worm of Guinea), Spirurída, for example, Thelazia spp. Wuchereria spp., Brugia spp., Onchocerca spp., Dirofilari spp. a, Dipetalonema spp., Setaria spp., Elaeophora spp., Spirocerca tupi, and Habronema spp, Spiny-headed worms (Acanthocephalans), e.g., Acanthocephalus spp., Macracanthorhynchus hirudinaceus and Ondeóla spp, Planarians (flatworms): Trematodes, e.g. example, Facióla spp., Fascioloides magna, Paragonimus spp., Dicrocoelium spp., Fasciolopsis buski, Clonorchis sinensis, Schistosoma spp., Tríchobilharzia spp., Alaria a lata, Paragonimus spp., and Nanocyetes spp, Cercomeromorpha, particularly Cestoda (taenias) , for example, Diphyllobothrium spp., Tenia spp., Echinococcus spp., Dipylidium caninum, Multiceps spp., Hymenolepis spp., Mesocestoides spp., Vampirolepis spp., Moniezia spp., Anoplocephala spp., Sirometra spp., Anoplocephala spp. , and Hymenolepis spp. The compounds of the general formula (I) and the compositions npfrCLn / Lznz / e / YiAi 108 that contain them are particularly useful for controlling pests of the order Diptera, Siphonaptera and Ixodida. In one embodiment, the present invention provides the use of the compounds of Formula (I) and compositions containing them to combat mosquitoes. In one embodiment, the present invention provides the use of the compounds of Formula (I) and compositions containing them to combat flies. In one embodiment, the present invention provides the use of the compounds of Formula (I) and compositions containing them to combat fleas. The use of the compounds of the present invention and the compositions containing them to combat ticks is another embodiment of the present invention. The compounds of the present invention are also especially useful for combating endoparasites (nematode worms, spiny-headed worms and planarians). In one embodiment, administration of the compounds of the present invention can be carried out both prophylactically and therapeutically. In another embodiment, the administration of the compounds of the present invention is carried out directly or in the form of suitable preparations, orally, topically / dermally or parenterally. For oral administration in warm-blooded animals, the compounds of the present invention can be formulated as animal feeds, animal feed premixes, animal feed concentrates, pills, solutions, pastes, suspensions, drops, gels, tablets, boluses. and capsules. Furthermore, the compounds of the present invention can be administered to animals in drinking water. For oral administration, the dosage form chosen should provide the animal with 0.01 mg / kg to 100 mg / kg body weight per day of the compound of the present invention, preferably with 0.5 mg / kg to 100 mg / kg body weight of the animal per day. npfrCLn / Lznz / e / YiAi 109 Alternatively, the compounds of the present invention may be administered to animals parenterally, for example, by intraruminal, intramuscular, intravenous or subcutaneous injection. The compounds of the present invention can be dispersed or dissolved in a physiologically acceptable vehicle for subcutaneous injection. The compounds of the present invention can be dispersed or dissolved in a physiologically acceptable vehicle for subcutaneous injection. Furthermore, the compound of the present invention can be administered to animals transdermally. For parenteral administration, the dosage form chosen should provide the animal with 0.01 mg / kg to 100 mg / kg body weight per day of the compound of the present invention. The compounds of the present invention can also be applied topically to animals in the form of infusions, powders, collars, lockets, sprays, shampoos, apply and pour formulations and in ointments or oil-in-water or water-in-oil emulsions. For topical application, infusions and aerosols generally contain from 0.5 ppm to 5000 ppm and preferably from 1 ppm to 3000 ppm of the compound of the present invention. Furthermore, the compounds of the present invention can be formulated as ear tags for animals, particularly quadrupeds, such as cattle and sheep. Suitable preparations are solutions such as oral solutions, concentrates for oral administration after dilution, solutions for use on the skin or in body cavities, pourable formulations, gels; emulsions and suspensions for oral or dermal administration; semi-solid preparations; formulations in which the active compound is processed into an ointment base or an oil-in-water or water-in-oil emulsion base; solid preparations such as powders, premixes or concentrates, granules, pellets, tablets, boluses, capsules; aerosols and inhalants, and shaped articles containing active compounds. Compositions suitable for injection are prepared by dissolving the active ingredient in a suitable solvent and optionally adding additional ingredients such as acids, bases, buffer salts, preservatives and solubilizers. npfrCLn / Lznz / e / YiAi 110 The solutions are filtered and filled sterile. Suitable solvents are physiologically tolerable solvents such as water, alkanes such as ethanol, butanol, benzyl alcohol, glycerol, propylene glycol, polyethylene glycols, N-methylpyrrolidone, 2-pyrrolidone and mixtures thereof. The active compounds may optionally be dissolved in physiologically tolerable vegetable or synthetic oils that are suitable for injection. Suitable solubilizers are solvents that promote the dissolution of the active compound in the main solvent or prevent its precipitation. Examples are polyvinylpyrrolidone, polyvinyl alcohol, polyoxyethylated castor oil, and polyoxyethylated sorbitan ester. Suitable preservatives are benzyl alcohol, trichlorobutanol, p-hydroxybenzoic acid esters and n-butanol. Oral solutions are administered directly. The concentrates are administered orally after prior dilution to the use concentration. Oral solutions and concentrates are prepared according to the state of the art and as described above for injection solutions; Sterile procedures are not necessary. Solutions for use on the skin are poured, spread, rubbed, sprayed or sprayed. Solutions for use on the skin are prepared according to the state of the art and in accordance with what is described above for injection solutions; Sterile procedures are not necessary. Other suitable solvents are polypropylene glycol, phenyl ethanol, phenoxyethanol, ester, such as ethyl or butyl acetate, benzyl benzoate, ethers such as alkylene glycol alkyl ether, for example, dipropylene glycol monomethyl ether, ketones such as acetone, methyl ethyl ketone, aromatic hydrocarbons, oils. vegetable and synthetic, dimethylformamide, dimethylacetamide, transcutol, solketal, propylenecarbonate and mixtures thereof. It may be advantageous to add thickeners during preparation. Suitable thickeners are inorganic thickeners such as bentonites, colloidal silicic acid, aluminum monostearate, organic thickeners such as npfrCLn / Lznz / e / YiAi 111 cellulose derivatives, polyvinyl alcohols and their copolymers, acrylates and methacrylates. Gels are applied or spread on the skin or inserted into body cavities. Gels are prepared by treating solutions that have been prepared as described in the case of injection solutions with sufficient thickener that results in a transparent material that has an ointment-like consistency. The thickeners used are the thickeners mentioned above. Pour-on formulations are applied or sprayed to limited areas of the skin, the active compound penetrates the skin and acts systemically. Pourable formulations are prepared by dissolving, suspending or emulsifying the active compound in suitable skin-compatible solvents or solvent mixtures. If appropriate, other auxiliaries such as colorants, bioabsorption promoting substances, antioxidants, light stabilizers and adhesives are added. Suitable solvents are, for example, water, alkanols, glycols, polyethylene glycols, polypropylene glycols, glycerol, aromatic alcohols such as benzyl alcohol, phenylethanol, phenoxyethanol, esters such as ethyl acetate, butyl acetate, benzyl benzoate, ethers such as alkylene glycol. alkyl ethers, such as dipropylene glycol monomethyl ether, diethylene glycol monobutyl ether, ketones such as acetone or methyl ethyl ketone, cyclic carbonates such as propylene carbonate, ethylene carbonate, aromatic and / or aliphatic hydrocarbons, vegetable or synthetic oils, DMF, dimethylacetamide, nalkylpyrrolidones such as methylpyrrolidone, n-butylpyrrolidone or noctylpyrrolidone, N-methylpyrrolidone, 2-pyrrolidone, 2,2-dimethyl-4-oxymethylene-1,3dioxolane or glycerol formal. Suitable dyes are, for example, all dyes permitted for use in animals and which can be dissolved or suspended. Suitable absorption promoting substances are, for example, dimethyl sulfoxide, dispersion oils such as isopropyl myristate, dipropylene glycol pelargonate, silicone oils and copolymers thereof with polyethers, fatty acid esters, triglycerides or fatty alcohols. npfrCLn / Lznz / e / viAi 112 Suitable antioxidants are, for example, sulfites or metabisulfites such as potassium metabisulfite, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole or tocopherol. Suitable light stabilizers are, for example, novantisolic acid. Suitable adhesives are, for example, cellulose derivatives, starch derivatives, polyacrylates or natural polymers, such as alginates or gelatin. Emulsions can be administered orally, cutaneously, or as injections. Emulsions are of the water-in-oil or oil-in-water type. These are prepared by dissolving the active compound in the hydrophobic phase or in the hydrophilic phase and homogenizing them with the solvent of the other phase with the help of suitable emulsifiers and, if appropriate, other auxiliaries such as colorants, absorption promoting substances, preservatives, antioxidants, light stabilizers or viscosity-improving substances. Suitable hydrophobic phases (oils) are: Liquid paraffins, silicone oils, natural vegetable oils such as sesame oil, almond oil, castor oil, synthetic triglycerides such as caprylic / capric granlyceride, the mixture of triglycerides with vegetable fatty acids of chain length C1-C12 or other specially selected natural fatty acids, partial mixtures of glycerides of saturated or unsaturated fatty acids possibly also containing hydroxyl groups, mono- and diglycerides of Cs-do fatty acids, esters of fatty acids such as ethyl stearate, di-adipate n-butyryl, hexyl laurate, dipropylene glycol perlargonate, esters of a branched fatty acid of medium chain length with saturated fatty alcohols of chain length C16-C18, isopropyl myristate, isopropyl palmitate, caprylic / capric acid esters of saturated fatty alcohols of chain length C12-C18, isopropyl stearate, oleyl oleate, decyl oleate, ethyl oleate, ethyl lactate, waxy fatty acid esters such as synthetic duck coccygeal gland fat, dibutyl phthalate , diisopropyl adipate and mixtures of esters related to the latter, fatty alcohols such as isotridecyl alcohol, 2-octyldodecanol, cetylstearyl alcohol, oleyl alcohol and fatty acids such as oleic acid and their mixtures. Suitable hydrophilic phases are npfrCLn / Lznz / e / YiAi 113 water, alcohols such as propylene glycol, glycerol, sorbitol and mixtures thereof. Suitable emulsifiers are, for example, nonionic surfactants, for example, polyethoxylated castor oil, polyethoxylated sorbitan monooleate, sorbitan monostearate, glycerol monostearate, polyoxyethyl stearate, alkylphenol polyglycol ether; ampholytic surfactants such as disodium N-lauryl-piminodipropionate or lecithin. Suitable anionic surfactants are, for example, sodium lauryl sulfate, fatty alcohol ether sulfates, mono / dialkyl polyglycol ether, orthophosphoric acid ester or monoethanolamine salt. Suitable active cationic surfactants are cetyltrimethylammonium chloride. Other suitable auxiliaries are, for example, substances that increase viscosity and stabilize the emulsion, such as carboxymethylcellulose, methylcellulose and other cellulose and starch derivatives, polyacrylates, alginates, gelatin, gum arabic, polyvinylpyrrolidone, polyvinyl alcohol, methyl vinyl ether copolymers and maleic anhydride, polyethylene glycols, waxes, colloidal silicic acid or mixtures of the aforementioned substances. Suspensions may be administered orally or topically / dermally. They are prepared by suspending the active compound in a suspending agent, if appropriate with the addition of other auxiliaries such as wetting agents, colorants, bioabsorption promoting substances, preservatives, antioxidants, light stabilizers. Liquid suspending agents are all homogeneous solvents and mixtures of solvents. Suitable wetting agents (dispersants) are the emulsifiers mentioned above. Other auxiliaries that may be mentioned have been provided above. Semi-solid preparations can be administered orally or topically / dermally. They differ from the suspensions and emulsions described above only by their higher viscosity. npirCLn / Lznz / e / YiAi 114 For the production of solid preparations, the active compound is mixed with suitable excipients, with the addition of auxiliaries, if appropriate, and brought to the desired form. Suitable excipients are all physiologically tolerable solid inert substances. Those used are organic and inorganic substances. Inorganic substances are, for example, sodium chloride, carbonates such as calcium carbonate, hydrogen carbonates, aluminum oxides, titanium oxide, silicic acids, clay earths, precipitated or colloidal silica, or phosphates. Organic substances are, for example, sugar, cellulose, food and feed such as milk powder, animal meals, grain flours and starches. Suitable auxiliaries are the preservatives, antioxidants and / or colorants mentioned above. Other suitable auxiliaries are lubricants and glidants such as magnesium stearate, stearic acid, talc, bentonites, disintegration-promoting substances such as starch or cross-linked polyvinylpyrrolidone, binders such as starch, gelatin or linear polyvinylpyrrolidone, and dry binders such as microcrystalline cellulose. In general, the parasitically effective amount means the amount of active ingredient necessary to achieve an observable effect on growth, including the effects of necrosis, death, retardation, prevention and elimination, destruction or otherwise reducing the occurrence and activity of the target organism. The parasitically effective amount may vary depending on the various compounds / compositions used in the present invention. A parasitically effective amount of the compositions will also vary depending on prevailing conditions, such as the desired parasiticidal effect and duration, target species, mode of application and the like. Compositions that can be used in the present invention generally comprise approximately between 0.001% to 95% of the compound of the present invention. Generally, it is favorable to apply the compounds of the present invention in total amounts of 0.5 mg / kg to 100 mg / kg per day, preferably 1 mg npfrCLn / Lznz / e / YiAi 115 / kg to 50 mg / kg per day. Ready-to-use preparations contain the compounds that act against parasites, preferably ectoparasites, in concentrations of 10 ppm to 80% by weight, preferably from 0.1% to 65% by weight, more preferably from 1% to 50% by weight, and even more preferably from 5% to 40% by weight. The preparations are diluted before use and contain the compounds that act against ectoparasites in concentrations of 0.5% to 90% by weight, preferably 1% to 50% by weight. Furthermore, the preparations comprise the compounds of the present invention against endoparasites in concentrations of 10 ppm to 2% by weight, preferably from 0.05% to 0.9% by weight, very particularly preferably from 0.005% to 0.25% by weight. In one embodiment, compositions comprising the compounds of the present invention are applied dermally / topically. In another embodiment, topical application is carried out in the form of shaped articles containing compounds such as necklaces, lockets, ear tags, bands for attachment to body parts, and adhesive strips and sheets. In general, it is favorable to apply solid formulations that release compounds of the present invention in total amounts of 10 mg / kg to 300 mg / kg, preferably 20 mg / kg to 200 mg / kg, even more preferably 25 mg / kg to 160 mg / kg body weight of the treated animal over the course of three weeks. For the preparation of formed articles, thermoplastics and flexible plastics, as well as elastomers and thermoplastic elastomers, are used. Suitable plastics and elastomers are polyvinyl resins, polyurethane, polyacrylate, epoxy resins, cellulose, cellulose derivatives, polyamides and polyester that are sufficiently compatible with the compounds of the present invention. A detailed list of plastics and elastomers, as well as procedures for the preparation of formed articles, is provided, for example, in WO 2003086075. Positive crop response: npfrCLn / Lznz / e / viAi 116 The compounds of the present invention not only control insect and mite pests effectively, but also show positive crop response such as plant growth-enhancing effects such as increased root growth, increased tolerance to drought, high salt, high temperature, cold, high or low radiation, improved flowering, improved nutrient utilization (e.g. better nitrogen assimilation), better quality plant product, greater number of productive tillers, greater resistance to fungi, insects, pests and the like, all of which results in higher yields. CHEMISTRY EXAMPLES: The following examples set forth the manner and process of making the compounds of the present invention, among others, and include the best way contemplated by the inventors to carry out the invention. Example 1: Synthesis of 2-(1-(3,5-dichlorophenyl)-2-(ethylsulfonyl)indolizin-3yl)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b]pyridine ( Compound no. 1): a) Step 1: 1-(2-Ethoxy-2-oxoethyl)pyridine-1-ium: To a stirred solution of pyridine (10.2 ml, 126 mmol) in acetonitrile (10 ml), ethyl 2-bromoacetate (15.4 ml, 139 mmol) was added and the reaction mixture was heated at reflux for 18 hours. Once the reaction was complete, the reaction mixture was allowed to cool to 25°C. The precipitate obtained in this way was filtered to obtain 1-(2-ethoxy-2-oxoethyl)pyridine-1-ium (20 g, 120 mmol, 95% yield).1H-NMR (400 MHz, DMSO-dS) δ 9.09-9.11 (m, 2H), 8.70-8.74 (m, 1 H), 8.25 (dd, J = 7.9, 6.7 Hz, 2H), 5.73 (s, 2H), 4.22 (q, J = 7.1 Hz, 2H), 1.21 (t, J = 7.1 Hz, 3H); ESI MS (m / z) 166.20 (MH)+. b) Step 2: Ethyl 2-fluoroindolizine-3-carboxylate: To a stirred solution of 1-(2-ethoxy-2-oxoethyl)pyridine-1-um (8 g, 48.1 mmol) in N, N-dimethyl formamide (80 ml), 2 ,2-difluorovinyl 4methylbenzenesulfonate (7.9 gr, 33.7 mmol), potassium carbonate (6.7 gr, 48.1 mmol) and triethylamine (6.7 ml, 48.1 mmol). The reaction mixture was heated at 70°C for 12 hours. After completion of the reaction, the reaction mixture was cooled to 25 °C. Water (150 ml) was added to the above reaction mixture and npfrCLn / Lznz / e / YiAi 117 extracted twice with ethyl acetate (300 ml). The combined ethyl acetate layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using ethyl acetate in hexane as eluent to obtain ethyl 2-fluoroindolizina-3-carboxylate (4.2 g, 20.3 mmol, 42% yield). -NMR (400 MHz, DMSO-d6) δ 9.29 (dq, J = 7.2, 1.0 Hz, 1H), 7.51 -7.65 (m, 1 H), 7.23-7.27 (m, 1 H), 6.72-7.08 (m , 1 H), 6.27-6.50 (m, 1 H), 4.33 (q, J = 7.1 Hz, 2H), 1.34 (t, J = 7.1 Hz, 3H); ESI MS (m / z) 208.20 (MH)+. c) Step 3: 2-Fluoro-N-(2-(methylamino)-5-(trifluoromethyl)pyridine-3yl)indolizine-3-carboxamide: To a stirred solution of potassium tert-butoxide (1.2 g, 10.9 mmol) in N, Ndimethyl formamide (5 ml), a solution of ethyl 2-fluoroindolizina-3carboxylate (0.9 g, 4.4 mmol) and N- 2-methyl-5-(trifluoromethyl)pyridine-2,3-diamine (1 g, 5.2 mmol) in N, N-dimethyl formamide (5 ml) at 0eC. The reaction mixture was left stirring at 25°C for 2 hours. Once the reaction was complete, the tetrahydrofuran was removed under reduced pressure to obtain the crude product, which was taken up in water (25 ml) and extracted with ethyl acetate (75 ml). The ethyl acetate layer was washed with brine (50 mL) and water (50 mL), dried over anhydrous sodium sulfate, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography using 40% ethyl acetate in hexane to give 2-fluoro-N-(2-(methylamino)-5(tnfluoromethyl)pyridine-3-yl) indolyzine-3-carboxamide (550 mg, 1.6 mmol, 36% yield). 1H-NMR (400 MHz, DMSO-d6) δ 9.38 (dd, J = 7.1, 0.7 Hz, 1H), 8.75 (d, J = 4.6 Hz, 1 H), 8.30 (t, J = 1.1 Hz, 1 H), 7.51 -7.72 (m, 2H), 7.17-7.21 (m, 1 H), 6.94-7.05 (m , 2H), 6.55 (s, 1H), 2.84-2.89 (d, J = 4.6 Hz, 3H); ESI MS (m / z) 352.95 (MH)+. d) Step 4: 2-(2-Fluoroindolizin-3-yl)-3-methyl-6-(trifluoromethyl)-3Himidazol[4,5-b]pyridine: A mixture of 2-fluoro-N-(2-(methylamino)-5-(trifluoromethyl)pyridine-3yl)indolyzine-3-carboxamide (1.4 g, 4 mmol), was irradiated with ptoluenesulfonic acid monohydrate (2.3 g, 11.9 mmol) in N-methyl-2-pyrrolidone (15 ml) in a microwave oven at 150 °C for 1 hour under a nitrogen atmosphere. npfrCLn / Lznz / e / YiAi 118 Once the reaction was complete, the reaction mixture was allowed to cool to 25 °C. Water (100 ml) was added to the above reaction mixture followed by extraction with ethyl acetate (200 ml). The ethyl acetate layer was washed with water (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 20% ​​ethyl acetate in hexane as eluent to obtain 2-(2-fluoroindolizán-3-ílo)-3methyl-6-(trifluoromethyl). l)-3H-imidazole[4,5-b]pyridine (830 mg, 2.5 mmol, 62% yield).1H-NMR (400 MHz, DMSO-Ó6) δ 9.12 (dd, J = 7.1 , 0.7 Hz, 1H), 8.78-8.82 (m, 1 H), 8.55 (d, J = 1.5 Hz, 1H), 7.65-7.75 (m, 1H), 7.16-7.19 (m, 1 H), 6.96 ( td, J = 7.0, 1.3 Hz, 1 H), 6.68 (s, 1 H), 3.92 (s, 3H); ESI MS (m / z) 335 (MH)+. e) Step 5: 2-(2-(Ethylsulfonyl)indolizin-3-yl)-3-methyl-6-(trifluoromethyl)-3Himidazol[4,5-b]pyridine: To a stirred solution of 2-(2-fluoroindol¡zín-3-yl)-3-methyl-6-(trifluoromethyl)3H-im¡dazole[4,5-b]p¡ ridina (830 mg, 2.5 mmol) in dry Ν,Ν-dimethylformamide (10 ml), sodium hydride (149 mg, 3.7 mmol) was added at 0 sC and the reaction mixture was allowed to stir for 30 minutes. To the above reaction mixture, ethanethiol (0.4 ml, 5 mmol) was added dropwise at 0aC and the reaction mixture was heated to 60aC for 1 hour. Once the reaction was complete, the reaction mixture was allowed to cool to 25 °C. Water (50 ml) was added to the reaction mixture, followed by extraction with ethyl acetate (150 ml). The ethyl acetate layer was washed with water (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using ethyl acetate in hexane as eluent to obtain 2-(2(Et¡lt¡o)indol¡z¡n-3-yl)-3-met¡ lo-6-(trifluoromethyl)-3H-midazol[4,5-b]pyridine (730 mg, 1.94 mmol, 78% yield). 1H-NMR (400 MHz, DMSO- c / 6) δ 8.83 (q, J = 0.9 Hz, 1H), 8.59-8.60 (m, 1 H), 8.43 (dd, J = 7.1, 0.7 Hz, 1H), 7.57 (dd, J = 7.8, 1.2 Hz, 1H), 7.00 (ddd, J = 9.0, 6.6, 1.0 Hz, 1H), 6.81 (s, 1H), 6.72 (td, J = 6.9, 1.2 Hz, 1H), 3.89 (s, 3H ), 2.90-2.96 (q, J = 7.1 Hz, 2H), 1.19 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 377.05 (MH)+. f) Step 6: 2-(2-(Ethylsulfonyl)indolyzin-3-yl)-3-methyl-6-(trifluoromethyl)-3Himidazole[4,5 -b]pyridine: npfrCLn / Lznz / e / YiAi 119 To a solution of 2-(2-(ethylt¡o)indol¡zín-3-yl)-3-methyl-6-(tnfluoromethyl)-3Hímidazol[4,5- b]pyridine (200 mg, 0.5 mmol) in dichloromethane (3 ml), m-chloroperbenzoic acid (306 mg, 1.1 mmol) was added in portions at 0-52C. The reaction mixture was stirred at 25aO for 2 hours. After completion of the reaction, the reaction mixture was diluted with aqueous sodium thiosulfate solution and extracted with dichloromethane (150 ml). The dichloromethane layer was washed with a saturated aqueous sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 40% ethyl acetate in hexane as eluent to obtain 2-(2-(ethylsulfonyl)indol¡z¡n-3-¡lo)-3-met¡ lo-6(trifluoromethyl)-3H-imidazole[4,5-b]pyridine (150 mg, 0.4 mmol, 69% yield).1H-NMR (400 MHz, DMSO-Ó6) δ 8.91 (t, J = 1.0 Hz, 1H), 8.70 (d, J = 1.5 Hz, 1 H), 8.14 (dd, J = 7.1, 1.0 Hz, 1 H), 7.71 -7.91 (m, 1 H) , 7.11 -7.1 6 (m, 2H), 6.88-6.91 (m, 1 H), 3.7 (s, 3H), 3.39 (q, J = 7.1 hz, 2H), 1.15 (t, J = 7.1 Hz, 3H ); ESI MS (m / z) 409 (MH)+. g) Step 7: 2-(1-Bromo-2-(ethylsulfonyl)indolizin-3-yl)-3-methyl-6-(trlfluoromethyl)-3H-jmidazol[4,5-b]pyridine: To a stirred solution of 2-(2-(ethylsulfonyl)indolízín-3-ílo)-3-methyl-6(trifluoromethyl)-3H-ímidazol[4,5-b ]pyridine (185 mg, 0.45 mmol) in dichloromethane (2 ml), N-bromosuccinimide (89 mg, 0.5 mmol) was added at 0°C, and the reaction mixture was stirred at 25°C for 30 minutes. After completion of the reaction, the reaction mixture was diluted with water (20 ml) and extracted three times with dichloromethane (50 ml). The combined dichloromethane layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 30% ethyl acetate in hexane to obtain 2-(1-bromo-2(ethylsulfonyl)indolizin-3-yl)- 3-methyl-6-(tnfluoromethyl)-3H-midazol[4,5-b]pindine (160 mg, 0.3 mmol, 72% yield). 1H-NMR (400 MHz, DMSO-d6) δ 8.90 (d, J = 1.8 Hz, 1 H), 8.69 (d, J = 1.8 Hz, 1 H), 8.11 (d, J = 7.3 Hz, 1 H), 7.68 (d, J = 9.2 Hz, 1 H), 7.24 (dd, J = 9.2, 6.7 Hz, 1 H), 6.90-6.94 (m, 1 H), 3.70 (s, 3H), 3.36npfrCLn / Lznz / e / YiAi 120 3.46 (m, 2H), 1.12 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 486.85, 489.05 [(MH)+Br79’81]· h) Step 8: 2-(1-(3,5-Dichlorophenyl)-2-(ethylsulfonyl)indolizin-3-yl)-3-methyl-6(trifluoromethyl)-3H-imidazole[4,5-b]pyridine : To a solution of 2-(1-bromo-2-(ethylsulfonyl)indolízín-3-ílo)-3-methyl-6(trifluoromethyl)-3H-ímídazole[4, 5-b]pyridine (110 mg, 0.2 mmol) and (3,5dichlorophenyl)boronic acid (43.1 mg, 0.2 mmol) in a mixture of 1,4-dioxane (2 ml) and water (0.2 ml), were Sodium carbonate (71.8 mg, 0.7 mmol) and tetrakis(triphenylphosphine)palladium(0) (13 mg, 0.01 mmol) were added. The reaction mixture was completely deoxygenated by vacuum / nitrogen cycling three times and heated in a microwave oven at 110sC ​​for 1.5 hour. After completion of the reaction, the reaction mixture was cooled to 25eC and filtered through a celite pad. The filtrate was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel using ethyl acetate in hexane as eluent to obtain 2(1 -(3,5-dichlorophenyl)-2- (eth¡lsulfon¡lo)indol¡z¡n-3-¡lo)-3-methyl-6-(trifluoromethyl)3H-im¡dazole[4,5-b]p¡r¡ dyne (73 mg, 0.1 mmol, 58% yield).1H-NMR (400 MHz, DMSO-d6) δ 8.92 (t, J = 2.2 Hz, 1 H), 8.71 (t, J = 2.2 Hz, 1H) , 8.15-8.17 (m, 1H), 7.68-7.74 (m, 3H), 7.52-7.55 (m, 1H), 7.16-7.20 (m, 1H), 6.93-6.99 (m, 1H), 3.79 (s, 3H), 3.05 (dtd, J = 63.8, 14.5, 7.3 Hz, 2H), 0.89-1.1 (m, 3H); ESI-MS(m / z) 553.90, 554.90 [(MH)+Cl35'37]. Example 2: Synthesis of 2-(2-(ethylsulfonyl)imidazole[1,2-a]pyridine-3-yl)-3methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b]pyridine (Compound no. . 2): a) Step 1: 2-(2-lminopyridine-1(2H)-yl)acetic acid: To a stirred solution of 2-chloroacetic acid (4.0 g, 42.3 mmol) in water (10 ml), triethylamine (6.8 ml, 48.7 mmol) was added dropwise at 25 °C. After stirring for 10 minutes, pyridine-2-amine (4.8 g, 50.8 mmol) was added and the resulting brown solution was heated at 90 °C for 5 hours. After cooling to 25aC, ethanol (20 ml) was added and the resulting suspension was stirred at 5aC for 2 hours. The precipitate was collected by filtration and washed with cold ethanol (30 ml) to obtain 2-(2-aminopyridine-1 (2H)-yl) acetic acid (4.2 g, 28 mmol, 65% yield). 1H-NMR (400 MHz, DMSO-d6) δ 8.11 (s, 1 H), 7.79 npfrCLn / Lznz / e / YiAi 121 7.91 (m, 2H), 6.98 (d, J = 7.8 Hz, 1 H), 6.82 (s, 1 H), 4.44 (s, 2H); ESI MS (m / z) 152.95 (MH)+. b) Step 2: 2-Chloroimidazole[1,2-a]pyridine: To a stirred solution of 2-(2-iminopyridine-1(2H)-yl)acetic acid (4.2 g, 27.6 mmol) in toluene (50 ml), phosphorus oxychloride (7.7 ml, 83 mmol) was added. ) drop by drop, and the resulting reaction mixture was heated at 100eC for 16 hours. After completion of the reaction, the reaction mixture was cooled to 25°C, cold water (500 ml) was added and the solution was stirred for 15 minutes. The aqueous layer was neutralized with 10% aqueous sodium hydroxide solution and extracted twice with dichloromethane (250 ml). The combined dichloromethane layers were washed with water (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using ethyl acetate in hexane as eluent to give 2chloroimidazole[1,2-a]pyridine (3.2 g, 21 mmol, 76% yield).1H-NMR ( 400 MHz, DMSO-c / 6) δ 8.50 (dt, J = 6.8, 1.2 Hz, 1 H), 8.05-8.08 (m, 1 H), 7.54 (dq, J = 9.1, 0.9 Hz, 1H), 7.33 (ddd, J = 9.2, 6.8, 1.3 Hz, 1H), 6.99 (td, J = 6.8, 1.2 Hz, 1H); ESI MS (m / z) 152.90 (MH)+. c) Step 3: Ethyl 2-Chloroimidazole[1,2-a]pyridine-3-carboxylate: To a stirred solution of 2-chloroimidazole[1,2-a]pyridine (0.5 g, 3.3 mmol) in tetrahydrofuran (10 ml), n-butyllithium (1.8 ml, 3.6 mmol) was added dropwise at 78sC . After stirring for 30 minutes, ethyl chlorocarbonate (0.36 g, 3.3 mmol) in tetrahydrofuran (10 ml) was added to the reaction mixture at the same temperature. The reaction mixture was left stirring for 1 hour at -78θC and subsequently at 25sC for 1 more hour. After completion of the reaction, the reaction was quenched by the addition of saturated ammonium chloride solution (20 ml) and extracted twice with ethyl acetate (100 ml). The combined ethyl acetate layers were washed with water (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash chromatography on silica gel using 30% ethyl acetate in hexane as eluent to give ethyl 2-Chloroimidazole[1,2-a]pyridine-3-carboxylate (0.5 g, 2.2 mmol, 68% performance).1H-NMR (400 MHz, DMSO-d6) δ 9.24 (dt, J = 6.9, 1.2 Hz, 1H), 7.77 npfrCLn / Lznz / e / YiAi 122 (dt, J = 9.0, 1.2 Hz, 1 H), 7.66 (ddd, J = 9.0, 6.9, 1.3 Hz, 1H), 7.31 (td, J = 6.9, 1.3 Hz, 1 H), 4.35 (q, J = 7.1 Hz, 2H), 1.45 (t, J = 6.8 Hz, 3H); ESI MS (m / z) 224.90 (MH)+. d) Step 4: 2-Chloro-N-(2-(methylamino)-5-(trifluoromethyl)pyridine-3-yl)imidazole[1,2-a]pyridine-3-carboxamide: To a stirred solution of potassium tert-butoxide (0.5 g, 4.5 mmol) in tetrahydrofuran (10 ml), a solution of ethyl 2-chloroimidazole[1,2a]pyridine-3-carboxylate (0.5 g) was added. , 2.2 mmol) and N-2-methyl-5-(trifluoromethyl)pyridine2,3-diamine (0.4 gr, 2.2 mmol) in tetrahydrofuran (10 ml) at 0sC. The reaction mixture was left stirring at 25eC for 1 hour. Once the reaction was complete, the tetrahydrofuran was removed under reduced pressure to obtain the crude product, which was taken up in water (20 ml) and extracted with dichloromethane (75 ml). The dichloromethane layer was washed with brine (50 mL) and water (50 mL), dried over anhydrous sodium sulfate, and concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography using 40% ethyl acetate in hexane to give 2-chloro-N-(2(methylamino)-5-(trifluoromethyl)pyrid. na-3-ílo)ímídazole[1,2-a]pyridine-3carboxamide (0.45 g, 1.2 mmol, 55% yield).1H-NMR (400 MHz, DMSO-d6) δ 9.16-9.22 ( m, 2H), 8.34 (q, J = 1.1 Hz, 1 H), 7.59-7.76 (m, 3H), 7.24 (td, J = 7.0, 1.4 Hz, 1 H), 7.03 (q, J = 4.6 Hz , 1H), 2.90 (d, J = 4.6 Hz, 3H); ESI MS (m / z) 369.85 (MH)+. e) Step 5: 2-(2-Chloroimidazole[1,2-a]pyridine-3-yl)-3-methyl-6- (trifluoromethyl)-3H-imidazole[4,5-b]pyridine: To a mixture of 2-chloro-N-(2-(methylamino)-5-(trifluoromethyl)pyridine-3yl)imidazole[1,2-a]pyridine-3- carboxamide (0.25 g, 0.68 mmol), p-toluenesulfonic acid monohydrate (0.39 g, 2.03 mmol) was irradiated in N-methyl-2-pyrrolidone (10 ml) in a microwave oven at 150 sC for 2 hours under a nitrogen atmosphere. . Once the reaction was completed, the reaction mixture was allowed to cool to 25sC. Water (50 ml) was added to the above reaction mixture, followed by extraction with ethyl acetate (150 ml). The ethyl acetate layer was washed with water (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by npfrCLn / Lznz / e / YiAi 123 Flash column chromatography on silica gel using 40% ethyl acetate in hexane as eluent to obtain 2-(2-Chloroimidazole[1,2-a]pyridina3-ílo)-3-methyl-6-(tr fluoromethyl)-3H-midazol[4,5-b]pyridine (0.2 g, 0.5 mmol, 76% yield). 1H-NMR (400 MHz, DMSO-Ó6) δ 8.89 (q, J = 0.9 Hz, 1H), 8.68-8.73 (m, 2H), 7.79 (dt, J = 9.0, 1.1 Hz, 1 H), 7.60 (ddd, J = 9.0, 7.0, 1.3 Hz, 1 H ), 7.20 (td, J = 7.0, 1.2 Hz, 1 H), 3.92 (s, 3H); ESI MS (m / z) 352.05 (MH)+. f) Step 6: 2-(2-(Ethylthio)imidazole[1,2-a]pyridine-3-yl)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b]pyridine: To a stirred solution of 2-(2-chloroimidazole[1,2-a]pyridine-3-yl)-3-methyl-6(trifluoromethyl)-3H-midazole[ 4,5-b]pyridine (0.3 g, 0.9 mmol) in dry N,Ndimethylformamide (5 ml), sodium hydride (0.1 g, 1.7 mmol) was added at 0 °C, and the reaction mixture was stirred for 30 minutes. To the above reaction mixture, ethanethiol (0.1 ml, 1.3 mmol) was added at 0aC, and the reaction mixture was heated to 60aC for 2 hours. Once the reaction was complete, the reaction mixture was allowed to cool to 25 °C. Cold water (150 ml) was added to the reaction mixture and the resulting precipitate was filtered, washed with water (10 ml) and dried under vacuum to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 40% ethyl acetate in hexane as eluent to obtain 2-(2(Ethylthio)¡m¡dazo[1,2-a]pyrádina- 3-Ilo)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5b]pyridine (0.25 g, 0.7 mmol, 78% yield). 1H-NMR (400 MHz , DMSOd6) δ 8.85 (t, J = 1.0 Hz, 1H), 8.63-8.65 (m, 2H), 7.74 (dt, J = 9.0, 1.1 Hz, 1 H), 7.50 (ddd, J = 9.0, 6.8, 1.2 Hz, 1 H), 7.08 (td, J = 6.8, 1.2 Hz, 1 H), 3.90 (s, 3H), 3.25 (q, J = 7.3 Hz, 2H), 1.23 (t, J = 6.8 Hz, 3H); ESI MS (m / z) 378.10 (MH)+. g) Step 7: 2-(2-(Ethylsulfonyl)imidazole[1,2-a]pyridine-3-yl)-3-methyl-6(trifluoromethyl)-3H-imidazole[4,5-b]pyridine: To a solution of 2-(2-(Ethylthio)midazol[1,2-a]pyridine-3-yl)-3-methyl-6(trifluoromethyl)-3H- Midazol[4,5-b]pihdine (0.2 g, 0.5 mmol) in dichloromethane (5 ml), m-chloroperbenzoic acid (0.3 g, 1 mmol) was added in portions at 0-5aC. The reaction mixture was stirred at 25°C for 2 hours. After completion of the reaction, the reaction mixture was diluted with aqueous sodium thiosulfate solution and extracted with dichloromethane (15 ml). The dichloromethane extract was washed with saturated aqueous sodium bicarbonate solution, dried over npfrCLn / Lznz / e / YiAi 124 anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 35% ethyl acetate in hexane as eluent to obtain 2-(2-(ethylsulfonyl)imidazole[1,2-a]pyridina- 3-yl)-3-methyl-6(trifluoromethyl)-3H-midazol[4,5-b]pyridine (0.1 g, 0.3 mmol, 67% yield).1H-NMR (400 MHz, DMSO-d6) δ 8.93-8.93 (m, 1H), 8.73 (dd, J = 2.1,0.6 Hz, 1 H), 8.47 (dt, J = 7.0, 1.1 Hz, 1 H), 7.94 ( dt, J = 9.2, 1.1 Hz, 1H), 7.68 (ddd, J = 9.0, 6.8, 1.2 Hz, 1H), 7.22 (td, J = 6.9, 1.1 Hz, 1H), 3.86 (s, 3H), 3.493.52 (q, J = 6.8 Hz, 2H), 1.15-1.24 (t, J = 7.6 Hz, 3H); ESI MS (m / z) 409.95 (MH)+. Example 3: Synthesis of 2-(8-(3,5-dichlorophenyl)-2-(ethylsulfonyl)indolizin-3yl)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b]pyridine ( Compound no. 6): a) Step 1: 3-Bromo-1-(2-ethoxy-2-oxoethyl)pyridine-1-ium: To a stirred solution of 3-bromopyridine (12.4 ml, 127 mmol) in acetonitrile (200 ml), ethyl 2-bromoacetate (15.5 ml, 139 mmol) was added and the reaction mixture was heated at reflux for 16 hours. After the reaction was completed, the reaction mixture was allowed to cool to 25°C, and the precipitate thus obtained was filtered to obtain 3-bromo-1 -(2-ethoxy-2-oxoethyl)pyridine- 1 -ium (30 g, 122 mmol, 97% yield).1H-NMR (400 MHz, CHLOROFORM-D) δ 9.56 (m, 1 H), 9.35 (s, 1 H), 8.62 (d, J = 8.3 Hz, 1 H), 6.28 (s, 2H), 4.36 (q, J = 7.1 Hz, 3H), 1.33-1.4 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 243.85, 245.85 [(MH)+Br79'81], b) Step 2: Ethyl 6-bromo-2-fluoroindolizine-3-carboxylate and ethyl 8-bromo2-fluoroindolizine-3-carboxylate: To a stirred solution of 3-bromo-1-(2-ethoxy-2-oxoethyl)pindine-1-ium (3 g, 12.2 mmol) in N, N-dimethyl formamide (80 ml), 2,2-difluorovinyl 4methylbenzenesulfonate (1 g, 4.3 mmol), potassium carbonate (0.85 g, 6.1 mmol) and triethylamine (0.85 ml, 6.1 mmol) were added. The reaction mixture was heated at 70eC for 16 hours. Once the reaction was completed, the reaction mixture was cooled to 25eC. Water (50 ml) was added to the above reaction mixture, which was extracted twice with ethyl acetate (200 ml). The combined ethyl acetate layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative reverse phase HPLC npfrCLn / Lznz / e / YiAi 125 to obtain ethyl 6-bromo-2-fluoroindolizine-3-carboxylate (240 mg, 0.8 mmol, 14% yield) and ethyl 8-bromo-2-fluoroindolizine-3-carboxylate (160 mg, 0.56 mmol , 9%). Yo. Ethyl 6-bromo-2-fluoroindolizine-3-carboxylate: 1H -NMR (400 MHz, DMSO-c / 6) δ 9.37-9.47 (m, 1 H), 7.63-7.71 (m, 1H), 7.35-7.41 (m, 1H), 6.58-6.69 (m, 1 H ), 4.35 (q, J = 7.1 Hz, 2H), 1.35 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 286.05, 288.05 [(MH)+Br79'81], i. Ethyl 8-bromo-2-fluoroindolizine-3-carboxylate: 1H -NMR (400 MHz, DMSO-tf6) δ 9.28-9.40 (m, 1 H), 7.58-7.64 (m, 1 H), 6.97 (t, J = 7.2 Hz, 1 H), 6.57 (d, J = 11.5 Hz, 1H), 4.33 (q, J = 7.2 Hz, 2H), 1.3 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 286, 288 [(MH)+Br79 81]. c) Step 3: 8-Bromo-2-fluoro-N-(2-(methylamino)-5-(trifluoromethyl)pyridine3-yl)indolizine-3-carboxamide: The reaction involving ethyl 6-bromo-2-fluoroindolizina-3-carboxylate (2.1 g, 7.3 mmol) and N-2-methyl-5-(trifluoromethyl)pindine-2,3 -dyamine (1 g, 5.23 mmol) as appropriate reagents, following the same synthetic procedure as described in Step 3 of Example 34, provided 8-bromo-2-fluoro-N-(2(methylamino )-5-(trifluoromethyl)pyridine-3-lo)indolezine-3-carboxamide (1.3 g, 3 mmol, 41% yield).1H-NMR (400 MHz, CHLOROFORM-D) δ 9.62 (d, J = 7.0 Hz, 1 H), 8.37 (d, J = 0.9 Hz, 1 H), 7.72 (dd, J = 6.7, 2.1 Hz, 1H), 7.46-7.52 (m, 1H), 7.33-7.38 (m, 1 H), 6.75 (t, J = 7.3 Hz, 1 H), 6.49 (s, 1 H), 5.13 (d, J = 4.3 Hz, 1 H), 3.05-3.08 (d, J = 5.2 Hz, 3H); ESI MS (m / z) 430.75, 432.75 [(MH)+Br79’81], d) Step 4: 2-(8-Bromo-2-fluoroindolizin-3-yl)-3-methyl-6-(trifluoromethyl)3H-imidazole[4,5-b]pyridine: The cyclization involving 8-bromo-2-fluoro-N-(2-(methylamino)-5(tnfluoromethyl)pyridin-3-yl)indolyzine-3-carboxamide (2.2 g, 5.10 mmol), and following the same synthetic procedure as described in Step 4 of Example 34, provided 2-(8-bromo-2-fluoroindol¡zín-3-¡lo)-3-methyl-6 (tnfluoromethyl)-3H-imidazole[4,5-b]pyridine (1.8 gr, 4.4 mmol, 85% yield). ESI MS (m / z) 412.70, 414.70 [(MH)+Br79’81], npfrCLn / Lznz / e / YiAi 126 e) Step 5: 2-(8-Bromo-2-(Ethylthio)indolizin-3-yl)-3-methyl-6-(trifluoromethyl)3H-imidazole[4,5-b]pyridine: 2-(8-Bromo-2-fluoroindol¡zín-3-ílo)-3-methyl-6-(trifluoromethyl)-3H-ímídazo[4,5b]pyridine ( 100 mg, 0.2 mmol) as appropriate starting material and, following the same synthetic procedure as described in Step 5 of Example 34, provided 2-(8-bromo-2-(Ethílthio)¡ndolíz¡n -3-ílo)-3-methyl-6-(trifluoromethyl)3H-imidazole[4,5-b]pyridine (50 mg, 0.1 mmol, 45% yield ).1H-NMR (400 MHz, DMSO-d6) δ 8.83 (d, J = 1.2 Hz, 1 H), 8.61 (d, J = 1.5 Hz, 1 H), 8.41 (d, J = 7.0 Hz, 1 H), 7.33 (dd, J = 7.3, 0.6 Hz, 1 H), 6.83 (d, J = 0.6 Hz, 1 H), 6.66 (t, J = 7.2 Hz, 1 H), 3.82 (s, 3H) , 2.98 (q, J = 7.3 Hz, 2H), 1.18 (q, J = 7.1 Hz, 3H); ESI MS (m / z) 454.95, 456.95 [(MH)+Br79·81], f) Step 6: 2-(8-Bromo-2-(ethylsulfonyl)indolizin-3-yl)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b]pyridine: The oxidation of 2-(8-bromo-2-(ethylthio)indolizin-3-yl)-3-methyl-6-(trifluoromethyl)3H-imidazole[4, 5-b]pyridine (840 mg, 1.84 mmol), following the same synthetic procedure as described in Step 6 of Example 34, provided 2-(8-bromo-2-(ethylsulfonyl) indol¡z¡n-3-¡lo)-3-methyl-6-(trifluoromethyl)-3Hímidazol[4,5-b]p¡nd¡na pyridine (800 mg, 1.6 mmol, 89% efficiency).1H-NMR (400 MHz, DMSO-c / e) δ 8.89-8.93 (m, 1H), 8.55-8.72 (m, 1H), 8.12-8.23 (m, 1H), 7.50- 7.57 (m, 1 H), 7.11 -7.26 (m, 1 H), 6.75-6.85 (m, 1 H), 3.72 (s, 3H), 3.39-3.51 (q, J = 6.8 Hz, 2H), 1.15 (t, J = 7.1 Hz, 3H); ESI MS (m / z) 487.05, 489.05 [(MH)+Br79’81]. g) Step 7: 2-(8-(3,5-Dichlorophenyl)-2-(ethylsulfomlo)indolizin-3-yl)-3-methyl6-(trifluoromethyl)-3H-imidazole[4,5-b]pyridine: The Suzuki coupling involving 2-(8-bromo-2-(ethylsulfonílo)indolízín-3-ílo)3-methyl-6-(trifluoromethyl)-3H-ím dazole[4,5-b]pindine (150 mg, 0.31 mmol) and (3,5dichlorophenyl)boronic acid (58.7 mg, 0.31 mmol), following the same synthetic procedure as described in Step 7 of Example 34, provided 2-(8-(3,5-dichlorophenyl)-2-(ethylsulfonyl)indolizin-3-yl)-3-methyl-6-(trifluoromet δ 8.93 (s , 1H), 8.73 (s, 1H), 8.22 (d, J = 7.1 Hz, 1H), 7.81 (s, 3H), 7.27 (d, J = 6.8 Hz, 1 H), 6.99-7.1 3 (m, 2H), 3.73 (s, 3H), 3.40 (q, J = 7.2 Hz, 2H), 1.11 (t, J = 7.3 Hz, 3H); ESI-MS(m / z) 553.15, 555.15 [(MH)+Cl35'37]. npfrCLn / Lznz / e / YiAi 127 Example 4: Synthesis of 2-(6-(3,5-dichlorophenyl)-2-(ethylsulfonyl)indolizin-3yl)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b]pyridine ( Compound no. 8): The title compound was prepared from ethyl 8-bromo-2-fluoroindolyzine-3carboxylate, as obtained in Step 2 of Example 42 and, following the same sequence of Steps 3-7, as described for the synthesis of 2(8-(3,5-dichlorophenyl)-2-(ethylsulfonyl)indolyzin-3-yl)-3-methyl-6-(trifluoromet ¡lo)3H-im¡dazo[4,5-b¡pyrid¡ne gave 2-(6-(3,5-dichlorophenyl)-2(ethylsulfon¡lo)¡ndoliz¡n-3-¡ lo)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5b]pyridine.1H-NMR (400 MHz, DMSO-d6) δ 8.92-8.93 (m, 1 H), 8.71 -8.71 (m, 1 H), 8.55 (d, J = 0.7 Hz, 1 H), 7.90-7.94 (m, 1 H), 7.73-7.77 (m, 2H), 7.62 (m, 1 H), 7.53 (dd, J = 9.4, 1.6 Hz, 1 H), 7.01 -7.28 (m, 1 H), 3.75 (s, 3H), 3.33-3.42 (m, 2H), 1.15 (t, J = 6.2Hz, 3H); ESI MS (m / z) 553.00, 555.00 [(MH)+Cl35'37]. Example 5: Synthesis of 2-(2-(Ethylthio)-5,7-dimethylpyrazole[1,5-a]pyrimidine-3yl)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b ]pyridine (Compound no. 9): a) Step 1: Ethyl 2-(Ethylthio)-5,7-dimethylpyrazole[1,5-a]pyrimidine-3carboxylate: To a stirred solution of ethyl 5-amino-3-(ethylthio)-1 H-pyrazole-4-carboxylate (2 g, 9.3 mmol) [prepared according to the procedure described in Acta Chimica Sinica 2003, 63, 855; Organic & Biomolecular Chemistry, 2010, 8, 3394] and 2,4pentanedione (1.15 ml, 11.15 mmol) in acetic acid (20 ml), two drops of concentrated sulfuric acid were added. The resulting mixture was heated at 50sC for 15 minutes. After the reaction was completed, the reaction mixture was cooled to 25sC. Water (5 ml) was added to the above reaction mixture, and the reaction mixture was extracted three times with ethyl acetate (10 ml). The combined ethyl acetate layers were dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography on silica gel using 20% ​​ethyl acetate in hexane as eluent to obtain ethyl 2-(Ethylthio)-5,7dimethylpyrazol[1,5-a]pyrimidina- 3-carboxylate (2.0 gr, 7.20 mmol, 77% yield).1H-NMR (400 MHz, DMSO-dS) δ 7.04 (d, J = 0.7 Hz, 1H), 4.25 (q, npfrCLn / Lznz / e / YiAi 128 J = 7.1 Hz, 2H), 3.17 (q, J = 7.3 Hz, 2H), 2.67-2.83 (m, 3H), 2.56 (d, J = 23.7 Hz, 3H), 1.36-1.53 ​​(m, 3H), 1.30 (q, J = 6.9 Hz, 3H); ESI MS (m / z) 280.20 (MH)+. b) Step 2: 2-(Ethylthio)-5,7-dimethylpyrazole[1,5-a]pyrimidine-3-carboxylic acid: To a stirred suspension of ethyl 2-(Ethylthio)-5,7-dimethyllprazole[1,5-a]pyrimidine-3carboxylate (2.3 g, 8.2 mmol) in a mixture of ethanol (37.5 ml ) and water (37.5 ml), lithium hydroxide monohydrate (5.18 gr, 123.0 mmol) was added. The reaction mixture was stirred at 60°C for 17 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure to remove ethanol. The residue was treated with a 1N hydrochloric acid solution and the resulting precipitate was 2-(Ethylthio)-5,7-dimethyl!lprazole[1,5-a]pyrimidine-3-ac! Carboxylic acid (88 mg, 0.35 mmol, 59% yield) was filtered, washed with water (10 ml) and dried under vacuum. 1H-NMR (400 MHz, DMSO-dS) δ 12.16 (s, 1H), 7.02 (d, J = 0.7 Hz, 1H), 3.15 (q, J = 7.3 Hz, 2H), 2.67 (d, J = 0.9 Hz, 3H), 2.53 (s, 3H), 1.37 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 252.15 (MH)+. c) Step 3: 2-(Ethylthio)-5,7-dimethyl-N-(2-(methylamino)-5-(trifluoromethyl)pyridine-3-yl)pyrazole[1,5-a]pyrimidine-3carboxamide: To a solution of 2-(ethylthio)-5,7-dimethylpyrazole[1,5-a]pyrimidine-3-carboxylic acid (500 mg, 2 mmol) in anhydrous N,N-dimethylformamide (27 ml), 1 -[bis(dimethylamino)methylene]-1 H-1,2,3-triazolo[4,5-b]pyridinium 3-hexafluorophosphate oxide (HATU) was added (908 mg, 2.4 mmol) and the reaction mixture was stirred at 0-5aC for 15 minutes. Subsequently, N-2-methyl-5-(trifluoromethyl)pyridine-2,3-diamine (761 mg, 4 mmol) and Ν were added to the above reaction mixture. Ν-diisopropylethylamine (1 ml, 6 mmol), and the reaction was heated at 100 °C for 16 hours. After completion of the reaction, water (40 ml) was added to the reaction mixture, which was then extracted three times with ethyl acetate (30 ml). The combined ethyl acetate layers were dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography on silica gel using 40% ethyl acetate in hexane as eluent to obtain 2-(ethylthio)5,7-dimethyl-N-(2-(methylamine)-5-( trifluoromethyl)pyridine-3-yl)pyrazole[1,5a]pyrimidine-3-carboxamide (510 mg, 1.20 mmol, 60% yield).1H-NMR npfrCLn / Lznz / e / YiAi 129 (400 MHz, DMSO-d6) δ 9.74 (s, 1 Η), 8.27 (d, J = 1.3 Hz, 1H), 8.05-8.07 (m, 1 H), 7.14-7.28 (m, 1 H), 6.80 (d, J = 4.9 Hz, 1 H), 3.22 (q, J = 7.3 Hz, 2H), 2.92 (d, J = 4.6 Hz, 3H), 2.76 (d, J = 0.5 Hz, 3H), 2.64 (s, 3H), 1.41 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 425.20 (MH)+. d) Step 4: 2-(2-(Ethylthio)-5,7-dimethylpyrazole[1,5-a]pyrimidine-3-yl)-3methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b ]pyridine: A mixture of 2-(Eth¡lt¡o)-5,7-dimethyl¡l-N-(2-(meth¡lano)-5-(trifluoromethyl)pyr¡d¡na3-¡ lo)pyrazole[1,5-a]plrimídine-3-carboxamide (380 mg, 0.90 mmol), was irradiated with p-toluenesulfonic acid monohydrate (511 mg, 2.7 mmol) in N-methyl-2pyrrolidone (8 e) in a microwave oven at 150eC for 1.5 hours under a nitrogen atmosphere. Once the reaction was complete, the reaction mixture was allowed to cool to 25 °C. Water (50 ml) was added to the above reaction mixture, followed by extraction with ethyl acetate (50 ml). The ethyl acetate layer was washed with water (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 40% ethyl acetate in hexane as eluent to obtain 2-(2-(ethio)5,7-dimethylpyrazole[1,5-a]pyrimid. na-3-¡lo)-3-methyl-6-(trifluoromethyl)-3Himidazol[4,5-b]pyridine (194 mg, 0.5 mmol, 53% yield ).1H-NMR (400 MHz, CDCI3) δ 8.64 (d, J = 1.2 Hz, 1H), 8.31 (d, J = 1.5 Hz, 1 H), 6.65 (d, J = 0.7 Hz, 1 H), 4.02 (s, 3H), 3.29 (q, J = 7.4 Hz, 2H), 2.79 (d, J = 0.7 Hz, 3H), 2.57 (s, 3H), 1.46 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 407.10 (MH)+. Example 6: Synthesis of 2-(2-(ethylsulfonyl)-5,7-dimethylpyrazole[1,5a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b ]pyridine (Compound no. 10): To a solution of 2-(2-(Ethylthio)-5,7-dimethylpyrazole[1,5-a]pyrimidin-3-yl)-3-methyl6-(trifluoromethyl)-3H- Midazol[4,5-b]pyridine (165 mg, 0.4 mmol) in dichloromethane (8 ml) m-chloroperbenzoic acid (255 mg, 0.8 mmol) was added in portions at 0-5°C. The reaction mixture was stirred at 25°C for 5 hours. After completion of the reaction, the reaction mixture was diluted with aqueous sodium thiosulfate solution and extracted with dichloromethane (20 ml). The dichloromethane layer was washed with a saturated aqueous sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated under pressure npirCLn / Lznz / e / YiAi 130 reduced to obtain the gross product. The crude product was purified by flash column chromatography on silica gel using 60% ethyl acetate in hexane as eluent to obtain 2-(2-(ethylsulfonyl)-5,7dimethylpyrazole[1,5-a]pyrm dina-3-lo)-3-methyl-6-(trifluoromethyl)-3H-midazol[4,5b]pyridine (92 mg, 0.2 mmol, 52% yield).1H- NMR (400 MHz, DMSOd6) δ 8.84 (s, 1H), 8.61 (d, J = 2.0 Hz, 1 H), 7.36 (d, J = 1.0 Hz, 1 H), 3.78 (s, 3H), 3.73 ( q, J = 7.3 Hz, 2H), 2.83 (s, 3H), 2.57 (s, 3H), 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 439.25 (MH)+. Example 7: Synthesis of 2-(2-(Ethylthio)-7-(4-fluorophenyl)pyrazole[1,5a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4, 5-b]pyridine (Compound no. 19): a) Step 1: Ethyl 2-(Ethylthio)-7-(4-fluorophenyl)pyrazole[1,5-a]pyrimidine-3carboxylate: To a stirred solution of ethyl 3-amino-5-(ethylthio)-1 H-pyrazole-4-carboxylate (1.9 g, 9 mmol) in acetic acid (65.4 ml), (E)-3-(dimethylamyl) was added. no)-1-(4fluorophenyl)prop-2-en-1-one (1.7 g, 9 mmol) and the resulting mixture was heated at 503C for 2 hours. After the reaction was completed, the acetic acid was removed under reduced pressure to obtain the crude product. The crude product was purified by column chromatography on silica gel using 30% ethyl acetate in hexane as eluent to obtain ethyl 2-(Ethylthio)-7-(4fluorophenyl)pyrazole[1,5-a]pyrimidine. -3-carboxylate (2.2 gr, 6.37 mmol, 71% yield).1H-NMR (400 MHz, DMSO-Ó6) δ 8.77 (d, J = 4.6 Hz, 1H), 8.208.25 (m, 2H ), 7.44-7.49 (m, 2H), 7.42 (d, J = 4.6 Hz, 1 H), 4.30 (q, J = 7.1 Hz, 2H), 3.09 (q, J = 7.3 Hz, 2H), 1.33 ( dt, J = 15.6, 7.2 Hz, 6H); ESI MS (m / z) 346.30 (MH)+. b) Step 2: 2-(Ethylthio)-7-(4-fluorophenyl)pyrazole[1,5-a]pyrimidine-3-carboxylic acid: To a stirred suspension of ethyl 2-(Ethylthio)-7-(4-fluorophenyl)pyrazol[1,5a]pyrimidine-3-carboxylate (2.2 g, 6.4 mmol) in a mixture of ethanol (30 ml) and water (30 ml), lithium hydroxide monohydrate (2.7 g, 63.7 mmol) was added. The reaction mixture was stirred at 60sC for 2 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to remove ethanol. The residue was treated with a 1N hydrochloric acid solution and the npfrCLn / Lznz / e / viAi 131 resulting precipitate of 2-(ethylthio)-7-(4-fluorophenyl)pyrazol[1,5-a]pyrimidine-3carboxylic acid (1.6 g, 5 mmol, 79% yield) was filtered, it was washed with water (10 ml) and dried under vacuum.1H-NMR (400 MHz, DMSO-c / 6) δ 8.44 (d, J = 4.6 Hz, 1 H), 8.28 (ddd, J = 12.1,5.3 , 3.2 Hz, 2H), 7.43-7.49 (m, 2H), 7.19 (d, J = 4.6 Hz, 1 H), 3.00 (q, J = 7.3 Hz, 2H), 1.32 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 317.90 (M)+. c) Step 3: 2-(Ethylthio)-7-(4-fluorophenyl)-N-(2-(methylamino)-5- (trifluoromethyl)pyridine-3-yl)pyrazole[1,5-a]pyrimidine-3 -carboxamide: To a suspension of 2-(Ethylthio)-7-(4-fluorophenyl)pyrazol[1,5-a]pyrimidine-3-carboxylic acid (500 mg, 1.58 mmol) in anhydrous dichloromethane (15 ml ), 2 drops of Ν,Ν-dimethylformamide were added, followed by an addition of oxalyl chloride (0.2 ml, 2.4 mmol), and the resulting reaction mixture was stirred at 25eC for 4 hours. The reaction mixture was evaporated under reduced pressure at a bath temperature of 60°C. The resulting residue was dissolved in anhydrous dichloromethane (15 ml) and added dropwise at 0°C to a stirred solution of N-2methyl-5-(trifluoromethyl)pyridine-2,3-diamine ( 304 mg, 1.6 mmol) and triethylamine (0.9 ml, 6.6 mmol). The reaction mixture was stirred at 25°C for 16 hours. After completion of the reaction, water (40 ml) was added to the reaction mixture, which was then extracted three times with ethyl acetate (20 ml). The combined ethyl acetate layers were dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography on silica gel using 40% ethyl acetate in hexane as eluent to obtain 2-(Ethylthio)-7-(4fluorophenyl)-N-(2-(methylamino)- 5-(trifluoromethyl)pinedine-3-lo)pyrazole[1,5a]pyrimidine-3-carboxamide (377 mg, 0.8 mmol, 49% yield).1H-NMR ( 400 MHz, DMSO-c / 6) δ 9.51 (s, 1 H), 8.85 (d, J = 4.6 Hz, 1 H), 8.28-8.34 (m, 3H), 7.90 (d, J = 1.8 Hz, 1 H), 7.49-7.53 (m, 3H), 6.92 (d, J = 4.6 Hz, 1 H), 3.14 (q, J = 7.2 Hz, 2H), 2.89 (d, J = 4.6 Hz, 3H), 1.33 -1.39 (m, 3H); ESI MS (m / z) 490.95 (M)+. d) Step 4: 2-(2-(Ethylthio)-7-(4-fluorophenyl)pyrazole[1,5-a]pyrimidine-3-yl)-3methyl-6-(trifluoromethyl)-3H-imidazole[4, 5-b]pyridine: A mixture of 2-(Ethylthio)-7-(4-fluorophenyl)-N-(2-(methylamino)-5(trifluoromethyl)pyridin-3-yl)pyrazole[1,5- a]pyrimidine-3-carboxamide (377 mg, 0.8 mmol), irradiated with p-toluenesulfonic acid monohydrate (439 mg, 2.3 mmol) npfrCLn / Lznz / e / YiAi 132 in N-methyl-2-pyrrolidone (8 ml) in a microwave oven at 150eC for 1.5 hours under a nitrogen atmosphere. Once the reaction was complete, the reaction mixture was allowed to cool to 25eC. Water (50 ml) was added to the above reaction mixture, followed by its extraction with ethyl acetate (150 ml). The ethyl acetate layer was washed with water (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 40% ethyl acetate in hexane as eluent to obtain 2-(2-(ethylthio)-7-(4-fluorophenyl)pyrazol[1, 5-a]pyrimidine-3-yl)-3-methyl-6(trifluoromethyl)-3H-imidazole[4,5-b]pyridine (185 mg, 0.4 mmol , 51% performance).1H-NMR (400 MHz, DMSO-dS) δ 8.77 (q, J = 0.9 Hz, 1H), 8.75 (d, J = 4.4 Hz, 1 H), 8.54-8.54 (m, 1H), 8.29-8.33 (m, 2H), 7.49-7.53 (m, 2H), 7.43 (d, J = 4.6 Hz, 1H), 3.97 (s, 3H), 3.17 (q, J = 7.3 Hz, 2H), 1.36 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 473.00 (MH)+. Example 8: Synthesis of 2-(2-(Ethylthio)pyrazole[1,5-a]pyrimidine-3-yl)-3-methyl-6(trifluoromethyl)-3H-imidazole[4,5-c]pyridine (Compound no. 22): a) Step 1: Ethyl 2-(Ethylthio)pyrazole[1,5-a]pyrimidine-3-carboxylate: To a stirred solution of ethyl 5-amino-3-(ethylthio)-1 H-pyrazole-4-carboxylate (1.3 g, 6 mmol) in acetic acid (38 ml), 3-(dimethylamino)acrolein ( 0.9 mi, 9.1 mmol). The reaction mixture was left stirring at 25sC for 24 hours. After completion of the reaction, the reaction mixture was neutralized using saturated aqueous sodium bicarbonate and extracted three times with ethyl acetate (20 mL). The combined ethyl acetate layers were dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using 30% ethyl acetate in hexane as eluent to obtain ethyl 2-(ethylthio)pyrazol[1,5-a]pyrimidine-3-carboxy. llate (0.9 gr, 3.5 mmol, 57% yield).1H-NMR (400 MHz, DMSO-Ó6) δ 9.18 (dd, J = 6.9, 1.7 Hz, 1H), 8.74 (q, J = 1.9 Hz, 1H), 7.20 (dd, J = 7.0, 4.3 Hz, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.16 (q, J = 7.3 Hz, 2H), 1.37 (t, J = 7.3 Hz, 3H), 1.25-1.31 (m, 3H); ESI MS (m / z) 252.10 (MH)+. b) Step 2: 2-(Ethylthio)pyrazole[1,5-a]pyrimidine-3-carboxylic acid: npfrCLn / Lznz / e / YiAi 133 To a stirred suspension of ethyl 2-(ethylthio)pyrazole[1,5-a]pyrimidine-3-carboxylate (0.9 g, 3.5 mmol) in a mixture of ethanol (50 ml) and water (50 mi), lithium hydroxide monohydrate (1.45 gr, 34.6 mmol) was added. The reaction mixture was stirred at 60sC for 2 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure to remove ethanol. The residue was treated with a 1N hydrochloric acid solution and the resulting precipitate of 2(ethylthio)pyrazole[1,5-a]pyrimidine-3-carboxylic acid (0.6 g, 2.8 mmol, 81% yield) was filtered, washed with water (10 ml) and dried under vacuum.1H-NMR (400 MHz, DMSO-c / 6) δ 12.38 (s, 1H), 9.16 (dd, J = 7.0, 1.8 Hz, 1H), 8.69 ( q, J = 2.0 Hz, 1H), 7.16 (dd, J = 6.7, 4.3 Hz, 1H), 3.14 (q, J = 7.3 Hz, 2H), 1.36 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 223.85 (M)+. c) Step 3: 2-(Ethylthio)-N-(5-(methylamino)-2-(trifluoromethyl)pyridine-4-yl)pyrazole[1,5-a]pyrimidine-3-carboxamide: To a suspension of 2-(ethylthio)pyrazol[1,5-a]pyrimidine-3-carboxylic acid (325 mg, 1.5 mmol) in anhydrous dichloromethane (14 ml), 2 drops of N,Ndimethylformamide were added. , followed by an addition of oxalyl chloride (0.2 ml, 2.2 mmol), and the resulting mixture was stirred at 25sC for 4 hours. The reaction mixture was evaporated under reduced pressure at a water bath temperature of 60eC. The resulting residue was dissolved in anhydrous dichloromethane (14 ml) and added dropwise at 0°C to a stirred solution of N-3-methyl-6-(trifluoromethyl)pyridine-3,4-diamond. na (278 mg, 1.5 mmol) and triethylamine (0.85 ml, 6.1 mmol). The reaction mixture was stirred at 25sC for 16 hours. After completion of the reaction, water (40 ml) was added to the reaction mixture, which was then extracted three times with ethyl acetate (20 ml). The combined ethyl acetate layers were dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography on silica gel using 40% ethyl acetate in hexane as eluent to obtain 2-(ethyl ethyl)-N-(5-(methylamine)-2- (trifluoromethyl)pyridine-4yl)pyrazole[1,5-a]pyrimidine-3-carboxamide (392 mg, 1 mmol, 68% yield).1H-NMR (400 MHz, CDCI3) δ 8.45 (d, J = 6.8 Hz, 1H), 8.26 (d, J = 3.9 Hz, 1 H), 8.11 (d, J = 6.1 Hz, 1 H), 6.95 (s, 1 H) , 6.72 (dd, J = 6.8, 4.2 Hz, 1 H), 5.18-4.61 (2H), 3.35 (s, 3H), 3.21 (q, J = 7.3 Hz, 2H), 1.41-1.44 (m, 3H) ; ESI MS (m / z) 397.05 (MH)+. npfrCLn / Lznz / e / YiAi 134 d) Step 4: 2-(2-(Ethylthio)pyrazole[1,5-a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5-c]pyridine: A mixture of 2-(ethylthio)-N-(5-(methylamino)-2-(trifluoromethyl)pyridine-4yl)pyrazole[1,5-a]pyrimidine-3 -carboxamide (392 mg, 1 mmol), was irradiated with p-toluenesulfonic acid monohydrate (564 mg, 3 mmol) in N-methyl-2-pyrrolidone (9 ml) in a microwave oven at 150 ° C for 1.5 hours under atmospheric of nitrogen. Once the reaction was complete, the reaction mixture was allowed to cool to 25°C. Water (50 ml) was added to the above reaction mixture, followed by extraction with ethyl acetate (150 ml). The ethyl acetate layer was washed with water (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 40% ethyl acetate in hexane as eluent to obtain 2-(2-(ethylthio)pyrazol[ 1,5a]pyramidine-3- lo)-3-methyl-6-(trifluoromethyl)-3H-midazol[4,5-c]pyridine (256 mg, 0.7 mmol, 68% performance).1H-NMR (400 MHz, DMSO-d6) δ 9.27 (dd, J = 6.8, 1.7 Hz, 1H), 9.14 (s, 1H), 8.70 (dd, J = 4.3, 1.6 Hz, 1 H) , 8.19 (d, J = 0.7 Hz, 1 H), 7.21 (dd, J = 6.8, 4.2 Hz, 1 H), 4.01 (s, 3H), 3.22 (q, J = 7.3 Hz, 2H), 1.321. 38 (m, 3H); ESI MS (m / z) 378.90 (MH)+. Example 9: Synthesis of 2-(2-(ethylsulfonyl)pyrazole[1,5-a]pyrimidine-3-yl)-3methyl-6-(trifluoromethyl)-3H-imidazole[4,5-c]pyridine (Compound no. . 2. 3): To a solution of 2-(2-(ethylthio)pyrazol[1,5-a]pyrimidina-3-yl)-3-methyl-6(trifluoromethyl)-3H-im Dazole[4,5-c]pyridine (187 mg, 0.5 mmol) in dichloromethane (9 ml), m-chloroperbenzoic acid (262 mg, 1 mmol) was added in portions at 05eC. The reaction mixture was stirred at 25θC for 5 hours. After completion of the reaction, the reaction mixture was diluted with aqueous sodium thiosulfate solution and extracted with dichloromethane (20 ml). The dichloromethane extract was washed with a saturated aqueous sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 60% ethyl acetate in hexane as eluent to obtain 2-(2-(ethylsulfonyl)pyrazole[1,5a]pyrmádina- 3-Ilo)-3-methyl-6-(tnfluoromethyl)-3H-Imidazole[4,5-c]pyridine (105 mg, 0.3 mmol, 52% yield).1H -NMR (400 MHz, DMSO-d6) δ 9.50 (dd, J = npfrCLn / Lznz / e / YiAi 135 7.1, 1.7 Hz, 1 Η), 9.22 (s, 1 Η), 8.87 (q, J = 2.0 Hz, 1 H), 8.25 (d, J = 0.7 Hz, 1 H), 7.51 (dd, J = 7.2 , 4.0 Hz, 1 H), 3.90 (s, 3H), 3.74 (q, J = 7.4 Hz, 2H), 1.24 (t, J = 7.5 Hz, 3H) ESI MS (m / z) 411.05 (MH)+ . Example 10: Synthesis of 2-(2-(ethylsulfonyl)-7-(4-fluorophenyl)pyrazole[1,5a]pyrimidin-3-yl)-3-methyl-6-(trifluoromethyl)-3H-imidazole[ 4,5-b]pyridine (Compound no. 25): To a solution of 2-(2-(Ethylthio)-7-(4-fluorophenyl)pyrazol[1,5-a]pyrimidine-3-yl)-3methyl-6-(tr fluoromethyl)-3H-midazol[4,5-b]pyridine (185 mg, 0.4 mmol) in dichloromethane (6 ml), m-chloroperbenzoic acid (208 mg, 0.8 mmol) in portions at 0-5sC. The reaction mixture was stirred at 25sC for 5 hours. After completion of the reaction, the reaction mixture was diluted with aqueous sodium thiosulfate solution and extracted with dichloromethane (15 ml). The dichloromethane layer was washed with a saturated aqueous sodium bicarbonate solution, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 60% ethyl acetate in hexane as eluent to obtain 2-(2-(ethylsulfonyl)-7-(4fluorophenyl)pyrazole[1,5-a]p¡ r¡m¡dina-3-¡lo)-3-methyl-6-(trifluoromethyl)-3Hímidazol[4,5-b]pyr¡dine (120 mg, 0.2 mmol, 61% efficiency).1H-NMR (400 MHz, DMSO-d6) δ 8.90 (d, J = 4.6 Hz, 1 H), 8.85 (d, J = 1.5 Hz, 1 H), 8.63 (d, J = 1.5 Hz, 1 H), 8.25-8.28 (m, 2H), 7.69 (d, J = 4.6 Hz, 1 H), 7.53-7.59 (m, 2H), 3.81 (s, 3H), 3.73 (q, J = 7.4 Hz, 2H), 1.26 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 505.10 (MH)+. Example 11: Synthesis of 2-(7-(3-chloro-5-fluorophenyl)-2-(Ethylthio)pyrazole[1,5a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)-3H- imidazole[4,5-b]pyridine (Compound no. 102): a) Step 1: 2-cyano-N-(2-(methylamino)-5-(trifluoromethyl)pyridine-3yl)acetamide: To a stirred solution of 2-cyanoacetic acid (7 g, 82 mmol), N2-methyl-5(trifluoromethyl)pyridine-2,3-diamine (12.58 g, 65.8 mmol) and hydroxybenzotriazole (HOBt) (15.12 gr, 99 mmol) in dimethylformamide (350 ml), 1-ethyl3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC-HCI) (18.93 gr, 99.0 mmol) and Ν,Ν-diisopropylethylamine were added (35.9 mi, 206 mmol). The resulting mixture is npfrCLn / Lznz / e / YiAi 136 stirred at 25sC for 24 hours under a nitrogen atmosphere. After the reaction was completed, water (100 ml) was added to the above reaction mixture and the reaction mixture was extracted three times with ethyl acetate (100 ml). The combined ethyl acetate layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography on silica gel using 30% ethyl acetate in hexane as eluent to obtain 2-cyano-N-(2(methylamino)-5-(trifluoromethyl)py r¡dina-3-ílo)acetamide (11.8 g, 45.7 mmol, 55.5% yield).1H-NMR (400 MHz, DMSO-άβ) δ 9.61 (s, 1H), 8.26 (d, J = 1.0 Hz, 1 H), 7.64 (d, J = 2.4 Hz, 1 H), 6.94 (d, J = 4.4 Hz, 1H), 3.83 (d, J = 17.6 Hz, 2H), 2.87 (d, J = 4.6Hz, 3H); ESI MS (m / z) 258 (M)+. b) Step 2: 2-(3-Methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b]pyridine-2yl)acetonitrile: A solution of 2-cyano-N-(2-(methylamino)-5-(trifluoromethyl)pyridine-3yl)acetamide (11.8 g, 45.7 mmol) in acetic acid (120 e) was heated at 100eC for 2 hours. Once the reaction was complete, the reaction mixture was allowed to cool to 25 °C. The reaction mixture was concentrated under reduced pressure to remove acetic acid. Water (100 ml) was added to the above concentrated reaction mixture and the reaction mixture was extracted three times with ethyl acetate (75 ml). The ethyl acetate layer was washed with water (100 ml), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 15% ethyl acetate in hexane as eluent to obtain 2-(3-methyl-6-(trifluoromethyl)-3H-mi. dazolo[4,5-b]pyridina2-lo)acetonitrile (9.0 g, 37.5 mmol, 82% yield).1H-NMR (400 MHz, DMSO-d6) δ 8.76 (t, J = 1.0 Hz, 1H), 8.55-8.56 (m, 1H), 4.69 (s, 2H), 3.82 (s, 3H); ESI MS (m / z) 240.95 (MH)+. c) Step 3: 3,3-Bis(Ethylthio)-2-(3-methyl-6-(trifluoromethyl)-3H-midazol[4,5-b]pyridine-2-yl)acrylonitrile To a stirred solution of 2-(3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5b]pyridine-2-lo)acetonitrilo (8.8 gr, 36.6 mmol) in acetonitrile (80 ml), potassium hydroxide (4.84 gr, 73.3 mmol) was added at 25 °C. The resulting reaction mixture was stirred for 1 hour at 25°C. The reaction mixture was cooled npfrCLn / Lznz / e / YiAi 137 additionally to -5aC and an addition of carbon disulfide (2.2 ml, 36.6 mmol) was added dropwise over 10 minutes. The reaction mixture was stirred for 1 hour at -5°C. Ethyl iodide (5.92 ml, 73.3 mmol) was added dropwise to the reaction mixture at 0 °C for 15 minutes. The reaction mixture was stirred again for 2 hours at 0aC and left at 25aC for 16 hours. The reaction mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography on silica gel using 10% ethyl acetate in hexane as eluent to obtain 3,3-bis(ethylthio)-2-(3methyl-6-(tnfluoromethyl). )-3H-imidazole[4,5-b]pyridine-2-yl)acrylonityl (12.4 g, 33.3 mmol, 91% yield). 1H-NMR (400 MHz, DMSO-c / 6) δ 8.84 (q, J = 1.0 Hz, 1 H), 8.62 (q, J = 0.9 Hz, 1 H), 3.87 (s, 3H), 3.25 (q, J = 7.3 Hz, 2H), 2.84 (q, J = 7.4 Hz, 2H), 1.37 (t, J = 7.2 Hz, 3H), 1.14 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 373.00 (MH)+. d) Step 4: 3-(Ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5b]pyridine-2-yl)-1 H-pyrazole-5-amine To a stirred solution of 3,3-bis(ethyl)-2-(3-methyl-6-(trifluoromethyl)-3H¡midazol[4,5-b]p¡ñd ¡na-2-yl)acrylonitrile (1 g, 2.69 mmol) in a mixture of acetonitrile (1 ml) and ethanol (2 ml), hydrazine monohydrate (0.17 ml, 2.69 mmol (79% wt) was added by volume)) drop by drop at 0aC. The reaction mixture was stirred at 0°C for 1 hour. The reaction mixture was diluted with ice water (20 ml) and the solid was precipitated. The precipitated solid was filtered, washed with water and dried under vacuum to obtain the crude product. The crude product was purified by column chromatography on silica gel using 100% ethyl acetate as eluent to obtain 3-(Ethylthio)-4-(3-methyl-6-(trifluoromethyl)-3Himidazole[ 4,5-b]pyridine-2-yl)-1 H-pyrazole-5-amine (720 mg, 2.1 mmol, 78% yield). 1H-NMR (400 MHz, DMSO-D6) δ 12.01 (s, 1H), 8.66 (s, 1H), 8.37 (s, 1H), 5.75 (s, 2H), 3.77 (s, 3H), 2.88 (q, J = 6.8 Hz, 2H), 1.15 ( t, J = 6.8 Hz, 3H); ESI MS (m / z) 343.00 (MH)+. e) Step 5: 2-(Ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3H-imidazole[4,5b]pyridine-2-yl)pyrazole[1,5-a]pyrimidine-7( 4H)-one To a stirred solution of 3-(ethylthio)-4-(3-methyl-6-(tñfluoromethyl)-3H¡midazol[4,5-b]piñdina-2- yl)-1 H-pyrazole-5-amine (550 mg, 1.61 mmol), together with its non-cyclized intermediate in acetic acid (5 ml), methyl 3,3 npfrCLn / Lznz / e / YiAi was added 138 dimethylpropanoate (0.34 ml, 2.41 mmol). The reaction mixture was heated at 100sC for 6 hours. The reaction mixture was cooled to 25eC and concentrated under reduced pressure to remove acetic acid. Water (20 ml) was added to the above concentrated reaction mixture and the reaction mixture was extracted three times with ethyl acetate (25 ml). The ethyl acetate layer was washed with water (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 5% methanol in dichloromethane as eluent to obtain 2-(ethylthio)-3-(3-methyl-6(trifluoromethyl)-3H-im! dazolo[4,5-b]pyridina-2-yl)pyrazol[1,5-a]pyrimidina-7(4H)one (375 mg, 0.95 mmol, 59% yield ).1H-NMR (400 MHz, DMSO-c / 6) δ 12.40 (s, 1 H), 8.80 (q, J = 0.9 Hz, 1 H), 8.56 (dd, J = 2.1, 0.6 Hz, 1 H ), 7.84 (d, J = 7.3 Hz, 1H), 5.87 (d, J = 7.3 Hz, 1 H), 3.77 (s, 3H), 3.16 (q, J = 7.3 Hz, 2H), 1.32 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 395.00(M-H)+. f) Step 6: 2-(7-Bromo-2-(Ethylthio)pyrazole[1,5-a]pyrimidine-3-yl)-3-methyl6-(trifluoromethyl)-3H-imidazole[4,5-b] pyridine To a stirred solution of 2-(ethylthio)-3-(3-methyl-6-(trifluoromethyl)-3Himidazol[4,5-b]pyrdina-2- yl)pyrazole[1,5-a]pyrimidine-7(4H)-one (1.05 gr, 2.66 mmol) in acetonitrile (28 ml), potassium carbonate (1.10 gr, 7.99 mmol) and oxybromide were added of phosphorus (2.29 gr, 7.99 mmol) at 25eC. The reaction mixture was further heated at 95θC for 4 hours. The reaction mixture was cooled to 0sC. The reaction mixture was diluted with a mixture of water and ice (50 ml). The pH of the reaction mixture was adjusted to 7-8 by slow addition of a saturated aqueous sodium bicarbonate solution. The reaction mixture was extracted three times with ethyl acetate (50 ml). The ethyl acetate layer was washed with water (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by flash column chromatography on silica gel using 50% ethyl acetate in hexane as eluent to obtain 2-(7-bromo-2-(ethylthio)pyrazole[1,5-a]p¡ rmádina-3-yl)-3-methyl-6-(trifluoromethyl)3H-midazol[4,5-b]pyridina (980 mg, 2.14 mmol, 80 % efficiency).1H-NMR (400 MHz, DMSO-c / 6) δ 8.77 (t, J = 1.1 Hz, 1H), 8.55 (d, J = 1.5 Hz, 1H), 8.48 (d, npfrCLn / Lznz / e / YiAi 139 J = 4.6 Hz, 1H), 7.65 (d, J = 4.6 Hz, 1H), 3.92 (s, 3H), 3.25 (q, J = 7.3 Hz, 2H), 1.40 (t, J = 7.3 Hz, 3H) ; ESI MS (m / z) 456.95, 458.95 [(MH)+Br79’81] g) Step 7: 2-(7-(3-Chloro-5-fluorophenyl)-2-(Ethylthio)pyrazole[1,5a]pyrimidine-3-yl)-3-methyl-6-(trifluoromethyl)- 3H-imidazole[4,5b]pyridine To a solution of 2-(7-bromo-2-(ethylthio)pyrazole[1,5-a]pyrimidina-3-yl)-3-methyl-6(tnfluoromethyl)-3H -imidazole[4,5-b]pyridine (170 mg, 0.37 mmol) and (3-chloro-5fluorophenyl)boronic acid (78 mg, 0.446 mmol) in a mixture of tetrahydrofuran (4 ml) and water (2 ml ), sodium carbonate (197 mg, 1.86 mmol) was added. The reaction mixture was completely deoxygenated by subjecting it to vacuum / nitrogen cycles three times. Tetrakis(triphenylphosphine)palladium(0) (12.9 mg, 0.01 mmol) was added to the reaction mixture and heated at 85°C for 4 hours. After completion of the reaction, the reaction mixture was cooled to 25 °C and filtered through a celite pad. The filtrate was concentrated under reduced pressure and the crude product was purified by flash column chromatography on silica gel using 20% ​​ethyl acetate in hexane as eluent to obtain 2-(7-(3-chloro-5-fluorophenyl)-2 -(ethylthio)pyrazol[1,5a]pyrimidina-3-lo)-3-methyl-6-(trifluoromethyl)-3H-m ¡dazole[4,5-b]p¡hdina (120 mg, 0.24 mmol, 64% yield).1H-NMR (400 MHz, DMSO-d6) δ 8.77-8.79 (m, 2H), 8.55 ( d, J = 1.5 Hz, 1H), 8.23 ​​(d, J = 1.5 Hz, 1 H), 8.10 (dq, J = 9.7, 1.2 Hz, 1 H), 7.79 (dt, J = 8.8, 2.1 Hz, 1 H), 7.55 (d, J = 4.6 Hz, 1 H), 3.96 (s, 3H), 3.16 (q, J = 7.3 Hz, 2H), 1.40 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 506.95, 508.95 [(MH)+OI35·37]. Example 12: Synthesis of 3-(7-(3,5-dichlorophenyl)-2-(ethylsulfonyl)pyrazole[1,5a]pyrimidine-3-yl)-6-(trifluoromethyl)-[1,2,4]triazolo [4,3-a]pyridine (Compound no. 111) a) Step 1: 2-Hydrazineyl-5-(trifluoromethyl)pyridine: To a stirred solution of 2-chloro-5-(trifluoromethyl)pyridine (10.0 g, 55.1 mmol) in ethanol, hydrazine hydrate (5.18 g, 123 mmol) was added. The resulting reaction mixture was stirred at 90 °C for 16 hours, and then cooled to 25anpfrCln / Lznz / e / YiAi 140 C and concentrated under reduced pressure to remove ethanol. Water (50 mL) was added to the above concentrated reaction mixture, and the reaction mixture was extracted three times with ethyl acetate (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain 2-hydrazinyl. -5(trifluoromethyl)pyridine (8.50 g, 48.00 mmol, 87% yield). 1H-NMR (400 MHz, DMSO-c / 6) δ 8.25 (d, J = 0.7 Hz, 2H), 7.68 (dd , J = 9.0, 2.4 Hz, 1H), 6.78 (d, J = 9.0 Hz, 1 H), 4.32 (s, 2H); ESI MS (m / z) 178.10 (MH)+. b) Step 2: 7-(3,5-Dichlorophenyl)-2-(ethylthio)-N'-(5- (trifluoromethyl)pyridine-2-yl)pyrazole[1,5-a]pyrimidine-3carbohydrazide: To a stirred solution of 2-hydrazinyl-5-(trifluoromethyl)pyridine (0.80 g, 4.52 mmol) in N,N-dimethylformamide (8 ml), 7-(3, 5-dichlorophenyl)-2(Ethylthio)pyrazole[1,5-a]pyrimidine-3-carboxylic acid (1.66 gr, 4.52 mmol), 1-(3-dimethylaminopropyl)-3-chlorh ethylcarbodiimide hydrate (1.29 gr, 6.77 mmol), 1-hydroxybenzotriazole (0.91 gr, 6.77 mmol) and Ν,Ν-diisopropylethylamine (1.75 ml, 13.55 mmol) at 0eC. The reaction mixture was stirred at 25 °C for 16 hours under a nitrogen atmosphere. Once the reaction was completed, water (20 ml) was added to the reaction mixture and the resulting precipitate was filtered and dried under reduced pressure to obtain 7-(3,5-dichlorophenyl)-2-(ethylthio)- N'-(5(trifluoromethylo)pyridine-2-yl)pyrazol[1,5-a]pyrimidine-3-carbohydrazide (1.2 gr, 2.27 mmol, 50% yield).1H -NMR (400 MHz, DMSO-Ó6) δ 9.78 (s, 1 H), 9.39 (s, 1H), 8.83 (dd, J = 11.9, 4.6 Hz, 1 H), 8.42 (d, J = 20.2 Hz, 1H), 8.24-8.29 (m, 2H), 7.91 -7.99 (m, 1H), 7.84 (dd, J = 8.9, 2.1 Hz, 1 H), 7.58-7.61 (m, 1 H), 6.77 (d, J = 8.7 Hz, 1H), 3.09 (q, J = 7.2 Hz, 2H), 1.40 (t, J = 7.2 Hz, 3H); ESI MS (m / z) 527.25 (MH)+. c) Step 3: 3-(7-(3,5-Dichlorophenyl)-2-(ethylthio)pyrazole[1,5-a]pyrimidine-3yl)-6-(trifluoromethyl)-[1,2,4]triazolo [4,3-a]pyridine: A 7-(3,5-Dichlorophenyl)-2-(ethylthio)-N'-(5-(trifluoromethyl)pyridina-2-yl)pyrazole[1, 5a]pyrimidine-3-carbohydrazide (1 g, 1.90 mmol), phosphoryl chloride (3 ml) was added and the resulting reaction mixture was heated at 90 °C for 6 hours. The reaction mixture was cooled to 25°C and concentrated under reduced pressure. The reaction mixture was further cooled to 0aC and the resulting mass was treated with a saturated sodium bicarbonate solution to make the pH basic (pH npfrCLn / Lznz / e / YiAi 141 9). The resulting mixture was extracted three times with ethyl acetate (50 ml). The combined ethyl acetate layers were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by column chromatography on silica gel using 25% ethyl acetate in hexane as eluent to obtain 3-(7-(3,5dichlorophenyl)-2-(eth¡lt¡o)pyrazol[1 ,5-a]pyrimádina-3-ílo)-6-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine (500 mg, 0.98 mmol , 52% performance).1H-NMR (400 MHz, DMSO-d6) δ 9.09 (d, J = 1.0 Hz, 1H), 8.72 (d, J = 4.4 Hz, 1H), 8.32 (d, J = 2.0 Hz, 2H), 8.09 (d, J = 9.8 Hz, 1 H), 7.96 (t, J = 2.0 Hz, 1 H), 7.68 (dd, J = 9.7, 1.6 Hz, 1 H), 7.56-7.58 ( m, 1H), 3.17 (q, J = 7.3 Hz, 2H), 1.42 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 508.70(MH)+. d) Step 4: 3-(7-(3,5-Dichlorophenyl)-2-(ethylsulfonyl)pyrazole[1,5- a]pyrimidine-3-yl)-6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine: To a solution of 3-(7-(3,5-dichlorophenyl)-2-(ethylthio)pyrazole[1,5-a]pyhmdina-3- lo)6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine (0.35 g, 0.68 mmol) in dichloromethane (8 ml), m-chloroperbenzoic acid was added ( 0.58 gr, 2.06 mmol, 60%) at 0aC. The resulting reaction mixture was stirred at 25°C for 16 hours. The reaction mixture was diluted with dichloromethane (20 mL) and washed twice with saturated aqueous sodium bicarbonate (20 mL), followed by water (10 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography using 30% ethyl acetate in hexane as eluent to obtain 3-(7-(3,5dichlorophenyl)-2-(ethylsulfonyl)pyrazole[1 ,5-a]pyrimidina-3-lo)-6-(trifluoromethyl)[1,2,4]triazolo[4,3-a]pyridine (210 mg, 0.388 mmol , 56% efficiency).1H-NMR (400 MHz, DMSO-d6) δ 8.90 (d, J = 4.4 Hz, 2H), 8.24 (d, J = 1.7 Hz, 2H), 8.15 (d, J = 9.5 Hz, 1 H), 8.01 (t, J = 2.0 Hz, 1 H), 7.82 (d, J = 4.6 Hz, 1 H), 7.74 (dd, J = 9.7, 1.6 Hz, 1 H), 3.62 (q , J = 7.3 Hz, 2H), 1.27 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 540.90(MH)+. Example 13: Synthesis of (7-(3,5-dichlorophenyl)-3-(3-methyl-6-(trifluoromethyl)3H-imidazole[4,5-b]pyridine-2-yl)pyrazole[1,5- a]pyrimidine-2-yl)(ethyl)(imino)□6-sulfanone (Compound no. 135): npfrCLn / Lznz / e / YiAi 142 To a stirred solution of 2-(7-(3,5-dichlorophenyl)-2-(ethylthio)pyrazol[1,5a]pyrimidine-3-yl)-3-met ¡lo-6-(trifluoromethyl)-3H-¡midazol[4,5-b]pyridine (312 mg, 0.60 mmol) and ammonium carbamate (140 mg, 1.79 mmol) in methanol ( 6 ml), iodobenzene diacetate (384 mg, 1.19 mmol) was added at 0°C. The resulting reaction mixture was stirred at 25°C for 16 hours. The reaction mixture was concentrated under reduced pressure. The crude residue was diluted with water (20 ml) and the mixture was extracted three times with ethyl acetate (50 ml). The ethyl acetate layer was washed with water (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product. The crude product was purified by preparative HPLC to obtain (7-(3,5-dichlorophenyl)-3-(3methyl-6-(trifluoromethyl)-3H-imidazole[4,5-b] pyridine-2-yl)pyrazole[1,5-a]pyrimidine2-yl)(ethyl)(mino)-n6-sulfanone (110 mg, 0.2 mmol, 44% yield) .1HRMN (400 MHz, DMSO-d6) δ 8.90 (d, J = 4.4 Hz, 1 H), 8.84 (d, J = 1.2 Hz, 1 H), 8.62 (t, J = 1.1 Hz, 1 H), 8.25 (d, J = 2.0 Hz, 2H), 7.98 (t, J = 2.0 Hz, 1 H), 7.75 (d, J = 4.4 Hz, 1 H), 4.80 (s, 1 H), 3.81 (s, 3H), 3.49-3.56 (m, 2H), 1.28 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 554.00(MH)+. The following compounds (Table 1) were obtained using procedures analogous to those described in Schemes 1-23 or in the Examples. Table 1: npfrCLn / Lznz / e / YiAi Comp d No. Compound Yam Analytical Data 1 2-(1 -(3,5-dichlorophenyl)-2(ethylsulfonyl)indolizin-3-yl)-3methyl-6-(trifluoromethyl)-3Himidazole [4,5-b]pyridine 1H-NMR (400 MHz, DMSO-Ó6) δ 8.92 (t, J = 2.2 Hz, 1 H), 8.71 (t, J = 2.2 Hz, 1H), 8.15 -8.17 (m, 1H), 7.68-7.74 (m, 3H), 7.52-7.55 (m, 1H), 7.16-7.20 (m, 1H), 6.93-6.99 (m, 1H), 3.79 (s, 3H) ), 3.05 (dtd, J = 63.8, 14.5, 7.3 Hz, 2H), 0.89-1.1 (m, 3H); ESI-MS(m / z) 553.90, (MH)+ 2 2-(2- (ethylsulfonyl)midazol[1,2a]pyridine-3-yl)-3-methyl-6( trifluoromethyl)-3Himidazol[4,5-b]pyridine 1H-NMR (400 MHz, DMSO-d6) δ 8.938.93 (m, 1 H), 8.73 (dd, J = 2.1,0.6 Hz, 1 H), 8.47 (dt, J = 7.0, 1.1 Hz, 1 H), 7.94 (dt, J = 9.2, 1.1 Hz, 1 H), 7.68 (ddd, J = 9.0, 6.8, 1.2 Hz, 1H), 7.22 (td, J = 6.9, 1.1 Hz, 1H), 3.86 (s, 3H), 3.49-3.52 (q, J = 6.8 Hz, 2H), 1.15-1.24 (t, J = 7.6 Hz, 3H); ESI MS (m / z) 409.95 (MH)+. 3 6-(1 -bromo-2- (ethylsulfonílo)índolizín-3-ílo)-7- 1H-NMR (400 MHz, DMSO-d6) δ 9.34 (s, 1H), 8.35-8.42 (m, 2H), 7.90-7.96 143 methyl-3-(trifluoromethyl)-7Hímidazol[4,5-c]pyridazine (m, 1 H), 7.56-7.73 (m, 1 H), 7.22 (td, J = 6.9, 1.1 Hz, 1 H), 3.94 (s, 3H), 3.52 (q, J = 7.4 Hz, 2H), 1.18 (t, J = 7.4 Hz, 3H); ESI MS (m / z) 410.00 (MH)+. 4 2-(2- (ethylsulfonyl)ímídazo[1,2- a]pyridine-3-ílo)-5- (trifluoromethyl)benzo[d]oxazo I 1H-NMR (400 MHz, DMSO- Ó6) δ 9.499.53 (m, 1H), 8.38-8.40 (m, 1H), 8.14 (dd, J = 14.3, 8.4 Hz, 1H), 8.05 (dt, J = 9.0, 1.2 Hz, 1H), 7.87-7.91 (m, 1H), 7.80 (ddd, J = 9.0, 6.8,1.2 Hz, 1 H), 7.51 (td, J = 7.0, 1.3 Hz, 1 H), 3.73-3.79 (q, J = 7.2 Hz, 2H), 1.31 (t, J = 6.8 Hz, 3H); ESI MS (m / z) 395.90 (MH)+. 5 2-(2-(ethylsulfonyl)-7(trifluoromethyl)indolyzin-3-yl)3-methyl-6-(trifluoromethyl)3H-imidazole[4,5-b] pyridine 1H-NMR (400 MHz, DMSO-c / 6) δ 9.32 (s, 1H), 8.34-8.36 (m, 2H), 8.26 (d, J = 6.7 Hz, 1H), 7.45 (s , 1H), 7.10 (dd, J = 7.5, 2.0 Hz, 1 H), 3.81 (s, 3H), 3.36-3.41 (m, 2H), 1.11 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 477.00 (MH)+. 6 2-(8-(3,5-dichlorophenyl)-2(ethylsulfonílo)índolizín-3-ílo)-3methyl-6-(trifluoromethyl)-3Himidazol[4,5-b]pyr 1H-NMR (400 MHz, DMSO-c / 6) δ 8.93 (s, 1 H), 8.73 (s, 1 H), 8.22 (d, J = 7.1 Hz, 1H), 7.81 (s, 3H), 7.27 (d, J = 6.8 Hz, 1H), 6.99-7.13 (m, 2H), 3.73 (s, 3H), 3.40 (q, J = 7.2 Hz, 2H), 1.11 (t, J = 7.3 Hz, 3H); ESI-MS(m / z) 553.15,(MH)+. 7 2-(1 -(3,5-dichlorophenyl)-2- (ethylsulfonyl)-7- (trifluoromethyl)idolizin-3-lo)3-methyl-6-(trifluoromethyl)3H- imidazole[4,5-b]pyridine 1H-NMR (400 MHz, DMSO-Ó6) δ 8.948.95 (m, 1H), 8.74 (d, J = 1.5 Hz, 1H), 8.38 (d, J = 7.6 Hz, 1 H), 7.72-7.87 (m, 4H), 7.16 (dd, J = 7.5, 1.8 Hz, 1 H), 3.78 (s, 3H), 2.90-3.10( m, 2H), 0.86 -1.01 (t, J = 7.6 Hz, 3H); ESI MS (m / z) 621.00, (MH)+ 8 2-(6-(3,5-dichlorophenyl)-2(ethylsulfonyl)indolizin-3-yl)-3methyl-6-(trifluoromet ¡lo)-3Himidazol[4,5-b]pyr¡dina 1H-NMR (400 MHz, DMSO-c / 6) δ 8.928.93 (m, 1H), 8.71-8.71 (m, 1H) , 8.55 (d, J = 0.7 Hz, 1H), 7.90-7.94 (m, 1 H), 7.73-7.77 (m, 2H), 7.62 (m, 1 H), 7.53 (dd, J = 9.4, 1.6 Hz , 1H), 7.01-7.28 (m, 1H), 3.75 (s, 3H), 3.33-3.42 (m, 2H), 1.15 (t, J = 6.2 Hz, 3H); ESI MS (m / z) 553.00,(MH)+ . 9 2-(2-(ethylthio)-5,7dimethylpyrazole[1,5a]pyrimidine-3-ílo)-3-methyl-6(trifluoromethyl)-3Himidazol[4,5-b]pyriíd ¡na 1H-NMR (400 MHz, CDCI3) δ 8.64 (d, J = 1.2 Hz, 1 H), 8.31 (d, J = 1.5 Hz, 1 H), 6.65 (d, J = 0.7 Hz, 1H), 4.02 (s, 3H), 3.29 (q, J = 7.4 Hz, 2H), 2.79 (d, J = 0.7 Hz, 3H), 2.57 (s, 3H), 1.46 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 407.10 (MH)+. 10 2-(2-(ethylsulfonyl)-5,7dimethylpyrazole[1,5a]pinmidine-3-¡lo)-3-methyl-6(trifluoromethyl)-3Himidazol[4,5-blp¡r 1H-NMR (400 MHz, DMSO-Ó6) δ 8.84 (s, 1 H), 8.61 (d, J = 2.0 Hz, 1 H), 7.36 (d, J = 1.0 Hz, 1 H), 3.78 (s, 3H), 3.73 (q, J = 7.3 Hz, 2H), 2.83 (s, 3H), 2.57 (s, 3H), npfrCLn / Lznz / e / YiAi 144 1.25 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 439.25 (MH)+. 11 2-(2-(ethylthio)-5,7dimethylpyrazol[1,5a]pyramidal-3-yl)-3-methyl-6(trifluoromethyl)-3Himidazole[4,5-c 1H-NMR pyramid (400 MHz, DMSO-c / 6) δ 9.13 (s, 1 H), 8.1 8 (s, 1 H), 7.06 (d, J = 0.6 Hz, 1H) , 4.00 (s, 3H), 3.21 (q, J = 7.3 Hz, 2H), 2.75 (s, 3H), 2.53 (d, J = 2.1 Hz, 3H), 1.36 (t, J = 7.3 Hz, 3H) ; ESI MS (m / z) 406.90 (MH)+. 12 2-(2-(ethylsulfonyl)-5,7dimethylpyrazole[1,5a]pyrimidina-3-yl)-3-methyl-6(trifluoromethyl)-3Himidazole[4,5-c ]pyridine 1H-NMR (400 MHz, DMSO-c / 6) δ 9.24 (s, 1 H), 8.26 (s, 1 H), 7.37 (d, J = 1.0 Hz, 1H), 3.89 (s, 3H), 3.73 (q, J = 7.4 Hz, 2H), 2.83 (d, J = 1.0 Hz, 3H), 2.57 (s, 3H), 1.26 (t, J = 7.5 Hz, 3H) ; ESI MS (m / z) 439.05(MH)+. 13 2-(2-(ethylthio)-5,7dimethylpyrazol[1,5a]pyrimidine-3-yl)-5((tnfluoromethyl)thio)benzo[d]o xazole 1H-NMR (400 MHz, DMSO-J6 ) δ 8.12 (d, J = 2.0 Hz, 1H), 7.93-7.95 (m, 1 H), 7.68 (dd, J = 8.4, 1.8 Hz, 1H), 7.13 (d, J = 1.1 Hz, 1 H) , 3.28 (d, J = 7.3 Hz, 2H), 2.74 (d, J = 0.7 Hz, 3H), 2.65 (d, J = 15.4 Hz, 3H), 1.45 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 425.05 (MH)+. 14 2-(2-(ethylthio)pyrazol[1,5a]pinmidine-3-yl)-3-methyl-6(trifluoromethyl)-3Himidazol[4,5-b]pyrily na 1H-NMR (400 MHz, DMSO-c / 6) δ 9.27 (dd, J = 7.1, 1.7 Hz, 1 H), 8.77 (s, 1 H), 8.71 (q, J = 2.0 Hz, 1H), 8.54 (s, 1 H), 7.21 (dd, J = 7.0, 4.3 Hz, 1 H), 3.92 (d, J = 18.6 Hz, 3H), 3.23 (q, J = 7.3 Hz, 2H), 1.38 (t , J = 7.3 Hz, 3H); ESI MS (m / z) 379.25 (MH)+. 15 2-(2-(ethylsulfonyl)-5,7dimethylpyrazol[1,5a]pyrimidine-3-yl)-5((tnfluoromethyl)sulfonyl)benz o[d]oxazole 1H -NMR (400 MHz, DMSO-d6) δ 8.67 (d, J = 2.0 Hz, 1 H), 8.31 (d, J = 8.6 Hz, 1H), 8.18-8.20 (m, 1 H), 7.43 (d, J = 1.0 Hz, 1H), 3.91 (q, J = 7.4 Hz, 2H), 2.80 (d, J = 0.7 Hz, 3H), 2.67 (s, 3H), 1.31 (t, J = 7.3 Hz, 3H) ; ESI MS (m / z) 489.25(MH)+. 16 2-(2-(ethylsulfonyl)pyrazol[1,5a]pyrimidine-3-yl)-3-methyl-6(trifluoromethyl)-3Himidazol[4,5-b]pyridine 1H-NMR ( 400 MHz, DMSO-c / 6) δ 9.50 (dd, J = 7.2, 1.6 Hz, 1H), 8.87 (dd, J = 4.0, 1.6 Hz, 1H), 8.84 (q, J = 0.9 Hz, 1 H) , 8.61 (dd, J = 2.1,0.7 Hz, 1 H), 7.51 (dd, J = 7.1, 4.2 Hz, 1H), 3.79 (s, 3H), 3.75 (q, J = 7.3 Hz, 2H), 1.21 -1.26 (m, 3H); ESI MS (m / z) 411.15 (MH)+. 17 2-(2-(Ethylthio)pyrazol[1,5a]pyrimidina-3-ílo)-5((trifluoromethyl)thio)benzo[d]o xazole 1H-NMR (400 MHz, DMSO-d6) δ 9.279.29 (m, 1H), 8.82-8.83 (m, 1H), 8.13 (d, J = 3.4 Hz, 1H), 7.95 (dd, J = 8.4, 1.3 Hz, 1H), 7.69 (dt, J = 8.5, 1.7 Hz, 1 H), 7.26-7.30 (m, 1H), 3.28 (t, J = 7.3 Hz, 2H), 1.43 (t, J = 7.3 Hz , 3H); ESI MS (m / z) 396.95 (MH)+. 145 18 2-(2-(ethylsulfonyl)pyrazole[1,5a]pyrimidine-3-yl)-5-((tnfluoromethyl)sulfonyl)benz o[d]oxazole 1H-NMR (400 MHz, DMSO- J6) δ 9.53 (dd, J = 7.1, 1.7 Hz, 1H), 9.05 (dd, J = 4.2, 1.5 Hz, 1 H), 8.67 (s, 1 H), 8.32 (d, J = 8.8 Hz, 1 H), 8.20 (d, J = 8.3 Hz, 1 H), 7.59 (dd, J = 7.1,4.2 Hz, 1 H), 3.95 (q, J = 7.3 Hz, 2H), 1.30 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 411.15 (MH)+. 19 2-(2-(ethylthio)-7-(4fluorophenyl)pyrazole[1,5a]pyrimidina-3-yl)-3-methyl-6(trifluoromethyl)-3Himidazole[4, 5-b]pyridine 1H-NMR (400 MHz, DMSO-c / 6) δ 8.77 (q, J = 0.9 Hz, 1 H), 8.75 (d, J = 4.4 Hz, 1H), 8.54- 8.54 (m, 1H), 8.29-8.33 (m, 2H), 7.49-7.53 (m, 2H), 7.43 (d, J = 4.6 Hz, 1H), 3.97 (s, 3H), 3.17 (q, J = 7.3 Hz, 2H), 1.36 (t, J = 7.3 Hz, 3H); ESI MS (m / z) 473.00 (MH)+. 20 2-(2-(ethylthio)-7-(4fluorophenyl)pyrazole[1,5a]pyrimidine-3-yl)-3-methyl-6(trifluoromethyl)-3Himidazole[4,5- c]pyridine 1H-NMR (400 MHz, CHLOROFORM-D) δ 8.92 (s, 1 H), 8.61 (d, J = 4.4 Hz, 1 H), 8.21 (s, 1H), 8.17 (dd, J = 8.9, 5.3 Hz, 2H), 7.31 (t, J = 8.7 Hz, 2H), 7.02 (d, J = 4.4 Hz, 1 H), 4.07 (s, 3H), 3.26 (q, J = 7.4 Hz, 2H), 1.46 (t, J = 7.5 Hz, 3H); ESI MS (m / z) 473.35 (MH)+. 21 2-(2-(ethylsulfonyl)-7-(4fluorophenyl)pyrazole[1,5a]pinm¡dina-3-yl)-3-methyl-6(trifluoromethyl)-3Himidazole[4,5-c 1H-NMR pyramid (400 MHz, DMSO-c / 6) δ 9.23 (s, 1H), 8.90 (d, J = 4.4 Hz, 1 H), 8.258.28 (m, 3H) , 7.69 (d, J = 4.4 Hz, 1H), 7.56 (t, J = 8.9 Hz, 2H), 3.92 (s, 3H), 3.72 (q, J = 7.4 Hz, 2H), 1.26 (t, J = 7.3Hz, 3H) ; ESI MS (m / z) 504.90 (MH)+. 22 2-(2-(ethí lthio)pyrazole[1,5a]pyrimidina-3-ílo)-3-methyl-6- (trifluoromethyl)-3H-imidazole[4,5 -c]pyridine 1H-NMR (400 MHz, DMSO-Ó6) δ 9.27 (dd, J = 6.8, 1.7 Hz, 1 H), 9.14 (s, 1 H), 8.70 (dd, J = 4.3 , 1.6 Hz, 1 H), 8.19 (d, J = 0.7 Hz, 1 H), 7.21 (dd, J = 6....

Claims

1. A compound of Formula (I), npfrCLn / Lznz / e / YiAi Formula (I) wherein, R1 is selected from the group consisting of Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl and Cs-Cs-cycloalkyl-Ci-Ce-alkyl; Y is independently selected from O or NRY; RY is selected from the group consisting of hydrogen, cyano, C1C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Ci-C4-haloalkyl, C2-C4-haloalkenyl, Cs-Cs-cycloalkyl and Cs-Cs-cycloalkyl-Ci-Cs-alkyl; A represents N or CR2; G represents N or C; provided that the two Gs are not simultaneously nitrogen; R2 is selected from the group consisting of hydrogen, halogen, cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2C6-haloalkenyl, Cs-Cs-cycloalkyl, OR4, CR4=NR5, NR5R6, S(O)0-2R7, C(=O)R8, S(O)o-iR9=NR10, N=S(O)0-i(R9)2, P(=O)(OR')2, Si(R')s, Ce-Cw-aryl, C7-Ci4-aralkyl and Cs-Cw-heterocyclyl;wherein each aliphatic group can be optionally substituted with one or more groups from R2a and the cyclic groups of R2 can be optionally substituted with one or more groups from R2b; R2a is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cscycloalkyl, OR4, CR4=NR5, NR5R6, S(O)0-2R7, C(=O)R8, S(O)o-iR9=NR10, N=S(O)qi(R9)2, Si(R')3, Ce-Cw-aryl, C7-Ci4-aralkyl and Cs-Cw-heterocyclyl; 172 R2b is selected from the group consisting of halogen, cyano, CiCe-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, OR4, CR4=NR5, NR5R6, S(O)0-2R7, C(=O)R8, Sí(R')3, S(0)o-iR9=NR10 and N=S(0)oi(R9)2;or two R2a or two R2b substituents, together with the atom to which they are attached or together with other atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)o-2 and Si(R')2, can form a 3 to 7 membered ring, which in turn can be substituted by one or more R2ab groups; R2ab is selected from the group consisting of halogen, cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, OR4, NR5R6, S(O)o-2R7, S(O)qi R9=NR10, N=S(O)oi(R9)2, Si(R')3, C6-Cio-aryl, C7-Ci4-aralkyl and Cs-Cio-heterocyclyl; Q represents a partially saturated or unsaturated 5- to 12-membered heterocyclic ring system that may optionally be substituted by one or more groups from R3;wherein said heterocyclic ring system does not represent unsubstituted benzothiazolyl and unsubstituted N-methyl benzimidazolyl; R3 is selected from the group consisting of halogen, cyano, Ci-Csalkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Ce-haloalkenyl, Cs-Cs-cycloalkyl, OR4, CR4=NR5, NR5R6, S(O)0-2R7, C(=O)R8, S(O)0iR9=NR10, N=S(O)oi(R9)2, P(=O)(OR')2, S1(R')3, C6-Cio-aryl, C7-Ci4-aralkyl and C3-Cio-heterocyclyl; wherein each aliphatic group can be optionally substituted with one or more groups of R3a and the cyclic groups of R3 can be optionally substituted with one or more groups of R3b; R3a is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cscycloalkyl, OR4, CR4=NR5, NR5R6, S(O)0-2R7, C(=O)R8, S(O)0-iR9=NR10, npfrCLn / Lznz / e / YiAi 173 N=S(0)oi(R9)2, Sí(R')3, Ce-Cio-aryl, C7-Ci4-aralkyl and C3-C10heterocyclyl;R3b is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6haloalkenyl, Cs-Ce-cycloalkyl, OR4, C(R')2-NR5R6, C(R')2-OR4, CR4=NR5, NR5R6, S(O)q-2R7, C(=O)R8, S(Q)o-iR9=NR10, N=S(O)0-i(R9)2, Si(R')3, Ce-Cio-aryl, CyCu-aralkyl and C3-Cio-heterocyclyl; two R3a or two R3b substituents together with the atom to which they are attached or together with other atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)m and Si(R')2, can form a 3 to 7 membered ring, which in turn can be substituted by one or more R3ab groups; wherein R3ab is selected from the group consisting of hydrogen, halogen, cyano, Ci-Ce-alkyl, Ci-Ce-haloalkyl, C3-C8-cycloalkyl, OR4, NR5R6, S(O)0-2R7;two R3 groups together with the atom to which they are attached or together with other atoms selected from the group consisting of C, N, O, S and optionally including 1 to 3 ring members selected from the group consisting of C(=O), C(=S), S(O)m and Si(R')2 can form a ring of three to seven members, which in turn can be substituted by one or more groups selected from the group consisting of halogen, cyano, R3c, OR3c, SR3c, NR3c2, Si(R3c)3, COOR3c, and CONR3c2; R3c is selected from the group consisting of hydrogen, halogen, Ci-Ce-alkyl and cyclic C3-8-alkyl of linear or branched chain; wherein each group of R3c is optionally substituted by one or more halogens; ring E represents a 5- or 6-membered heterocyclic ring fused to ring D; in which ring E is optionally replaced by one or more groups of R11;R11 is selected from the group consisting of halogen, cyano, C1-C6alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6 npfrCLn / Lznz / e / YiAi 174 haloalkenyl, Cs-Cs-cycloalkyl, OR4, CR4=NR5, NR5R6, S(0)o-2R7, C(=O)R8, S(0)o-iR9=NR10, N=S(O)qi(R9)2, P(=O)(OR')2, Yes(R')3, C6-Cio-aryl, C7-C14aralkyl and C3-Cio-heterocyclyl; wherein each aliphatic group can be optionally substituted with one or more groups of R11a and the cyclic groups of R11 can be optionally substituted with one or more groups of RHb; R11a is selected from the group consisting of halogen, cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-halaloalkyl, Cs-Cs-cycloalkyl, OR4, CR4=NR5, NR5R6, S(O)0-2R7, C(=O)R8, S(O)o-iR9=NR10, N=S(O)0-i(R9)2, Si(R')3, C6-Cio-aryl, C7Cu-aralkyl and C3-Cio-heterocyclyl;R11b is selected from the group consisting of halogen, cyano, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Cshaloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, OR4, C(R')2NR5R6, C(R')2-OR4, CR4=NR5, NR5R6, S(O)o-2R7, C(=O)R8, S(O)ciR9=NR10, N=S(O)qi(R9)2, Sí(R')3, C6-Cio-aryl, C7-Ci4-aralkyl and Cs-Cw-heterocyclyl; R4 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cscycloalkyl, S(O)2R7, Si(R')3, Cs-C-io-aryl, C7-Ci4-aralkyl and C3-C10heterocyclyl; wherein each aliphatic group can be optionally substituted with R4a and the cyclic groups of R4 can be optionally substituted with one or more groups of R4b; R4a is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cscycloalkyl, OR', NR'R, S(O)q-2R', C(=O)R', Si(R')3, Ce-Cio-aryl, C7-C14aralkyl and Cs-Cio-heterocyclyl;R4b is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-Cs-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-Ce-haloalkenyl, Cs-Cs-cycloalkyl, OR', NR'R, S(O)d-2R', C(=O)R', Si(R')3, Ce-Cio-aryl, C7-Ci4-aralkyl and Cs-Cio-heterocyclyl; npfrCLn / Lznz / e / YiAi 175 R5 is selected from the group consisting of hydrogen, Ci-Cs-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Cs-haloalkyl, C2-C6-haloalkenyl, Cs-Cscycloalkyl, OR4, NR'R, S(O)q-2R7, C(=O)R8, Si(R')3, C6-Cio-aryl, C7-C14-aralkyl and C3-Cio-heterocyclyl; wherein each aliphatic group can be optionally substituted with R5a and the cyclic groups of R5 can be optionally substituted with one or more groups of R5b; R5a is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cscycloalkyl, OR', NR'R, S(O)g-2R', C(=O)R', Si(R')3, Ce-Cio-aryl, C7-C14aralkyl and Cs-Cio-heterocyclyl;R5b is selected from the group consisting of halogen, cyano, C1Cs-alkyl, Cs-Cs-alkenyl, Cs-Cs-alkynyl, Ci-Cs-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, OR', NR'R, S(O)q-2R', Si(R')3, C(=O)R', Ce-Cw-aryl, C7-Ci4-aralkyl and C3-Cio-heterocyclyl; R6 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Cs-haloalkyl, C2-C6-haloalkenyl, Ci-Cs-cycloalkyl and C(=O)R8; R7 is selected from the group consisting of Ci-Cs-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, NR5R6, Ce-Cio-aryl, C7-Ci4-aralkyl, and C3-Cio-heterocyclyl; wherein each aliphatic group can be optionally substituted with one or more groups from R7a and the cyclic groups of R7 can be optionally substituted with one or more groups from R7b;R7a is selected from the group consisting of halogen, cyano, C1Ce-alkyl, C2-C6-alkenyl, Cs-Cs-alkynyl, Ci-Ce-haloalkyl, Cs-Cs-cycloalkyl, OR', NR'R, S(O)q-2R', C(=O)R', Ce-Cio-aryl, C7-Ci4-aralkyl and Cs-Cio-heterocyclyl; R7b is selected from the group consisting of halogen, cyano, C1Cs-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Cs-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, OR', NR'R, S(O)o-2R', C(=O)R', Cs-Cioaryl, C7-Ci4-aralkyl and C3-Cio-heterocyclyl; npfrCLn / Lznz / e / YiAi 176 R8 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cscycloalkyl, OR4, NR5R6, N=S(O)ci(R9)2, Cs-Cw-aryl, C7-Ci4-aralkyl and CsCio-heterocyclyl; wherein each aliphatic group can be optionally substituted with one or more groups of R8a and the cyclic groups of R8 can be optionally substituted with one or more groups of R8b;R8a is selected from the group consisting of halogen, cyano, CiCe-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, Cs-Cscycloalkyl, OR', NR'R, S(O)q-2R', C(=O)R', Cs-Cw-aryl, C7-Ci4-aralkyl and Cs-Cio-heterocyclyl; R8b is selected from the group consisting of halogen, cyano, CiCe-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl, C2-C6-haloalkenyl, Cs-Cs-cycloalkyl, OR', NR'R, S(O)q-2R', C(=O)R', Ce-Cwaryl, C7-Ci4-aralkyl and C3-Ci-heterocyclyl; R9 is selected from the group consisting of Ci-Ce-alkyl, C2-C6-alkenyl, C2-Ce-alkynyl, Ci-Ce-haloalkyl, C2-Ce-haloalkenyl, Cs-Cs-cycloalkyl and C(=O)R8; R10 is selected from the group consisting of hydrogen, cyano, Ci-Cealkyl, C2-Ce-alkenyl, C2-C6-alkyl, Ci-Ce-haloalkyl, C2-Cshaloalkenyl, Cs-Cs-cycloalkyl, Si(R')3, S(0)o-2R7 and C(=O)R8; R' is selected from the group consisting of halogen, cyano, R, OR, N(R)2, S(0)o-2R, C(=O)R, C(=O)OR and C(=O)N(R)2R8;R is selected from the group consisting of hydrogen, Ci-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-Ce-haloalkyl and Cs-Cs-cycloalkyl; wherein each may be optionally substituted with halogen; each group from R1 to R11, R2a, R2b, R2ab, R3a, R3b, R3ab, R3c, R4a, R4b, R5a, R5b, R7a, R7b, R8a and R8b may be optionally substituted by one or more groups selected from the group consisting of halogen, cyano, R', OR', SR', N(R')2, COOR' and CON(R')2; m is an integer ranging from 0 to 2; npfrCLn / Lznz / e / YiAi 177 or its salts, isomers / structural isomers, stereoisomers, diastereomers, enantiomers, tautomers, polymorphs, metal complexes or agrochemically acceptable N-oxides.; 2. The compound of Formula (I) according to Claim 1, wherein Q is selected from the group consisting of Q1 to Q10; wherein # indicates the point of attachment to ring D; Gi, G2, G4 and Gs independently represent N or CR3; Gs is NR6, O, S; Z is O or S; and n is an integer ranging from 0 to 4.

3. The compound of Formula (I) according to Claim 1, wherein Q is selected from the group consisting of Q1a to Q1b, Q1a Q1c Q1d, Q1h Q2a Q4a Q10b, wherein # indicates the point of attachment to ring D, R6 is selected from the group consisting of hydrogen, Ci-Ce-alkyl, and Ca-w-cyclic alkyl; wherein each group of R6 is optionally substituted by one or more halogens and n is an integer ranging from 0 to 4.

4. The compound of Formula (I) according to Claim 1, wherein the fused ring DE is selected from the group consisting of DE-1 to DE-15; DE-5 179 wherein # indicates the attachment point to ring Q and · indicates the attachment point to the -S(Y)mR1 group and n is an integer ranging from 0 to 4.

5. The compound of Formula (I) according to Claim 1, wherein Q is selected from Q1a, Q1b, Q1c, Q1h, Q2b, Q3a, Q5b, Q5d, Q6a, Q6b, Q7a, Q8a, Q9a or Q9b; wherein # indicates the point of attachment to ring D; R3 is selected from the group consisting of halogen, cyano, Ci-Ce10 alkyl, Ci-Ce-haloalkyl, Cs-Cs-cycloalkyl and S(Y)o-2R7; R6 is selected from the group consisting of hydrogen, Ci-Ce-alkyl and Cs-Cio-cycloalkyl; The fused rings D and E are selected from the group consisting of DE-7 DE-11 180 wherein # indicates the attachment point to ring Q and · indicates the attachment point to the -S(Y)mR1 group; R2 is selected from the group consisting of halogen, cyano, Ci-Cs-alkyl, Ci-Cs-haloalkyl, Cs-Cs-cycloalkyl, Ce-Cs-aryl, Cy-Cg-aralkyl and Cs-Cs-heterocyclyl;wherein each aliphatic group can be optionally substituted with one or more groups from R2a and the cyclic groups of R2 can be optionally substituted with one or more groups from R2b; m is an integer ranging from 0 to 2; n is an integer ranging from 0 to 4; R11 is selected from the group consisting of halogen, cyano, Ci-Cealkyl, Ci-Ce-haloalkyl, Cs-Cs-cycloalkyl, OR4, NR5R6, Cs-Cw-aryl, C7-C14aralkyl and Cs-Cio-heterocyclyl; wherein each aliphatic group can be optionally substituted with one or more groups from R11a and the cyclic groups of R11 can be optionally substituted with one or more groups from R11b.

6. The compound of the Formula (I) according to the Claim 1, wherein said compound of the Formula (I) is selected from 2-(1 -(3,5-dichlorophenyl)2-(ethylsulfano)ndoliz-3-lo)-3-metalo-6-(trifluorometalo)-3H-midazol[4,5b]pyridana; 2-(2-(ethylsulfonilo)imidazol[1,2-a]pir¡d·na-3-ilo)-3-met·lo-6-(tnfluoromet·lo)-3H-imidazol[4,5-b]pir·d·na; 6-(1 -bromo-2(et·lsulfon·lo)·ndol·z·n-3-·lo)-7-met·lo-3-(thfluoromet·lo)-7H-·m·dazol[4,5c]piridazina; 2-(2-(ethylsulfonilo)m¡dazol[1,2-a]pirid¡na-3-¡lo)-5(trifluorometilo)benzo[d]oxazol; 2-(2-(ethylsulfon¡lo)-7-(tr¡fluoromet¡lo)indol¡zin3-¡lo)-3-metilo-6-(tr¡fluoromet¡lo)-3H-¡m¡dazol[4,5-b]p¡r¡d¡na; 2-(8-(3,5d·chlorofen·lo)-2-(ethylsulfon·lo)·ndol·z·n-3-·lo)-3-met·lo-6-(tr·fluoromet·lo)-3Himidazol[4,5-b]pir·d·na; 2-(1 -(3,5-dichlorophenyl)-2-(et¡lsulfon¡lo)-7(tr¡fluoromet¡lo)¡ndol¡z¡n-3-¡lo)-3-metilo-6-(tr¡fluorometilo)-3H-¡m¡dazol[4,5b]pirid¡na;2-(6-(3,5-dichlorophenol)-2-(et¡lsulfon¡lo)¡ndol¡z¡n-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-b]pyridine; 2-(2-(ethylthio)-5,7-d¡methylp¡razol[1,5a]p¡r¡m¡d¡na-3-¡lo)-3-methylo-6-(tr¡fluoromethyl)-3H-¡m¡dazol[4,5-b]p¡r¡d¡na; 2-(2(ethylsulfonyl)-5,7-d¡met¡lp¡razol[1,5-a]pyr¡m¡d¡na-3-yl)-3-met¡lo-6(trifluoromethyl)-3H-im¡dazol[4,5-b]pyrid¡na; 2-(2-(ethylthio)-5,7-d¡methylp¡razol[1,5 npfrCLn / Lznz / e / YiAi 181 a]p¡r¡m¡d¡na-3-¡lo)-3-met¡lo-6-(tr¡fluoromethylo)-3H-¡m¡dazol[4,5-c]p¡r¡d¡na; 2-(2(ethylsulfonyl)-5,7-d¡met¡lp¡razol[1,5-a]pyr¡m¡d¡na-3-yl)-3-met¡lo-6(trifluoromethyl)-3H-im¡dazol[4,5-c]p¡r¡d¡na; 2-(2-(ethyl)-5,7-d¡methylp¡razol[1,5a]pyr¡m¡d¡na-3-¡lo)-5-((tr¡fluoromethyl)t¡o)benzo[d]oxazol; 2-(2(ethylthio)pyrazol[1,5-a]p¡nmidine-3-¡lo)-3-met¡lo-6-(tr¡fluorOiTieth¡lo)-3Him¡dazol[4,5-b]pind¡na; 2-(2-(ethylsulfonyl)-5,7-d¡met¡lp¡razol[1,5-a]pirim¡d¡na3-¡lo)-5-((trifluoromethyl)sulfon¡lo)benzo[d]oxazol;2-(2(ethylsulfonyl)p¡razol[1,5-a]pyrim¡d¡ne-3-¡lo)-3-methyl-6-(tr¡fluorOmet¡lo)-3Himidazol[4,5-b]pyr¡done; 2-(2-(Ethylthio)p¡razol[1,5-a]pyrmidin-3-¡lo)-5((trifluoromethyl)t¡o)benzo[d]oxazole; 2-(2-(ethylsulfonyl)p¡razol[1,5-a]pinmid¡na3-¡lo)-5-((trifluoromethyl)sulfon¡lo)benzo[d]oxazole; 2-(2-(ethylthio)-7-(4fluorophenyl)pyrazol[1,5-a]p¡r¡m¡d¡ne-3-yl)-3-methyl-6-(tr¡luoroiThiethyl)-3Him¡dazol[4,5-b]pyridone; 2-(2-(ethylthio)-7-(4-fluorophen¡lo)prazol[1,5-a]pyrimid¡ne3-¡lo)-3-methyl-6-(tr¡luoromethyl)-3H-m¡dazol[4,5-c]p¡r¡d¡ne; 2-(2(ethylsulfonyl)-7-(4-fluorophen¡lo)p¡razol[1,5-a]pyrimidin-3-¡lo)-3-methyl-6(tnfluoromethyl)-3H-m¡dazol[4,5-c]p¡r¡d¡ne; 2-(2-(ethylthio)p¡razol[1,5a]p¡r¡midene-3-lo)-3-methyl-6-(trifluoromethyl)-3H-m¡dazol[4,5-c]p¡ridene; 2-(2(ethylsulfonyl)pyrazol[1,5-a]pyrim¡d¡ne-3-¡lo)-3-methyl-6-(trifluoromethyl)-3Him¡dazol[4,5-c]pyr¡done; 2-(7-(3,5-dichlorophenyl)-2-(Ethlth)prazol[1,5a]p¡r¡m¡d¡ne-3-lo)-3-methyl-6-(tr¡luoromethyl)-3H-m¡dazol[4,5-c]p¡r¡d¡ne;2-(2(ethylsulfonyl)-7-(4-fluorophen¡lo)p¡razol[1,5-a]pyr¡midene-3-yl)-3-methyl-6(trifluoromethyl)-3H-im¡dazole[4,5-b]pyridine; 2-(7-(3,5-dichlorophenyl)-2(ethylsulfonyl)p¡razol[1,5-a]p¡r¡m¡d¡n-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Himidazol[4,5-b]pindine; 2-(2-(ethylthio)-7-(4-(trifluoromethox¡)phenyl)p¡razol[1,5a]p¡r¡m¡d¡ne-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3H-¡m¡dazol[4,5-b]p¡r¡d¡ne; 2-(2(Ethylt¡o)-7-(4-(tr¡fluoromethox¡)phenyl)p¡razol[1,5-a]p¡r¡midin-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-c]p¡ridine; 2-(2-(ethylsulfonyl)-7-(4(trifluoromethoxy)phen¡lo)p¡razol[1,5-a]pyrimid¡ne-3-¡lo)-3-methyl-6(tr¡fluoromethyl)-3H-im¡dazol[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-7-(4(trifluoromethoxy)phen¡lo)pyrazol[1,5-a]pyrim¡din-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-c]p¡r¡d¡ne; 2-(2-(ethylthio)-7-(4(trifluoromethoxy)phen¡lo)pyrazole[1,5-a]pinmidin-3-¡lo)-5((trifluoromethyl)t¡o)benzo[d]oxazole;2-(2-(ethylsulfonyl)-7-(4(trifluoromethox¡)phen¡lo)pyrazol[1,5-a]pinmidin-3-¡lo)-5npfrCLn / Lznz / e / YiAi 182 ((trifluoromet¡lo)sulfonyl)benzo[d]oxazole; 2-(2-(ethylthio)-7-(4fluorophenyl)pyrazol[1,5-a]pyrimidin-3-yl)-5((trifluoromethyl)t¡o)benzo[d]oxazole; 2-(2-(ethylsulfonyl)-7-(4fluorophenyl)pyrazol[1,5-a]pyrim¡d¡n-3-yl)-5((trifluoromethyl)sulfon¡lo)benzo[d]oxazole; 2-(7-(4-chlorophenyl)-2(ethylthio)p¡razol[1,5-a]pinm¡d¡n-3-l)-3-methyl-6-(trifluoromethyl)-3Himidazol[4,5-c]p¡nd¡n; 2-(7-(4-chlorophenyl)-2-(Ethylt¡o)p¡razol[1,5-a]pyrim¡dine-3yl)-3-methyl-6-(trifluoromethyl)-3H-m¡dazol[4,5-b]p¡ridine; 2-(7-(4-chlorophenyl)2-(ethylsulfonyl)pyrazol[1,5-a]p¡rim¡din-3-¡lo)-3-methyl-6-(trifluoromethyl)-3Himidazol[4,5-c]pindine; 2-(7-(4-chlorophenyl)-2-(ethylt¡o)prazole[1,5-a]pyrim¡din-3¡lo)-5-((tnfluoromethyl)t¡o)benzo[d]oxazole; 2-(7-(4-chlorophenyl)-2(ethylsulfonyl)p¡razol[1,5-a]pyr¡midn-3-¡lo)-3-methyl-6-(tr¡luoromethyl)-3H¡midazol[4,5-b]pyridine;2-(7-(4-chlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5a]pyr¡midn-3-¡lo)-5-((tr¡luoromethyl)sulfonyl)benzo[d]oxazole; 2-(7-(3,5dichlorophenyl)-2-(et¡lsulfon¡lo)p¡razol[1,5-a]pyrmidin-3-yl)-3-methyl-6(tnfluoromethyl)-3H-im¡dazol[4,5-c]p¡r¡d¡ne; 2-(7-(3,5-dichlorophenyl)-2(Ethylthio)p¡razol[1,5-a]p¡ramidin-3-¡lo)-5-((trifluoromethyl)t¡o)benzo[d]oxazole; 2(7-(3,5-dichlorophenyl)-2-(et¡lsulfon¡lo)prazole[1,5-a]pinmidin-3-¡lo)-5((trifluoromethyl)sulfon¡lo)benzo[d]oxazole; 2-(2-(ethylthio)-5-phenylpyrazol[1,5a]p¡r¡d¡ne-3-¡lo)-3-methyl-6-(tr¡luoromethyl)-3H-¡m¡dazol[4,5-c]p¡r¡d¡ne; 2-(2(ethylthio)-5-phenylpyrazol[1,5-a]pyr¡midene-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Himidazole[4,5-c]pyridene; 2-(2-(ethylsulfonyl)-5-phen¡lpyrazol[1,5-a]pyrim¡d¡ne-3yl)-3-methyl-6-(tr¡luoromethyl)-3H-¡m¡dazol[4,5-b]p¡r¡dene; 2-(2-(ethylsulfonyl)5-phenylpyrazol[1,5-a]p¡nm¡d¡ne-3-¡lo)-3-rnethyl-6-(tnfluorOmet¡lo)-3Himidazol[4,5-c]p¡nd¡ne;2-(6-chloro-2-(ethylthio)pyrazol[1,5-a]pyr¡midn-3-yl)-3methyl-6-(tnfluoromethyl)-3H-m¡mdazol[4,5-b]pyridn; 2-(2-(ethylthio)-6phenylpyrazol[1,5-a]pyr¡midene-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Himidazol[4,5-b]pyrimidene; 2-(6-chloro-2-(ethylsulfonyl)p¡razol[1,5-a]pyrim¡d¡n-3yl)-3-methyl-6-(tr¡fluoromethyl)-3H-¡m¡dazol[4,5-b]pyridine; 2-(2-(Ethylthio)-5-(4(trifluoromethoxy)phen¡lo)pyrazol[1,5-a]pyrim¡din-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-c]p¡r¡d¡ne; 2-(6-chloro-2-(ethylthio)pyrazol[1,5a]p¡r¡d¡ne-3-lo)-3-methyl-6-(tr¡fluoromethyl)-3H-¡m¡dazol[4,5-c]p¡r¡rd¡ne; 2-(6chloro-2-(ethylsulfonyl)p¡razol[1,5-a]pyrmid¡ne-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)3H-imidazole[4,5-c]pyrid¡ne; 2-(2-(ethylsulfonyl)-6-phen¡lp¡razol[1,5-a]p¡rim¡d¡n-3 npfrCLn / Lznz / e / YiAi 183 ylo)-3-methyl-6-(tr¡fluoromethyl)-3H-midazol[4,5-b]p¡rid¡n; 2-(2-(ethylthio)-5-(4(trifluoromethoxy)phen¡lo)pyrazol[1,5-a]pyrim¡dine-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-¡m¡dazol[4,5-b]pyridine;2-(2-(ethylsulfonyl)-5-(4(trifluoromethoxy)phen¡lo)pyrazol[1,5-a]pinmidin-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-c]pyrid¡ne; 2-(2-(ethylthio)-5-(4fluorophenyl)pyrazol[1,5-a]pyrmid¡n-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3H¡midazol[4,5-b]pind¡n; 2-(6-(4-chlorophenyl)-2-(ethylt¡o)p¡razol[1,5-a]pyrim¡dine-3yl)-3-methyl-6-(tr¡fluoromethyl)-3H-m¡dazol[4,5-b]p¡ridine; 2-(2-(ethylsulfonyl)5-(4-(tr¡fluoromethox¡)phen¡lo)pyrazol[1,5-a]pyrimidin-3-¡lo)-3-methyl-6(tnfluoromethyl)-3H-im¡dazol[4,5-b]pind¡na; 2-(2-(ethylthio)-5-(4fluorophenyl)pyrazol[1,5-a]pyr¡midene-3-yl)-3-methyl-6-(tr¡fluoromethyl)-3Himidazole[4,5-c]pyr¡dene; 2-(2-(ethylsulfonyl)-5-(4-fluorophenyl)p¡razol[1,5a]p¡r¡m¡d¡ne-3-lo)-3-methyl-6-(tr¡fluoromethyl)-3H-m¡dazol[4,5-c]p¡r¡d¡ne; 2-(2(ethylsulfonyl)-5-(4-fluorophen¡lo)prazol[1,5-a]pyr¡midin-3-¡lo)-3-methyl-6(tr¡fluoromethyl)-3H-imidazol[4,5-b]pyr¡dine;2-(6-(4-chlorophenyl)-2(ethylsulfonyl)p¡razol[1,5-a]pyr¡mid¡ne-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Him¡dazol[4,5-b]pind¡ne; 2-(2-(ethylthio)-6-phen¡lpyrazol[1,5-a]pinmidin-3-¡lo)-3methyl-6-(tr¡luoromethyl)-3H-¡m¡dazol[4,5-c]p¡rdine; 2-(5-(3,5-dichlorophenyl)-2(ethylthio)pyrazol[1,5-a]p¡nmid¡ne-3-¡lo)-3-methyl-6-(trifluorOrriet¡lo)-3Him¡dazol[4,5-b]pind¡ne; 2-(2-(ethylsulfonyl)-6-phen¡lpyrazol[1,5-a]pinm¡din-3¡lo)-3-methyl-6-(trifluoromethyl)-3H-¡m¡dazol[4,5-c]pind¡l; 2-(5-(3,5dichlorophen¡lo)-2-(et¡lsulfonyl)prazol[1,5-a]pyrmidin-3-yl)-3-methyl-6(tnfluoromethyl)-3H-im¡dazol[4,5-b]pyridine; 2-(5-(3,5-dichlorophenyl)-2(Ethylthio)pyrazol[1,5-a]pyrimidin-3-¡lo)-3-methyl-6-(trifluoromethyl)-3Himidazol[4,5-c]p¡nd¡na; 2-(5-(3,5-dichlorophenyl)-2-(ethylsulfon¡lo)p¡razol[1,5a]p¡r¡m¡d¡ne-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3H-m¡dazol[4,5-c]p¡r¡d¡ne; 2-(6bromo-2-(ethylthio)p¡razol[1,5-a]pyrimidin-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3H¡midazol[4,5-b]p¡ndine;2-(6-bromo-2-(ethylsulfonyl)p¡razol[1,5-a]pyrim¡d¡n-3yl)-3-methyl-6-(tr¡fluoromethyl)-3H-¡m¡dazol[4,5-b]pyridine; 2-(6-(3,5dichlorophenyl)-2-(et¡lt¡o)p¡razol[1,5-a]pyr¡midn-3-yl)-3-methyl-6(trifluoromethyl)-3H-m¡mdazol[4,5-b]p¡rdyne; 2-(6-(4-chlorophenyl)-2(ethylthio)pyrazol[1,5-a]pyr¡midin-3-¡lo)-3-methyl-6-(trifluoromethyl)-3Him¡dazol[4,5-c]pyr¡done; 2-(6-(4-chlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5a]p¡r¡m¡d¡ne-3-yl)-3-methyl-6-(tr¡fluoromethyl)-3H-¡m¡dazol[4,5-c]p¡r¡d¡ne; 2-(2 npfrCLn / Lznz / e / YiAi (ethylthio)-5-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)p¡razol[1,5-a]pyrimidin-3-¡lo)-3methyl-6-(tnfluoromethyl)-3H-¡m¡dazol[4,5-c]pyr¡done; 2-(6-(3,5-dichlorophenyl)-2(ethylsulfonyl)p¡razol[1,5-a]p¡r¡m¡d¡n-3-¡lo)-3-methyl-6-(trifluoromethyl)-3Himidazol[4,5-b]pin; 2-(2-(ethylthio)-5-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazol[1,5-a]pyrim¡d¡n-3-yl)-3-methyl-6(trifluoromethyl)-3H-¡m¡dazol[4,5-b]pyridine;2-(2-(ethylsulfonyl)-5-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazol[1,5-a]pinmidin-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-c]pyrid¡ne; 2-(2-(ethylsulfonyl)-5-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazol[1,5-a]pyrim¡d¡n-3-¡lo)-3-methyl-6(tnfluoromethyl)-3H-im¡dazol[4,5-b]pind¡n; 2-(6-(3,5-dichlorophenyl)-2(ethylthio)pyrazol[1,5-a]pyr¡midin-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Himidazol[4,5-c]pyr¡dine; 2-(6-(3,5-dichlorophen¡lo)-2-(ethylsulfonyl)pyrazol[1,5a]p¡r¡m¡d¡ne-3-yl)-3-methyl-6-(trifluoromethyl)-3H-m¡dazol[4,5-c]p¡r¡d¡ne; 2-(2(ethylt¡o)-6-(4-(trifluoromethoxy)phenyl)p¡razol[1,5-a]p¡nmidin-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-6-(4(trifluoromethoxy)phen¡lo)p¡razol[1,5-a]p¡nmidin-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-¡m¡dazol[4,5-b]pyridine; 2-(5-(4-chlorophenyl)-2(ethylthio)pyrazol[1,5-a]pyr¡midin-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Himidazol[4,5-b]pyr¡done;2-(5-(4-chlorophenyl)-2-(Ethylt¡o)prazol[1,5-a]pyrimid¡n-3¡lo)-3-methyl-6-(trifluoromethyl)-3H-midazol[4,5-c]p¡nd¡ne; 2-(2-(Ethylthio)-6-(4(trifluoromethoxy)phen¡lo)p¡razol[1,5-a]pinmidin-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-c]p¡rdine; 2-(2-(ethi lthio)-7-(4-( 1,1,2,2tetrafluoroethoxy)phenyl)pyrazol[1,5-a]pyrim¡d¡na-3-¡lo)-3-methyl-6(tnfluoromethyl)-3H-im¡dazol[4,5-b]pind¡na; 2-(5-(4-chlorophenyl)-2(ethylsulfonyl)pyrazol[1,5-a]pyrim¡d¡ne-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Himidazol[4,5-b]pyr¡done; 2-(5-(4-chlorophenyl)-2-(ethylsulfonyl)pyrazol[1,5a]p¡r¡m¡d¡ne-3-yl)-3-methyl-6-(tr¡fluoromethyl)-3H-¡m¡dazol[4,5-c]p¡r¡rd¡ne; 2-(2(ethylsulfonyl)-7-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)p¡razol[1,5-a]pyrimidin-3yl)-3-methyl-6-(tr¡fluoromethyl)-3H-¡m¡dazol[4,5-b]pyridine; 2-(2-(ethylsulfonyl)7-(4-(1,1,2,2-tetrafluoroethoxy)phenyl)pyrazol[1,5-a]pyr¡mid¡ria-3-yl)-3-methyl-6(trifluoromethyl)-3H-¡m¡dazol[4,5-c]pyrid¡ne;3-(7-(3,5-d¡lorophenyl)-2(Ethylthio)pyrazol[1,5-a]pyrim¡dine-3-yl)-7-(tr¡luoromethyl)-[1,2,4]triazolo[4,3a]pyridine; 2-(2-(ethylthio)-7-(4-( 1,1,2,2-tetrafluoroethoxy)phenyl)pyrazol[1,5a]p¡r¡m¡dene-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3H-midazol[4,5-c]p¡r¡dene; 3-(7npfrCLn / Lznz / e / YiAi 185 (3,5-dichlorophen¡lo)-2-(et¡lsulfonyl)p¡razol[1,5-a]pyr¡midin-3-¡lo)-7(trifluoromethyl)-[1,2,4]triazolo[4,3-a]p¡ridine; 2-(2-(et¡ lthium)-6-(4-( 1,1,2,2tetrafluoroethoxy)phenyl)p¡razol[1,5-a]pyrim¡d¡n-3-¡lo)-3-methyl-6(tr¡fluoromethyl)-3H-midazol[4,5-b]p¡nd¡na; 2-(2-(ethylsulfonyl)-6-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazol[1,5-a]pyrim¡d¡n-3-yl)-3-methyl-6(trifluoromethyl)-3H-¡m¡dazol[4,5-b]pyridine; 2-(7-(3-chlorophenyl)-2(Ethylthio)pyrazol[1,5-a]pyr¡midin-3-¡lo)-3-methyl-6-(tnfluoromethyl)-3Himidazol[4,5-b]pyr¡done; 2-(7-(3,5-difluorophenyl)-2-(Eth¡lt¡o)p¡razol[1,5a]p¡r¡m¡d¡ne-3-lo)-3-methyl-6-(trifluoromethyl)-3H-m¡dazol[4,5-b]p¡r¡d¡ne;2-(7(3-chlorophenyl)-2-(ethylsulfon¡lo)p¡razol[1,5-a]pyr¡midin-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-6-(4(trifluoromethoxy)phen¡lo)pyrazol[1,5-a]p¡rimid¡ne-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-¡m¡dazol[4,5-c]pyrid¡ne; 2-(7-(3,5-difluorophenyl)-2(ethylsulfonyl)pyrazol[1,5-a]pyrim¡d¡ne-3-¡lo)-3-methyl-6-(tr¡luoromethyl)-3Him¡dazol[4,5-b]pyridone; 2-(7-(3-chloro-5-fluorophen¡l)-2-(ethylthio)prazol[1,5a]p¡r¡m¡d¡ne-3-¡lo)-3-methyl-6-(trifluoromethyl)-3H-m¡dazol[4,5-b]p¡r¡d¡n; 2-(7(3-chloro-5-fluorophen¡lo)-2-(ethylsulfon¡lo)pyrazol[1,5-a]pyr¡mid¡n-3-yl)-3-methyl6-(trifluoromethyl)-3H-m¡dazol[4,5-b]pind¡ne; 2-(7-(3,4-dichlorophenyl)-2(ethylsulfonyl)p¡razol[1,5-a]pyr¡mid¡ne-3-¡lo)-3-methyl-6-(tr¡luoromethyl)-3Him¡dazol[4,5-b]pyridone; 7-(3,5-dichlorophenyl)-2-(et¡lt¡o)-3-(1-methyl-5(trifluoromethyl)-l H-benzo[d]imidazol-2-¡lo)p¡razol[1,5-a]pinmidine; 2-(ethylthio)3-(1 -methyl-5-(trifluoroinethl)-1 H-benzo[d]im¡dazol-2-¡lo)p¡razol[1,5a]pyr¡mide;7-(3,5-dichlorophenyl)-2-(et¡lsulfon¡lo)-3-(1 -methyl-5(trifluoromethyl)-l H-benzo[d]imidazol-2-¡lo)p¡razol[1,5-a]pyrim¡d¡ne; 2(ethylsulfonyl)-3-(1 -methyl-5-(trifluoromethyl)-1 H-benzo[d]imidazol-2yl)pyrazol[1,5-a]pyrim¡d¡ne; 2-(2-(ethylsulfonyl)-6-(4-(1,1,2,2tetrafluoroethoxy)phenyl)pyrazol[1,5-a]p¡r¡midin-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-¡m¡dazol[4,5-c]pyrid¡ne; 3-(7-(3,5-dichlorophenyl)-2(ethylthio)pyrazol[1,5-a]pyr¡midine-3-¡lo)-6-(trifluoromethyl)-[1,2,4]triazolo[4,3a]pyridine; 3-(7-(3,5-dichlorophen¡lo)-2-(ethylsulfonyl)pyrazol[1,5-a]pyr¡m¡dn-3yl)-6-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine; 2-(7-(2,3-dichlorophenyl)-2(ethylthio)pyrazol[1,5-a]pyr¡midin-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Him¡dazol[4,5-b]pyridine; 2-(2-(ethylthio)-7-phenylpyrazol[1,5-a]pyrimidin-3-¡lo)-3methyl-6-(tr¡luoromethyl)-3H-m¡dazol[4,5-b]pyr¡done;2-(7-(2,3-dichlorophenyl)-2 npfrCLn / Lznz / e / YiAi 186 (ethylsulfonyl)p¡razol[1,5-a]pyrmid¡n-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Him¡dazol[4,5-b]pyridn; 2-(2-(ethylsulfonyl)-7-phen¡lpyrazol[1,5-a]pyrimidin-3¡lo)-3-methyl-6-(trifluoromethyl)-3H-m¡dazol[4,5-b]p¡nd¡na; 2-(7-(4-chloro-3fluorophenyl)-2-(Ethylt¡o)pyrazol[1,5-a]p¡r¡m¡dene-3-¡lo)-3-methyl-6(tr¡fluoromethyl)-3H-imidazol[4,5-b]pyr¡dene; 2-(7-(3,5-dichlorophenyl)-2(Ethylthio)p¡razol[1,5-a]pyrmidin-3-yl)-3-methyl-6-(tnfluoromethyl)-3H¡midazol[4,5-b]pin; 2-(7-(4-chloro-3-fluorophenyl)-2(ethylsulfonyl)p¡razol[1,5-a]p¡rim¡d¡ne-3-¡lo)-3-methyl-6-(tr¡fluorOmet¡lo)-3Himidazol[4,5-b]pyr¡done; 2-(7-(4-chloro-3-fluorophenyl)-2-(ethylt¡o)p¡razol[1,5a]p¡r¡m¡d¡ne-3-yl)-3-methyl-6-(tr¡fluoromethyl)-3H-m¡dazol[4,5-c]p¡r¡rd¡ne; 2-(7(2,4-dichlorophenyl)-2-(Ethylthio)pyrazol[1,5-a]pyr¡midene-3-yl)-3-methyl-6(tr¡luoromethyl)-3H-imidazole[4,5-b]pyr¡dene;2-(7-(2,4-dichlorophenyl)-2(ethylsulfonyl)pyrazol[1,5-a]pyrim¡d¡ne-3-¡lo)-3-methyl-6-(trifluoromethyl)-3H¡midazol[4,5-b]pind¡ne; 2-(7-(2,4-dichlorophenyl)-2-(Ethylt¡o)p¡razol[1,5a]p¡r¡mid¡ne-3-yl)-3-methyl-6-(trifluoromethyl)-3H-m¡dazol[4,5-c]p¡r¡ridine; 2-(7(3-chloro-5-fluorophen¡lo)-2-(ethylt¡o)pyrazol[1,5-a]pyrimid¡ria-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-m¡dazol[4,5-c]pyridine; 2-(7-(3-chloro-5-fluorophenyl)-2(ethylsulfonyl)pyrazol[1,5-a]pyr¡mide-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Him¡dazol[4,5-c]pyr¡dine; 2-(7-(3,5-bis(trifluoromethyl)phen¡lo)-2(ethylthio)p¡razol[1,5-a]pinm¡d¡na-3-¡lo)-3-methyl-6-(trifluoromethyl)-3H¡midazol[4,5-b]pinm¡l; 2-(2-(ethylthio)-7-(3-(trifluoromethyl)phenyl)p¡razol[1,5a]p¡r¡m¡d¡ne-3-yl)-3-methyl-6-(trifluoromethyl)-3H-¡m¡dazol[4,5-b]p¡r¡d¡ne; 2-(2(ethylthio)-7-(3-fluorophen¡lo)p¡razol[1,5-a]pyrim¡d¡ne-3-yl)-3-methyl-6(tnfluoromethyl)-3H-im¡dazol[4,5-b]pind¡ne;2-(7-(3,5bis(tnfluoromethyl)phen¡lo)-2-(et¡lsulfonyl)pyrazol[1,5-a]pinmidin-3-¡lo)-3methyl-6-(tnfluoromethyl)-3H-¡m¡dazol[4,5-b]pyrid¡ne; 2-(2-(ethylsulfonyl)-7-(3(trifluoromethyl)phen¡lo)p¡razol[1,5-a]pyr¡midin-3-yl)-3-methyl-6(trifluoromethyl)-3H-¡m¡dazol[4,5-b]pyridine; 2-(2-(ethylsulfonyl)-7-(3fluorophenyl)pyrazol[1,5-a]pyr¡midin-3-yl)-3-methyl-6-(tr¡fluororonetyl)-3Him¡dazol[4,5-b]pyridine; 2-(2-(ethylt¡o)-7-methylp¡razol[1,5-a]pyrmidin-3-¡lo)-3methyl-6-(trifluoromethyl)-3H-m¡dazol[4,5-b]pyr¡done; 2-(2-(ethylthio)-7-(3fluorophenyl)pyrazol[1,5-a]pyr¡midene-3-yl)-3-methyl-6-(tr¡fluoromethyl)-3Him¡dazole[4,5-c]pyr¡dene; 2-(2-(ethylsulfon¡lo)-7-methylpyrazol[1,5-a]pyrim¡d¡n-3¡lo)-3-methyl-6-(trifluoromethyl)-3H-im¡dazol[4,5-b]p¡nd¡ne; 2-(2-(ethylthio)-7-(3 npfrCLn / Lznz / e / YiAi 187 (trifluoromethyl)phenyl)pyrazol[1,5-a]pyrim¡din-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-c]p¡r¡dine;(7-(3,5-dichlorophenyl)-3-(3-methyl6-(tr¡fluoromethyl)-3H-¡m¡mdazol[4,5-b]p¡r¡d¡n-2-hlo)p¡razol[1,5-a]pyrim¡d¡n-2¡lo)(ethyl)(imino)-6-sulfanone; 2-(2-(ethylsulfonyl)-7-(3(trifluoromethyl)phen¡lo)p¡razol[1,5-a]pyrim¡din-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-¡m¡dazol[4,5-c]pyrid¡ne; 2-(2-(ethylsulfonyl)-7-(3fluorophenyl)pyrazol[1,5-a]pyr¡midene-3-yl)-3-methyl-6-(tr¡fluoromethyl)-3Himidazole[4,5-c]pyr¡dene; 2-(2-(ethylthio)-7-methylpyrazol[1,5-a]pyr¡midin-3-¡lo)-3methyl-6-(tnfluoromethyl)-3H-¡m¡dazol[4,5-c]pyr¡done; 2-(7-(3-chloro-4fluorophenyl)-2-(ethylt¡o)pyrazol[1,5-a]pyr¡midine-3-¡lo)-3-methyl-6(trifluoromethyl)-3H-im¡dazol[4,5-b]pindine; 2-(2-(ethylthio)-5,7bis(trifluoromethyl)p¡razol[1,5-a]pyr¡mid¡na-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)3H-im¡dazol[4,5-b]p¡ridine; 2-(2-(ethylsulfonyl)-5,7bis(tr¡fluoromethyl)p¡razol[1,5-a]pyr¡mid¡ne-3-¡lo)-3-methyl-6-(trifluoromethyl)3H-imidazol[4,5-b]pyridine;2-(et¡lthio)-3-(3-methyl-6-(tr¡fluoromethyl)-3H¡midazol[4,5-b]pyr¡d¡n-2-¡lo)p¡razol[1,5-a]pyr¡dn-7(4H)-one; 2-(7-bromo-2(ethylthio)p¡razol[1,5-a]pyrim¡d¡ne-3-¡lo)-3-methyl-6-(trifluoromethyl)-3Himidazol[4,5-b]pyr¡done; 2-(ethylsulfonyl)-N-methyl-3-(7-(tr¡fluoromethyl)[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)pyrazol[1,5-a]pyrinidin-7-ainine; 6-(8-(4chloro-3-fluorophen¡lo)-2-(ethylsulfon¡lo)¡ndol¡zn-3-¡lo)-7-methyl-3-(tr¡luoromethyl)7H-imidazol[4,5-c]p¡r¡daz¡ne; 2-(2-(ethylsulfonyl)-7-(5-methyl-3(trifluoromethyl)-1 H-pyrazol-1 -yl)pyrazol[ 1,5-a]pyrimidin-3-¡lo)-3-methyl-6(tnfluoromethyl)-3H-im¡dazol[4,5-b]pyridine; 2-(ethylthio)-N-methyl-3-(3-methyl-6(tr¡fluoromethyl)-3H-im¡dazol[4,5-b]pyr¡d¡n-2-¡lo)p¡razol[1,5-a]pyrim¡dn-7amine; 2-(2-(ethylsulfonyl)-7-(3-fluorophenoxy¡)p¡razol[1,5-a]pyr¡midin-3-¡lo)-3methyl-6-(tnfluoromethyl)-3H-¡m¡dazol[4,5-b]pyr¡done;6-(8-(4-cloro-3fluorofenilo)-2-(et¡lsulfon¡lo)¡m¡dazol[1,2-a]piridina-3-¡lo)-7-met¡lo-3(trifluoromet¡lo)-7H-¡m¡dazol[4,5-c]p¡ridaz¡na; 2-(6-(3,5-diclorofenilo)-2(etilsulfonilo)pirazol[1,5-a]pirim¡d¡na-3-¡lo)-6-(trifluoromet¡lo)¡midazol[1,2a]pirazina; 4-(2-(etilsulfon¡lo)-3-(7-met¡lo-3-(trifluorometilo)-7H-¡m¡dazol[4,5c]p¡ridaz¡na-6-¡lo)¡ndol¡z¡n-8-¡lo)-2-fluorobenzon¡tr¡lo; 2-(8-(ciclopropylmet¡lo)2-(etilsulfonilo)¡m¡dazol[1,2-a]piridina-3-¡lo)-3-met¡lo-6-(tr¡fluorometilo)-3Himidazol[4,5-b]pir¡d¡na; 2-(7-(4-cloro-1 H-pirazol-1 -ilo)-2(etilsulfonilo)p¡razol[1,5-a]pirim¡d¡na-3-¡lo)-3-met¡lo-6-(tr¡fluoromet¡lo)-3HnpfrCLn / Lznz / e / YiAi 188 im idazol [4,5-b]pi ridina; 2-(2-(etilsulfonilo)-7-(5-met¡lo-1 H-1,2,4-triazol-1 ilo)pirazol[1,5-a]p¡r¡mid¡na-3-ilo)-3-met¡lo-6-(tr¡fluorometilo)-3H-¡m¡dazol[4,5b] pi ridi na; 2-(2-(ethylsulfonilo)-7-(1 -methyl-1H-pirazol-5-¡lo)p¡razol[1,5a]p¡r¡m¡d¡na-3-¡lo)-3-rnet¡lo-6-(tr¡fluorornetilo)-3H-¡m¡dazol[4,5-b]p¡hd¡na;2-(2(et Isulfon i lo)-7-(1 -methyl-3-(trifluoromethyl)-1 H-pyrazol-5-yl)p¡razol[1,5a]pyrim¡d¡ne-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3H-m¡dazol[4,5-b]pyrid¡ne; 2-(7cyclopropyl-2-(et¡lsulfon¡lo)p¡razol[1,5-a]pyr¡midene-3-¡lo)-6-(tr¡fluoromethyl)[1,2,4]triazolo[1,5-a]pyrazine; 2-(2-(ethylsulfonyl)-7-(1 -methyl-3(trifluoromethyl)-l H-pyrazol-5-yl)p¡razol[1,5-a]pyrimidin-3-yl)-7(trifluoromethyl)¡m¡dazol[1,2-c]pyrim¡done; 4-(2-(ethylsulfonyl)-3-(7(trifluoromethyl)¡midazol[1,2-a]pyridin-2-¡lo)p¡razol[1,5-a]pyrimid¡n-7yl)morpholine; 2-(7-(4-chloro-3-fluorophenyl)-2-(ethylsulfonyl)p¡razol[1,5a]pyrimidine-3-lo)-7-(trifluoromethyl)-[1,2,4]triazolo[1,5-c]pyrimidine; 2-(2(et Isulfonylo)-7-(1 H-1,2,4-triazol-1 -yl)pyrazol[1,5-a]pyr¡midin-3-¡lo)-7(trifluoromethyl)-[1,2,4]triazolo[1,5-c]pyrim¡d¡ne; 2-(2-(ethylsulfonyl)-5,7bis(trifluoromethyl)p¡razol[1,5-a]pyr¡mid¡ne-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)3H-im¡dazol[4,5-b]pyridine;6-(1 -bromo-2-(ethylsulfon¡lo)-8-methyllindol¡zone-3yl)-7-methyl-3-(tr¡fluororonetyl)-7H-¡m¡dazol[4,5-c]pindazone; 6-(8-bromo-2(et¡lsulfon¡lo)¡ndol¡zn-3-¡lo)-3-(difluoiOmet¡lo)-7-methyl-7H-¡m¡dazol[4,5c]pindazine; 2-(2-(ethylsulfon¡lo)-7-methox¡prazolo[1,5-a]pyrmidin-3-lo)-3methyl-6-(tr¡fluoromethyl)-3H-im¡dazolo[4,5-b]p¡hd¡ne; 2-(2-(ethylsulfonyl)-7(methylt¡o)pyrazol[1,5-a]pyrimidin-3-¡lo)-3-methyl-6-(tr¡fluoromethyl)-3Himidazol[4,5-b]pyr¡dine; 2-(ethylsulfonyl)-3-(3-methyl-6-(tr¡fluoromethyl)-3Himidazol[4,5-b]pyr¡d¡n-2-yl)p¡razol[1,5-a]pinmid¡n-7(4H)-tone; 2-(2(ethylsulfonyl)-7-(1,1,2,2-tetrafluoroethoxy)pyrazol[1,5-a]p¡rim¡d¡ne-3-¡lo)-3methyl-6-(tr¡fluoromethyl)-3H-¡m¡dazol[4,5-b]p¡ri¡dene; 2-(7-ethox¡-2(ethylsulfonyl)p¡razol[1,5-a]pyrimid¡n-3-¡lo)-6-(trifluoromethyl)m¡dazol[1,2a]pyrazine; d¡ethyl((2-(et¡lsulfon¡lo)-3-(6-(trifluoromethyl)¡m¡dazol[1,2-a]pyrazine2-¡lo)pyrazol[1,5-a]pyrimidine-7-lo)im¡no)-A6-sulfanone;2-(ethylsulfonyl)-N,Nd¡met¡l-3-(3-methyl-6-(trifluoromethyl)-3H-¡m¡dazol[4,5-b]pyrdine-2yl)imidazole[1,2-a]pindine-8-am¡ne; 6-(2-(ethylsulfonyl)-7-(5(trifluoromethyl)pyrid¡n-2-¡lo)pyrazol[1,5-a]p¡hmidin-3-yl)-7-methyl-3(trifluoromethyl)-7H-im¡dazol[4,5-c]p¡r¡dazine; 2-(7-(4-chloro-3-fluorophenyl)-2(ethylsulfonyl)p¡razol[1,5-a]p¡rim¡d¡n-3-¡lo)-3,5-dimethyl-6-(tr¡fluoromethyl)-3,5npfrCLn / Lznz / e / YiAi 189 dihydro-4H-midazol[4,5-c]p¡r¡d¡n-4-one; Measurement of 2-(2-(ethylsulfonyl)-7-(3(trifluoromethyl)-l H-1,2,4-triazol-1 -yl)p¡ razol[ 1,5-a]. na-3-yl)-3,5dimethyl-6-(tr¡luoromethyl)-3,5-dihydro-4H-m¡dazol[4,5-c]p¡r¡d¡n-4-one; 2-(7(3-chloro-5-fluorophenyl)-2-(ethylsulfon¡lo)pyrazol[1,5-a]pyrimid¡n-3-¡lo)-6(trifluoromethyl)-[1,2,4]triazolo[1,5-a]pyrazine; 2-(7-(3,5-dichlorophenyl)-2(ethylsulfonyl)pyrazol[1,5-a]pyrim¡d¡n-3-¡lo)-7-(tr¡fluoromethyl)¡m¡dazol[1,2cjpyrimidine;2-(7-(4-chloro-3-fluorophenyl)-2-(ethylsulfonyl)pyrazol[1,5a]pyr¡m¡d¡na-3-¡lo)-6-meth¡lo-7-(tr¡fluoromethyl)-[1,2,4]triazole[1,5-c]pyrim¡dine5(6H)-ona; 2-(7-(5-chlorop¡r¡d¡na-2-¡lo)-2-(ethylsulfon¡lo)prazol[1,5-a]pirim¡d¡na3-¡lo)-6-(trifluoromethyl)-[1,2,4]triazole[1,5-a]pyridine; 2-(2-(ethylsulfonyl)-7-(5methyl-3-(trifluoromethyl)-1 H-pyrazol-1-yl)pyrazol[1,5-a]pyrimidine-3-yl)-6methyl-7-(trifluoromethyl)-[1,2,4]triazole[1,5-c]p¡r¡mid¡na-5(6H)-ona; 2-(2(ethylsulfonyl)-7-(3-(trifluoromethyl)-1H-1,2,4-triazol-1-yl)pyrazol[1,5a]pyr¡m¡d¡na-3-¡lo)-7-(trifluoromethyl)-[1,2,4]triazole[1,5-c]pyrim¡d¡na; ethyl(3-(3met¡lo-6-(trifluoromet¡lo)-3H-¡m¡dazol[4,5-c]p¡r¡d¡na-2-¡lo)p¡razol[1,5a]p¡rim¡d¡na-2-¡lo)(met¡l¡m¡no)-A6-sulfanone.; 7. A composition for controlling or preventing insect and / or mite pests comprising a biologically effective amount of the compound of Formula (I) or its agronomically acceptable salts, isomers / structural isomers, stereoisomers, diastereomers, enantiomers, tautomers, polymorphs, metal complexes or N-oxides according to Claim 1 and at least one additional component selected from the group consisting of surfactants and auxiliaries.

8. The composition according to Claim 7, wherein said composition further comprises at least one additional biologically active compatible compound selected from fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers or nutrients.

9. The composition according to Claim 7, wherein said biologically effective amount of the compound of Formula (I) ranges from 0.1% to 99% by weight with respect to the total weight of the composition, preferably ranging from 5% to 50% by weight with respect to the total weight of the composition.

10. A combination comprising a biologically effective amount of the compound according to Claim 1 and at least one additional biologically active compatible compound selected from fungicides, insecticides, nematicides, acaricides, biopesticides, herbicides, plant growth regulators, antibiotics, fertilizers, and nutrients.

11. A method for combating insect and mite pests comprising contacting the insect and mite pests, their habitat, breeding ground, food supply, plant, seed, soil, area, material or environment in which the insect and mite pests are growing or may grow, or the materials, plants, seeds, soils, surfaces or spaces to be protected from pest attack or infestation with a biologically effective amount of the compound of Formula (I) or salts, metal complexes, N-oxides, isomers, polymorphs, composition or combination thereof according to Claims 1, 7 or 10.

12. A method for protecting crops from attack or infestation by insect and mite pests, consisting of putting the crop in contact with a biologically effective amount of the compound or its salts, metal complexes, N-oxides, isomers, polymorphs, composition or combination thereof according to Claims 1, 7 or 10.

13. The method according to Claims 11 or 12, wherein said method comprises applying effective doses of the compound of Formula (I) in quantities ranging from 1 gai to 5000 gal per hectare in agricultural or horticultural crops.

14. A method for protecting seeds, plants and parts of plants from soil insects, and for protecting seedlings, roots and shoots from soil insects and foliar insects, comprising contacting the seeds before sowing and / or after pre-germination with the compound of Formula (I) or its salts, metal complexes, N-oxides, isomers, polymorphs, composition or combination thereof according to Claims 1, 7 or 10.

15. The use of the compound of Formula (I) or salts, metal complexes, oxides, isomers, polymorphs, compositions or combinations thereof according to Claims 1, 7 or 10, for controlling insect and mite pests in agricultural crops, horticultural crops, household pest control, and vectors and parasites in animals. npfrCLn / Lznz / e / viAi 191 16. The use of the compound of Formula (I) according to Claim 15, wherein said agricultural crops are cereals, maize, sorghum, bajra, rice, soybeans, oilseeds and other leguminous plants, fruits and fruit trees, grapes, nuts and nut trees, citrus and citrus trees, horticultural plants, cucurbits, oilseed plants, tobacco, coffee, tea, cocoa, sugar beet, sugar cane, cotton, potato, tomato, onion, pepper, other vegetables and ornamental plants.

17. A seed comprising a compound of Formula (I) or its salts, metal complexes, N-oxides, isomers, polymorphs, composition or combination according to Claims 1, 7 or 10, wherein the amount of compound of Formula (I) in said seed varies approximately from 0.0001% to 1% by weight.